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Abstract	  Title:	  Characterization	  of	  the	  assembly	  of	  Human	  Cytomegalovirus	  
gH/gL/gO	  and	  gH/gL/UL128-­‐131	  complexes	  and	  studies	  on	  their	  functions	  during	  
virus	  entry	  and	  tropism	  
	  
Chairperson:	  Dr.	  Jesse	  Hay	  
Research	  Advisor:	  Dr.	  Brent	  J	  Ryckman	  
	  
Human	  cytomegalovirus	  (HCMV)	  is	  a	  human	  pathogen	  that	  can	  cause	  severe	  
diseases	  in	  immunocompromised	  individuals,	  and	  also	  is	  a	  leading	  cause	  for	  
congenital	  infection,	  making	  it	  a	  major	  public	  health	  concern.	  Currently,	  there	  is	  no	  
effective	  vaccine	  available	  and	  antiviral	  treatment	  is	  often	  associated	  with	  problems,	  
like	  drug	  toxicity,	  and	  drug	  resistance.	  Intervention	  in	  the	  virus	  entry	  process	  during	  
the	  replication	  cycle	  could	  serve	  as	  a	  useful	  therapeutic	  strategy.	  The	  overall	  aims	  of	  
the	  research	  in	  this	  dissertation	  are	  to	  characterize	  the	  roles	  of	  HCMV	  two	  gH/gL	  
glycoprotein	  complexes	  during	  virus	  entry	  and	  tropism,	  and	  to	  study	  the	  molecular	  
basis	  for	  the	  regulation	  of	  the	  assembly	  of	  those	  two	  complexes.	  The	  work	  has	  
revealed	  that	  gH/gL/gO	  complex	  promotes	  virus	  fusion	  into	  all	  cell	  types	  whereas	  
gH/gL/UL128-­‐131	  complex	  provides	  a	  non-­‐fusion	  but	  necessary	  function	  for	  virus	  
entry	  into	  select	  cell	  types.	  Importantly,	  the	  work	  also	  demonstrated	  that	  different	  
HCMV	  strains	  vary	  dramatically	  in	  the	  relative	  abundance	  of	  those	  two	  gH/gL	  
complexes	  on	  the	  virion	  envelope,	  and	  that	  could	  have	  a	  fundamental	  impact	  on	  
virus	  efficiency	  of	  entry.	  The	  regulation	  of	  the	  assembly	  of	  those	  two	  complexes	  is	  
likely	  influenced	  by	  multiple	  viral	  factors.	  This	  work	  will	  help	  us	  better	  understand	  
the	  molecular	  biology	  of	  how	  HCMV	  initiates	  infection	  of	  different	  cell	  types,	  and	  
will	  aid	  in	  the	  development	  of	  antiviral	  strategies	  in	  the	  future.	  
	   	  
	   iii	  
TABLE	  OF	  CONTENTS	  
TABLE	  OF	  CONTENTS	  ............................................................................................................	  iii	  
LIST	  OF	  FIGURES	  .......................................................................................................................	  v	  
LIST	  OF	  TABLES	  ......................................................................................................................	  vii	  
ACKNOWLEDGEMENTS	  .......................................................................................................	  viii	  
CHAPTER	  1.	   INTRODUCTION	  ............................................................................................	  1	  
Overview	  of	  HCMV	  pathogenesis	  ..............................................................................................	  2	  
HCMV	  epidemiology	  ........................................................................................................................	  2	  
HCMV	  pathogenesis	  in	  immunocompromised	  individuals	  ............................................	  5	  
HCMV	  congenital	  infection	  ...........................................................................................................	  6	  
HCMV	  pathogenesis	  in	  immunocompetent	  individuals	  ..................................................	  7	  
Overview	  of	  HCMV	  biology	  ..........................................................................................................	  8	  
HCMV	  virion	  structure	  ...................................................................................................................	  8	  
HCMV	  replication	  cycle	  ...............................................................................................................	  15	  
HCMV	  latent	  infection	  .................................................................................................................	  23	  
HCMV	  genetic	  diversity	  ..............................................................................................................	  25	  
HCMV	  cell	  tropism	  and	  entry	  ...................................................................................................	  28	  
HCMV	  in	  vivo	  cell	  tropism	  and	  viral	  dissemination	  ........................................................	  28	  
HCMV	  in	  vitro	  cell	  tropism	  and	  associated	  adaptive	  genetic	  changes	  ....................	  30	  
HCMV	  entry	  and	  membrane	  fusion	  event	  ..........................................................................	  33	  
HCMV	  core	  fusion	  machinery	  and	  accessory	  glycoproteins	  .......................................	  36	  
HCMV	  gH/gL/UL128-­‐131	  and	  gH/gL/gO	  complexes	  in	  entry	  and	  tropism	  ........	  39	  
Focus	  of	  the	  dissertation	  ............................................................................................................	  44	  
CHAPTER	  2.	   COMPARATIVE	  ANALYSIS	  OF	  gO	  ISOFORMS	  REVEALS	  THAT	  
STRAINS	  OF	  HUMAN	  CYTOMEGELOVIRUS	  DIFFER	  IN	  THE	  RATIO	  OF	  gH/gL/gO	  
AND	  gH/gL/UL128-­‐131	  IN	  THE	  VIRION	  ENVELOPE	  ...................................................	  47	  
INTRODUCTION	  .............................................................................................................................	  48	  
MATERIALS	  AND	  METHODS	  ....................................................................................................	  52	  
RESULTS	  ............................................................................................................................................	  57	  
DISCUSSION	  .....................................................................................................................................	  75	  
CHAPTER	  3.	   CHARACTERIZATION	  OF	  HUMAN	  CYTOMEGALOVIRUS	  gH/gL	  
COMPLEXES	  FUNCTION	  DURING	  VIRUS	  ENTRY	  AND	  TROPISM	  .............................	  82	  
INTRODUCTION	  .............................................................................................................................	  83	  
MATERIALS	  AND	  METHODS	  ....................................................................................................	  86	  
RESULTS	  ............................................................................................................................................	  90	  
	   iv	  
DISCUSSION	  ..................................................................................................................................	  105	  
CHAPTER	  4.	   CHARACTERIZATION	  OF	  THE	  VIRAL	  FACTORS	  THAT	  INFLUENCE	  
HUMAN	  CYTOMEGALOVIRUS	  gH/gL	  COMPLEXES	  ASSEMBLY	  .............................	  113	  
INTRODUCTION	  ..........................................................................................................................	  114	  
MATERIALS	  AND	  METHODS	  .................................................................................................	  117	  
RESULTS	  .........................................................................................................................................	  121	  
DISCUSSION	  ..................................................................................................................................	  130	  
CHAPTER	  5.	   GENERAL	  DISCUSSION	  AND	  FUTURE	  DIRECTIONS	  ......................	  136	  
REFERENCES	  .........................................................................................................................	  149	  
	  
	   	  
	   v	  
LIST	  OF	  FIGURES	  
	  
Figure	  1-­‐1	  Model	  for	  the	  relationship	  between	  socioeconomic	  status	  and	  the	  
cumulative	  HCMV	  seroprevalence	  by	  age.	  .............................................................................	  5	  
Figure	  1-­‐2	  HCMV	  virion	  structure.	  .....................................................................................................	  9	  
	  Figure	  1-­‐3	  Schematic	  genome	  organization	  of	  HCMV.	  ...........................................................	  10	  
Figure	  1-­‐4	  Structure	  of	  HCMV	  capsid	  in	  a	  T-­‐16	  symmetry.	  ..................................................	  11	  
Figure	  1-­‐5	  Schematic	  of	  HCMV	  replication	  cycle.	  ......................................................................	  17	  
Figure	  1-­‐6	  Schematic	  of	  gH/gL/gO	  and	  gH/gL/UL128-­‐131	  complexes.	  ........................	  44	  
Figure	  1-­‐7	  HCMV	  distinct-­‐function	  tropism	  model.	  .................................................................	  46	  
Figure	  2-­‐1	  Phylogenetic	  relationships	  of	  predicted	  gO	  amino	  acid	  sequences	  
encoded	  by	  lab	  strains	  and	  clinical	  isolates	  of	  HCMV.	  ...................................................	  58	  
Figure	  2-­‐2	  Comparisons	  of	  amino	  acid	  sequences	  of	  gO	  encoded	  by	  laboratory	  
strains,	  and	  clinical	  isolates	  of	  HCMV.	  ..................................................................................	  60	  
Figure	  2-­‐3	  Expression	  of	  HCMV	  gO	  isoforms	  by	  replication-­‐defective	  adenovirus	  
(Ad)	  vectors.	  ....................................................................................................................................	  61	  
Figure	  2-­‐4	  Western	  blot	  detection	  of	  gO	  isoforms	  by	  anti-­‐peptide	  rabbit	  sera.	  ..........	  63	  
Figure	  2-­‐5	  Effects	  of	  distinct	  gO	  isoforms	  on	  the	  intracellular	  trafficking	  of	  a	  
common	  isoform	  of	  gH/gL.	  .......................................................................................................	  66	  
Figure	  2-­‐6	  Detection	  of	  Golgi-­‐associated	  glycoforms	  of	  gO	  isoforms	  during	  
coexpression	  with	  gH/gL.	  	  	  ........................................................................................................	  67	  
Figure	  2-­‐7	  Analysis	  of	  disulfide	  bonds	  in	  the	  interactions	  between	  gH/gL	  and	  gO	  
isoforms.	  ............................................................................................................................................	  69	  
	   vi	  
Figure	  2-­‐8	  Comparative	  analysis	  of	  gH/gL/gO	  complexes	  from	  different	  strains	  of	  
HCMV.	  .................................................................................................................................................	  71	  
Figure	  2-­‐9	  Suppression	  of	  UL128-­‐131	  expression	  enhances	  incorporation	  of	  
gH/gL/gO	  into	  the	  Merlin	  virion	  envelope.	  ........................................................................	  74	  
Figure	  3-­‐1	  Comparison	  of	  glycoprotein	  concentrations	  in	  the	  virion	  envelope	  of	  
different	  HCMV	  strains.	  ...............................................................................................................	  91	  
Figure	  3-­‐2	  Comparison	  of	  gH/gL	  complexes	  in	  the	  virion	  envelope	  of	  different	  HCMV	  
strains.	  ................................................................................................................................................	  93	  
Figure	  3-­‐3	  Comparison	  of	  gH/gL	  complexes	  in	  the	  virion	  envelope	  of	  Merlin	  (ME)	  or	  
Merlin-­‐Trimer	  (ME-­‐T).	  ................................................................................................................	  94	  
Figure	  3-­‐4	  Particle-­‐to-­‐PFU	  analysis	  of	  HCMV.	  ............................................................................	  95	  
Figure	  3-­‐5	  HCMV	  plaque	  formation	  from	  infectious	  centers.	  ..............................................	  99	  
Figure	  3-­‐6	  Neutralization	  of	  HCMV	  by	  UL130,	  and	  UL131	  specific	  antibodies.	  .......	  101	  
Figure	  3-­‐7	  Effects	  of	  polyethylene	  glycol	  (PEG)	  on	  infection	  by	  gH/gL/UL128-­‐131-­‐
rich,	  and	  gH/gL/gO-­‐rich	  HCMV.	  ...........................................................................................	  103	  
Figure	  3-­‐8	  Effects	  of	  polyethylene	  glycol	  (PEG)	  on	  HCMV	  plaque	  formation	  on	  
epithelial	  cells.	  .............................................................................................................................	  104	  
Figure	  4-­‐1	  Comparison	  of	  glycoproteins	  expression	  level	  in	  the	  fibroblasts	  cells	  
infected	  with	  strains	  of	  HCMV	  TR	  and	  ME.	  ......................................................................	  122	  
Figure	  4-­‐2	  Western	  blotting	  analysis	  of	  the	  maturation	  of	  HCMV	  gH/gL	  in	  the	  
infected	  fibroblast	  cells.	  ...........................................................................................................	  124	  
Figure	  4-­‐3	  Characterizations	  of	  HCMV	  gO	  inter-­‐strain	  swap	  mutants.	  ........................	  127	  
Figure	  4-­‐4	  Characterizations	  of	  HCMV	  gH	  N-­‐term	  inter-­‐strain	  swap	  mutants.	  ........	  129	  
	   vii	  
LIST	  OF	  TABLES	  
	  
Table	  1-­‐1.	  Pathogenesis	  comparison	  of	  human	  herpesviruses.	  .............................................	  3	  
Table	  1-­‐2.	  Comparison	  of	  host	  range,	  cell	  tropism	  and	  site	  of	  latency	  among	  human	  




	   	  
	   viii	  
ACKNOWLEDGEMENTS	  
	  
I	  would	  like	  to	  express	  my	  most	  sincere	  thanks	  to	  my	  research	  mentor	  Dr.	  Brent	  
Ryckman.	  I	  feel	  extremely	  grateful	  for	  having	  the	  opportunity	  to	  learn	  from	  such	  a	  
talented	  and	  brilliant	  scientist.	  During	  the	  seven	  years	  of	  study	  in	  Ryckman	  lab,	  
Brent	  has	  always	  been	  patient	  and	  dedicated	  in	  mentoring	  and	  training	  of	  me.	  The	  
tremendous	  amount	  of	  time	  that	  he	  spent	  helping	  me	  in	  the	  lab	  has	  made	  me	  into	  
the	  scientist	  who	  I	  am	  today.	  He	  is	  the	  person	  who	  helped	  me	  realized	  my	  dream	  
and	  raised	  me	  up	  to	  more	  than	  I	  can	  be.	  His	  enthusiasm	  in	  science	  and	  persistent	  
pursuit	  of	  ignorance	  will	  always	  be	  an	  inspiration	  that	  I	  would	  look	  up	  to	  in	  the	  
future.	  	  
	  
I	  also	  have	  a	  lot	  of	  thanks	  to	  my	  committee	  members	  Dr.	  J.	  Stephen	  Lodmell,	  Dr.	  
Jesse	  Hay,	  Dr.	  Bruce	  Bowler,	  and	  Dr.	  Jack	  Nunberg	  for	  their	  guidance	  and	  advice	  
regarding	  my	  projects	  and	  dissertation.	  Their	  effort	  and	  time	  are	  deeply	  
appreciated.	  I	  feel	  fortunate	  to	  complete	  my	  Ph.D.	  study	  in	  such	  a	  positive	  
environment	  that	  they	  contributed	  to	  create.	  
	  
I	  want	  to	  thank	  my	  lab	  members	  for	  their	  support	  as	  well.	  Being	  thousands	  of	  
miles	  away	  from	  my	  families	  and	  friends	  in	  China	  and	  studying	  abroad	  by	  myself	  
sometimes	  can	  be	  hard,	  luckily	  enough	  I	  have	  such	  a	  “lab-­‐family”	  in	  Missoula	  and	  I	  
am	  grateful	  for	  the	  care	  and	  happiness	  they	  gave	  to	  me.	  Here	  I	  would	  like	  to	  
specially	  thank	  Dr.	  Jean-­‐Marc	  Lanchy	  for	  his	  generosity	  of	  sharing	  his	  scientific	  
knowledge	  and	  expertise	  whenever	  I	  am	  seeking	  for	  a	  good	  source	  of	  discussion	  or	  
help.	  He	  also	  taught	  me	  lab	  techniques	  that	  contributed	  greatly	  to	  the	  research	  work	  
in	  this	  dissertation.	  
	  
Last	  but	  not	  least,	  my	  deepest	  gratitude	  goes	  to	  my	  parents	  Xianghua	  Zhou	  and	  
Xiumei	  Li	  for	  their	  unconditional	  love	  and	  support.	  There	  are	  not	  enough	  words	  to	  
describe	  how	  thankful	  I	  am	  to	  both	  of	  them.	  Dad	  and	  Mom,	  thank	  you	  for	  always	  
being	  there	  for	  me,	  no	  matter	  laughter	  and	  tears,	  ups	  and	  downs.	  Thank	  you	  for	  
working	  so	  hard	  to	  provide	  me	  with	  the	  equal	  education	  opportunity	  as	  other	  
children,	  which	  I	  know	  was	  not	  easy	  during	  the	  time	  I	  grew	  up	  in	  China	  and	  
sometimes	  even	  meant	  you	  had	  to	  make	  sacrifice.	  Thank	  you	  for	  everything	  and	  I	  





	   1	  
CHAPTER	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Human	  cytomegalovirus	  (HCMV)	  is	  an	  enveloped,	  double-­‐stranded	  DNA	  virus,	  a	  
prototypic	  member	  of	  beta-­‐herpesvirus	  family.	  Like	  all	  the	  other	  herpesviruses,	  
HCMV	  is	  widely	  spread	  in	  human	  population.	  Although	  primary	  infection	  in	  healthy	  
individuals	  is	  normally	  subclinical,	  persistent	  and	  latent	  infection	  will	  be	  established	  
for	  a	  lifetime.	  In	  immunocompromised	  individuals,	  like	  AIDS	  patients	  and	  solid-­‐
organ	  or	  bone	  marrow	  transplant	  recipients,	  HCMV	  infection	  or	  reactivation	  can	  
lead	  to	  severe	  diseases,	  causing	  high	  morbidity	  and	  mortality.	  HCMV	  is	  also	  a	  
leading	  cause	  for	  congenital	  birth	  defects	  and	  can	  lead	  to	  serious	  neurological	  
sequelae	  in	  children.	  The	  different	  disease	  manifestations	  correlate	  well	  with	  the	  
virus	  ability	  to	  establish	  infection	  in	  a	  wide	  range	  of	  cells	  in	  human	  body.	  	  This	  
dissertation	  is	  focused	  on	  the	  molecular	  mechanisms	  of	  HCMV	  entry	  into	  different	  
cell	  types.	  The	  work	  has	  improved	  our	  understanding	  of	  the	  mechanisms	  about	  
HCMV	  entry	  and	  tropism,	  which	  may	  help	  direct	  vaccine	  design	  that	  can	  be	  applied	  
to	  HCMV	  susceptible	  individuals	  in	  the	  future.	  	  
Overview	  of	  HCMV	  pathogenesis	  
HCMV	  epidemiology	  	  
HCMV	  is	  also	  known	  as	  human	  herpes	  virus	  5	  (HHV5).	  There	  are	  eight	  human	  
herpesviruses,	  which	  are	  herpes	  simplex	  virus	  1	  (HSV-­‐1,	  HHV1),	  herpes	  simplex	  
virus	  2	  (HSV-­‐2,	  HHV2),	  varicella	  zoster	  virus	  (VZV,	  HHV3),	  Epstein-­‐Barr	  virus	  (EBV,	  
HHV-­‐4),	  HHV6,	  HHV7	  and	  Kaposi’s	  Sarcoma	  virus	  (KSHV,	  HHV8).	  HSV-­‐1,	  HSV-­‐2	  and	  
VZV	  belong	  to	  alpha-­‐herpesvirus	  subfamily;	  HCMV	  and	  HHV6/7	  belong	  to	  beta-­‐
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herpesvirus	  subfamily;	  EBV	  and	  KSHV	  belong	  to	  gamma-­‐herpesvirus	  subfamily.	  The	  
pathogenesis	  features	  of	  all	  the	  human	  herpesviruses	  are	  compared	  in	  Table	  1-­‐1.	  	  
Table	  1-­‐1.	  Pathogenesis	  comparison	  of	  human	  herpesviruses.	  
	  
	  



























































































































B,	  T,	  NK-­‐cell	  tumor;	  















B	  cell	  tumors;	  
endothelial	  tumors	  	  
N/A	  
*Data	  and	  information	  shown	  in	  the	  table	  above	  is	  summarized	  from	  (1).	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HCMV	  primary	  infection	  is	  usually	  not	  associated	  with	  overt	  symptoms,	  
although	  some	  adults	  may	  experience	  mild	  mononucleosis-­‐like	  symptoms	  including	  
fever,	  fatigue	  or	  malaise.	  Following	  primary	  infection,	  HCMV,	  like	  all	  the	  other	  
herpesviruses,	  establishes	  a	  life-­‐long	  persistent	  or	  latent	  infection.	  Reactivation	  
happens	  periodically	  and	  reinfection	  with	  multiple	  HCMV	  strains	  may	  also	  occur	  (2–
7).	  HCMV	  is	  shed	  in	  various	  body	  fluids,	  particularly	  in	  saliva	  and	  urine.	  The	  person-­‐
to-­‐person	  transmission	  usually	  happens	  via	  close	  contact	  with	  body	  fluids,	  blood	  
transfusion	  or	  organ	  transplantation.	  HCMV	  is	  widespread,	  ranging	  from	  20%	  to	  95%	  
in	  the	  population,	  depending	  on	  the	  geographic	  locations,	  ethnicity	  and	  
socioeconomic	  status	  (SES).	  Primary	  infection	  can	  be	  acquired	  as	  a	  fetus,	  a	  neonate,	  
a	  child	  or	  an	  adult.	  It	  was	  estimated	  that	  the	  seroprevalence	  (as	  measured	  by	  the	  
presence	  of	  HCMV-­‐specific	  IgG	  in	  the	  serum)	  of	  HCMV	  was	  36.3%	  among	  6-­‐11	  years	  
old,	  49.3%	  among	  20-­‐29	  years	  old	  and	  90.8%	  in	  those	  above	  80	  years	  old	  in	  the	  
United	  States	  (8,	  9).	  Interestingly,	  several	  publications	  have	  showed	  that	  the	  uptake	  
of	  HCMV	  was	  much	  faster	  and	  occurred	  in	  a	  much	  younger	  group	  in	  the	  low	  SES	  
groups	  than	  in	  the	  high	  SES	  groups	  (Figure.	  1-­‐1)(10,	  11).	  The	  reason	  for	  this	  
differential	  is	  less	  clear.	  It	  is	  possible	  that	  factors,	  such	  as	  over-­‐crowded	  living	  place,	  
inadequate	  sanitation	  and	  different	  maternal-­‐infant	  feeding	  habits,	  could	  influence	  
the	  chance	  of	  HCMV	  acquisition	  in	  the	  young	  age.	  
	   	  










Figure	   1-­‐1	   Model	   for	   the	   relationship	   between	   socioeconomic	   status	   and	   the	  
cumulative	  HCMV	  seroprevalence	  by	  age.	  	  
(Modified	  from	  (10)).	  
HCMV	  pathogenesis	  in	  immunocompromised	  individuals	  
HCMV	  is	  often	  referred	  to	  as	  an	  “opportunistic	  pathogen”,	  which	  mainly	  reflects	  
the	  fact	  that	  this	  virus	  causes	  overt	  disease	  manifestations	  when	  host	  immune	  
system	  is	  weakened	  or	  immature.	  In	  HIV/AIDS	  patients,	  whose	  immune	  system	  
suffer	  severe	  infliction	  from	  loss	  of	  CD4	  T	  cells,	  reactivation	  or	  reinfection	  by	  HCMV	  
can	  cause	  serious	  diseases,	  including	  retinitis,	  pneumonitis,	  gastrointestinal	  
diseases,	  and	  encephalitis,	  with	  retinitis	  accounting	  for	  85%	  of	  the	  cases	  (12).	  
Antiretroviral	  drugs	  that	  maintain	  the	  blood	  CD4	  T	  cells	  counts	  above	  100	  
cells/mm3	  exhibit	  efficient	  prophylaxis	  treatment	  for	  HCMV	  retinitis	  in	  AIDS	  
patients,	  confirming	  the	  notion	  that	  sufficient	  immune	  response	  is	  an	  absolute	  
requirement	  for	  controlling	  HCMV	  infection.	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For	  solid-­‐organ	  or	  bone	  marrow	  transplant	  recipients,	  who	  have	  been	  on	  
immunosuppression	  drugs,	  HCMV	  reactivation	  or	  reinfection	  is	  common,	  ranging	  
from	  20~70%	  during	  the	  first	  year	  post	  transplantation.	  The	  infection	  is	  often	  
associated	  with	  diseases	  including	  pneumonia,	  retinitis,	  hepatitis	  and	  encephalitis	  
(13).	  Moreover,	  HCMV	  likely	  contributes	  to	  the	  graft	  failure	  in	  hematopoietic	  stem	  
cell	  transplantation	  by	  inducing	  bone	  marrow	  hypoplasia	  (14).	  Also,	  in	  the	  case	  of	  
solid-­‐organ	  transplantation,	  HCMV	  infection	  is	  associated	  with	  both	  acute	  and	  
chronic	  graft	  rejections	  (15).	  	  It	  was	  thought	  that	  HCMV-­‐mediated	  injury	  and	  
inflammation	  response	  can	  lead	  to	  the	  state	  of	  transplant	  vascular	  sclerosis,	  which	  
eventually	  results	  in	  graft	  failure	  due	  to	  ischemia.	  Antiviral	  drugs	  that	  inhibit	  HCMV	  
DNA	  replication,	  like	  ganciclovir	  or	  its	  analogs,	  can	  delay	  the	  graft	  rejection	  and	  
improve	  the	  patient	  outcomes	  related	  to	  HCMV	  infection	  (16).	  	  
HCMV	  congenital	  infection	  
HCMV	  is	  the	  leading	  cause	  for	  congenital	  infections	  and	  birth	  defects	  in	  the	  
United	  States,	  affecting	  from	  0.2%	  to	  as	  high	  as	  6%	  of	  all	  live	  births	  (17,	  18).	  It	  was	  
estimated	  that	  each	  year	  in	  the	  United	  States,	  about	  40,000	  children	  are	  born	  with	  
congenital	  HCMV	  infection,	  resulting	  in	  an	  estimated	  400	  deaths	  and	  leaving	  8,000	  
children	  with	  permanent	  neurological	  sequelae,	  such	  as	  hearing	  loss,	  vision	  loss,	  
mental	  retardation	  or	  movement	  disabilities	  (19–21).	  Annual	  economic	  costs	  of	  
caring	  for	  those	  affected	  children	  were	  estimated	  at	  $1-­‐$2	  billion	  in	  the	  United	  
States	  (19).	  Moreover,	  while	  HCMV-­‐associated	  diseases	  in	  AIDS	  or	  transplant	  
patients	  can	  be	  prevented,	  controlled	  or	  cured	  by	  antiviral	  drugs,	  HCMV-­‐associated	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congenital	  injuries	  are	  usually	  irreversible	  even	  with	  antiviral	  therapy.	  These	  huge	  
economic	  burdens	  and	  severe	  health	  problems	  highlight	  the	  priority	  of	  HCMV	  
vaccine	  development	  (22,	  23).	  	  
Congenital	  HCMV	  infection	  is	  caused	  by	  vertical	  transmission	  of	  the	  virus	  from	  
mother	  to	  fetus	  through	  placenta,	  as	  a	  result	  of	  the	  following	  situations:	  maternal	  
primary	  infection,	  reinfection	  with	  different	  strains,	  or	  reactivation	  of	  latent	  virus	  
(24–28).	  Women	  who	  experience	  primary	  infection	  during	  pregnancy	  have	  a	  
transmission	  rate	  about	  30~40%,	  which	  is	  higher	  compared	  to	  women	  who	  
experience	  non-­‐primary	  infection	  (i.e.,	  reinfection	  or	  reactivation)	  (18,	  29).	  
Moreover,	  maternal	  primary	  infection	  is	  more	  likely	  to	  result	  in	  severe	  sequelae	  in	  
children	  born	  with	  HCMV	  congenital	  infections	  (9,	  18).	  These	  observations	  indicate	  
that	  the	  preexisting	  maternal	  immunity	  provides	  some,	  although	  incomplete	  
protection	  to	  fetus	  from	  HCMV.	  This	  “incomplete	  maternal	  protection”	  might	  be	  due	  
to	  the	  limit	  of	  the	  preexisting	  immunity	  to	  control	  the	  reinfection	  conducted	  by	  new	  
strains	  of	  the	  virus	  or	  the	  reactivation	  of	  the	  existing	  virus.	  	  
HCMV	  pathogenesis	  in	  immunocompetent	  individuals	  
As	  aforementioned,	  HCMV	  infection	  in	  healthy	  individuals	  is	  generally	  
asymptomatic,	  due	  to	  a	  competent	  immune	  system	  that	  controls	  the	  virus	  
replication	  efficiently.	  And	  it	  may	  also	  reflect	  the	  fact	  that	  HCMV	  is	  an	  ancient	  virus	  
evolved	  from	  a	  progenitor	  more	  than	  100	  million	  year	  ago	  (30,	  31),	  and	  this	  long-­‐
time	  coevolution	  with	  human	  hosts	  leads	  to	  a	  fine-­‐balanced	  coexistence	  status.	  
Therefore,	  HCMV	  is	  generally	  thought	  to	  be	  an	  innocuous	  human	  pathogen.	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However,	  recent	  studies	  have	  raised	  the	  concern	  for	  HCMV	  pathogenesis	  even	  in	  
healthy	  individuals.	  First,	  for	  healthy	  seropositive	  individuals	  who	  have	  been	  
critically	  ill	  because	  of	  burns,	  septic	  shock	  or	  heart	  disease,	  reactivation	  of	  HCMV	  
happens	  at	  30%	  rate,	  leading	  to	  viremia	  and	  in	  some	  cases,	  increasing	  mortality	  
(32).	  In	  addition,	  HCMV	  persistent	  infection	  seems	  to	  contribute	  to	  the	  dysfunction	  
and	  down-­‐regulation	  of	  immune	  system	  exhibited	  in	  elderly	  individuals	  (12,	  33).	  
Moreover,	  there	  is	  evidence	  suggesting	  that	  HCMV	  infection	  might	  be	  associated	  
with	  some	  human	  autoimmune	  diseases,	  although	  the	  causative	  linkage	  is	  still	  
lacking	  to	  date	  (34).	  HCMV	  may	  also	  be	  involved	  in	  the	  development	  and	  
acceleration	  of	  atherosclerosis	  through	  a	  chronic	  inflammatory	  process	  (35,	  36).	  
Although	  there	  are	  still	  a	  lot	  of	  controversies	  in	  the	  literature	  about	  the	  negative	  
role	  of	  HCMV	  in	  affecting	  healthy	  individuals,	  this	  virus	  might	  be	  an	  underestimated	  
pathogen	  and	  may	  associate	  with	  more	  diseases	  than	  what	  is	  previously	  
acknowledged.	  	  	  
Overview	  of	  HCMV	  biology	  
HCMV	  virion	  structure	  
HCMV	  double-­‐stranded	  linear	  DNA	  genome	  is	  encased	  inside	  of	  an	  icosahedral	  
capsid,	  which	  is	  surrounded	  by	  a	  less	  structured	  layer	  of	  viral	  proteins,	  called	  
tegument.	  These	  components	  are	  enclosed	  in	  a	  lipid	  bilayer	  envelope	  that	  is	  studded	  
by	  a	  number	  of	  viral	  glycoproteins	  (Figure.	  1-­‐2).	  Mature	  virion	  size	  is	  about	  
200~300	  nanometer	  (nm)	  in	  diameter.	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Figure	  1-­‐2	  HCMV	  virion	  structure.	  
a)	  Electron	  microscopy	  picture	  (37).	  b)	  Schematic	  picture	  (38).	  
1)	  Genome	  
Compared	  to	  other	  human	  herpesviruses,	  HCMV	  contains	  the	  biggest	  genome	  
of	  >230Kb	  (39).	  Due	  to	  high	  packing	  density,	  HCMV	  genome	  is	  estimated	  to	  be	  at	  a	  
liquid-­‐crystalline	  state	  inside	  of	  the	  capsid	  (40).	  The	  coding	  capacity	  of	  HCMV	  is	  big	  
compared	  to	  other	  herpesviruses,	  with	  more	  than	  200	  predicted	  open	  reading	  
frames	  (ORFs)	  (39,	  41–43).	  The	  genome	  is	  composed	  of	  the	  unique	  long	  (UL)	  and	  
unique	  short	  (US)	  segments,	  which	  are	  flanked	  by	  terminal	  repeated	  sequences	  TRL	  
(ab)	  and	  TRS	  (ca)	  on	  one	  end	  and	  internal	  repeated	  sequences	  IRL	  (b’a’)	  (lab	  strain	  
contains	  IRL	  while	  clinical	  strain	  does	  not)	  and	  IRS	  (a’c’)	  on	  the	  other	  end,	  resulting	  
in	  a	  total	  TRL-­‐UL-­‐(IRL)-­‐IRS-­‐US-­‐TRS	  configuration	  (Figure.	  1-­‐3).	  HCMV	  genes	  are	  
named	  with	  a	  prefix	  based	  on	  the	  segments	  where	  they	  are	  located	  and	  are	  
numbered	  sequentially	  (39),	  for	  instance,	  ORF	  74	  in	  UL	  region	  is	  named	  UL74,	  and	  
the	  protein	  encoded	  by	  this	  ORF	  is	  named	  pUL74.	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  Figure	  1-­‐3	  Schematic	  genome	  organization	  of	  HCMV.	  
	  The	  letters	  within	  each	  segment	  depicts	  the	  following	  features:	  terminal	  repeat	   long	  (TRL),	  unique	  
long	   (UL),	   internal	   repeat	   long	   (IRL),	   internal	   repeat	   short	   (IRS),	   unique	   short	   (US),	   and	   terminal	  
repeat	  short	  (TRS)	  (modified	  from	  (41)).	  
2)	  Capsid	  	  
HCMV	  capsid	  is	  about	  130	  nm	  in	  diameter	  (44).	  There	  are	  four	  main	  component	  
proteins:	  major	  capsid	  protein	  (MCP;	  pUL86),	  minor	  capsid	  protein	  (mCP;	  pUL85),	  
minor	  capsid	  binding	  protein	  (mC-­‐BP;	  pUL46),	  and	  smallest	  capsid	  protein	  (SCP;	  
pUL48.5).	  MCP	  is	  the	  most	  abundant	  component	  in	  capsid	  (45–49).	  The	  162	  
capsomeres	  (150	  hexons	  plus	  12	  pentons)	  are	  formed	  by	  MCP,	  which	  are	  located	  at	  
the	  vertices	  of	  the	  T=16	  icosahedral	  symmetry.	  Heterotrimers	  formed	  by	  two	  mCP	  
and	  one	  mC-­‐BP	  comprise	  of	  the	  320	  triplexes	  located	  in	  between	  the	  capsomeres	  
(Figure.	  1-­‐4)	  (44,	  50–52).	  SCP	  decorates	  each	  MCP	  hexon	  in	  the	  mature	  capsid	  and	  
stabilizes	  the	  capsid	  structure	  through	  interaction	  with	  tegument	  proteins	  (53).	  One	  
of	  the	  penton	  is	  shared	  with	  or	  occupied	  by	  a	  portal	  complex	  (formed	  by	  pUL104),	  
through	  which	  the	  genome	  enters	  or	  leaves	  the	  capsid	  (54).	  
	   	  










Figure	  1-­‐4	  Structure	  of	  HCMV	  capsid	  in	  a	  T-­‐16	  symmetry.	  
The	  arrows	  point	  to	  penton,	  hexon	  and	  triplex	  (modified	  from	  (51)).	  
3)	  Tegument	  	  
HCMV	  tegument	  is	  an	  approximately	  60-­‐100	  nm	  thick	  unstructured	  layer	  of	  
proteins	  (50,	  55).	  It	  contains	  the	  most	  abundant	  proteins	  in	  the	  virion	  (49,	  56).	  Most	  
of	  the	  viral	  tegument	  proteins	  are	  phosphorylated,	  thus	  they	  are	  usually	  named	  with	  
the	  prefix	  pp,	  for	  phosphoprotein.	  Since	  no	  common	  signal	  sequences	  were	  found	  to	  
specifically	  direct	  proteins	  into	  tegument,	  the	  packaging	  mechanisms	  of	  tegument	  
are	  less	  clear.	  However,	  phosphorylation,	  interactions	  with	  viral	  capsid	  or	  the	  C-­‐
terminal	  tail	  of	  envelope	  glycoproteins	  might	  facilitate	  the	  incorporation	  process.	  
Besides	  viral	  proteins,	  about	  70	  cellular	  proteins	  were	  found	  in	  the	  HCMV	  virions,	  
most	  of	  which	  were	  probably	  in	  the	  layer	  of	  tegument	  (49).	  Moreover,	  viral	  or	  
cellular	  RNA	  molecules	  are	  also	  packaged	  into	  tegument.	  The	  significance	  and	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It	  has	  been	  appreciated	  for	  a	  long	  time	  that	  HCMV	  tegument	  proteins	  could	  
involve	  in	  the	  early	  stages	  of	  the	  infection,	  thus	  they	  are	  packaged	  within	  the	  virion	  
as	  a	  “tool	  box”	  to	  ensure	  their	  presence	  upon	  a	  new	  round	  of	  infection	  before	  the	  de	  
novo	  proteins	  synthesis.	  For	  example,	  upon	  entry,	  viral	  tegument	  protein	  pUL47	  
facilitate	  genome-­‐containing	  capsid	  moving	  along	  microtubules	  to	  the	  nuclear	  pore	  
through	  interactions	  with	  the	  capsid	  protein,	  and	  might	  also	  help	  the	  subsequential	  
DNA	  release	  into	  the	  nucleus	  (57).	  In	  addition,	  viral	  tegument	  proteins	  could	  also	  
play	  a	  critical	  role	  in	  gene	  expression.	  For	  example,	  after	  viral	  DNA	  is	  released	  into	  
nucleus,	  a	  cellular	  protein	  Daxx	  is	  recruited	  to	  major	  immediate	  early	  promoters	  to	  
repress	  viral	  gene	  transcription.	  Tegument	  protein	  pp71,	  encoded	  by	  UL82,	  gets	  
inside	  of	  the	  nucleus	  independently	  from	  the	  capsid	  and	  induces	  the	  proteasome	  
degradation	  of	  Daxx,	  thus	  activating	  viral	  immediate-­‐early	  (IE)	  gene	  expression	  (58,	  
59).	  If	  this	  process	  occurs	  successfully,	  HCMV	  proceeds	  into	  lytic	  infection,	  however,	  
if	  pp71	  gets	  trapped	  in	  the	  cytoplasm	  and	  Daxx	  represses	  IE	  gene	  expression,	  latent	  
infection	  would	  be	  established	  (56).	  Furthermore,	  viral	  tegument	  protein	  also	  
influences	  late	  stages	  of	  the	  infection,	  e.g.	  assembly	  and	  egress.	  pp150,	  encoded	  by	  
UL32,	  likely	  directs	  capsid	  to	  the	  assembly	  compartments	  for	  its	  packaging	  into	  the	  
mature	  viral	  particle	  (60).	  	  
Last	  but	  not	  least,	  viral	  tegument	  proteins	  could	  modulate	  host	  cell	  antiviral	  
immune	  response.	  pp65,	  gene	  product	  of	  UL83,	  is	  the	  most	  abundant	  protein	  in	  the	  
virion	  (49).	  While	  the	  gene	  is	  totally	  dispensable	  for	  virus	  replication	  in	  tissue	  
culture,	  the	  product	  of	  it	  is	  very	  important	  for	  virus	  immune	  evasion.	  pp65	  achieves	  
this	  goal	  through	  several	  mechanisms,	  including:	  1)	  it	  mediates	  the	  phosphorylation	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of	  viral	  IE	  proteins	  to	  block	  the	  recognition	  of	  IE	  proteins	  by	  MHC	  class	  I	  molecules	  
(61);	  2)	  it	  downregulates	  the	  surface	  presentation	  of	  MHC	  class	  II	  molecules	  by	  
targeting	  them	  to	  lysosomal	  degradation	  (62);	  and	  3)	  it	  attenuates	  the	  interferon	  
response	  (63).	  Since	  pp65	  plays	  such	  an	  important	  role	  in	  counteracting	  host	  
immune	  response,	  it	  is	  probably	  not	  surprising	  that	  it	  is	  a	  major	  antigen	  target	  for	  
cytotoxic	  T	  lymphocytes	  (64).	  	  
In	  conclusion,	  HCMV	  viral	  proteins	  residing	  in	  the	  tegument	  layer	  are	  involved	  
in	  a	  wide	  variety	  of	  events	  during	  viral	  replication	  cycle.	  Thus	  a	  better	  
understanding	  of	  their	  functions	  will	  benefit	  the	  intervention	  strategies	  against	  
HCMV	  in	  the	  future.	  	  
4)	  Envelope	  
Herpesvirus	  acquires	  its	  viral	  envelope	  through	  an	  envelopment-­‐
deenvelopment-­‐reenvelopment	  process.	  Viral	  capsid	  acquires	  the	  primary	  envelope	  
through	  budding	  into	  the	  inner	  nuclear	  membrane,	  loses	  that	  envelope	  while	  exiting	  
the	  outer	  nuclear	  membrane.	  Once	  getting	  into	  the	  cytoplasm,	  viral	  capsid	  acquires	  
the	  secondary	  envelope	  (which	  is	  the	  final	  envelope)	  through	  budding	  into	  the	  
Golgi-­‐derived	  assembly	  apparatus	  membrane.	  HCMV	  potentially	  encodes	  75	  
membrane-­‐associated	  proteins,	  at	  least	  25	  of	  which	  are	  found	  on	  the	  envelope	  (41,	  
49).	  Most	  of	  the	  envelope	  proteins	  are	  glycosylated.	  Thus,	  they	  are	  often	  named	  with	  
a	  prefix	  g,	  for	  glycoprotein.	  The	  functions	  of	  most	  of	  those	  glycoproteins	  are	  still	  
elusive,	  but	  the	  hypothesis	  is	  that	  they	  mainly	  participate	  in	  the	  initiation	  of	  an	  
infection.	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Early	  studies	  have	  identified	  three	  families	  of	  glycoprotein	  complexes	  on	  HCMV	  
envelope	  (designated	  as	  gC-­‐I,	  gC-­‐II,	  and	  gC-­‐III)	  (65,	  66).	  The	  functions	  and	  
compositions	  of	  those	  complexes	  are	  becoming	  clearer	  now:	  gC-­‐I	  is	  the	  
homotrimeric	  complexes	  of	  gB.	  gB,	  encoded	  by	  UL55,	  is	  the	  fusion	  protein	  that	  
mediates	  the	  membrane	  fusion	  between	  viral	  envelope	  and	  cellular	  membrane	  (67).	  
Besides	  acting	  as	  a	  fusogen,	  gB	  is	  also	  thought	  to	  initiate	  HCMV	  absorption	  onto	  the	  
target	  cell	  through	  interactions	  with	  cell	  surface	  proteins,	  like	  heparan	  sulfate	  
proteoglycans	  (HSPGs)	  (68,	  69).	  gC-­‐II	  is	  the	  heterodimeric	  complex	  formed	  by	  gM	  
disulfide-­‐linked	  to	  gN	  (70).	  gM/gN,	  encoded	  by	  UL100	  and	  UL73	  respectively,	  are	  
the	  most	  abundant	  component	  on	  the	  virion	  envelope	  (49).	  	  gM/gN	  are	  essential	  for	  
virus	  replication,	  and	  studies	  suggest	  that	  the	  complex	  likely	  participate	  in	  both	  
viral	  initial	  attachment	  and	  also	  assembly	  and	  egress	  processes	  (71,	  72).	  gC-­‐III	  is	  the	  
disulfide-­‐linked	  gH/gL/gO	  complex	  (73–76).	  Recently,	  another	  gH/gL	  complex	  was	  
identified,	  gH/gL/UL128-­‐131	  (UL128-­‐131	  are	  small	  proteins	  encoded	  by	  UL128-­‐
131	  genes)	  (77–80).	  Both	  gH/gL	  complexes	  are	  very	  important	  for	  HCMV	  entry.	  The	  
characterization	  of	  their	  functions	  is	  one	  of	  the	  research	  focuses	  of	  this	  dissertation,	  
thus	  more	  detail	  will	  be	  described	  or	  discussed	  in	  the	  following	  chapters.	  	  
Viral	  envelope	  glycoproteins	  are	  the	  main	  immunogens.	  Anti-­‐gB,	  anti-­‐gM,	  anti-­‐
gN,	  anti-­‐gH,	  anti-­‐gL	  and	  anti-­‐UL128-­‐131	  neutralizing	  antibodies	  have	  all	  been	  
described	  (81–85).	  Among	  all	  the	  glycoproteins	  listed	  above,	  gB,	  gH/gL,	  gM	  and	  
UL128-­‐131	  are	  highly	  conserved	  among	  all	  strains	  of	  HCMV,	  while	  gN	  and	  gO	  are	  
highly	  variable	  in	  amino	  acid	  sequences	  (86–89).	  The	  significance	  of	  this	  sequence	  
diversity	  is	  less	  clear,	  but	  might	  reflect	  an	  immune	  evasion	  role	  of	  these	  proteins.	  
	   15	  
Besides	  viral	  glycoproteins,	  HCMV	  envelope	  also	  contains	  numbers	  of	  cellular	  
proteins,	  such	  as	  CD46,	  CD55,	  CD59	  and	  annexin	  II	  (90–93).	  CD46,	  CD55,	  and	  CD59	  
are	  the	  host-­‐encoded	  complement	  regulatory	  proteins.	  The	  incorporation	  of	  these	  
proteins	  into	  virion	  envelope	  might	  be	  a	  smart	  way	  of	  the	  virus	  to	  prevent	  
complement-­‐mediated	  lysis	  (91).	  Annexin	  II	  is	  a	  ubiquitous	  host	  protein	  distributed	  
on	  cell	  surface	  or	  on	  the	  intracellular	  membranes.	  It	  is	  involved	  in	  a	  lot	  of	  cell	  
processes,	  including	  cell	  mobility,	  endocytosis,	  and	  exocytosis.	  Annexin	  II	  might	  
enhance	  virus	  binding	  to	  phospholipid	  membrane,	  but	  it	  is	  not	  found	  to	  influence	  
HCMV	  entry	  into	  fibroblast	  cells	  (94,	  95).	  Another	  possibility	  is	  that	  annexin	  II,	  as	  
part	  of	  the	  virion,	  might	  play	  a	  role	  in	  modulating	  host	  cell	  responses	  during	  viral	  
replication.	  
HCMV	  replication	  cycle	  
1)	  Attachment	  and	  entry	  
Virus	  replication	  cycle	  begins	  by	  attachment	  and	  entry	  process,	  which	  is	  
initiated	  by	  the	  random	  collision	  between	  virus	  particle	  and	  the	  target	  cell,	  followed	  
by	  tethering	  of	  viral	  particle	  to	  cell	  surface	  and	  then	  entering	  of	  the	  virus	  into	  the	  
cell.	  Studies	  have	  shown	  that	  HCMV	  attachment	  is	  initiated	  by	  low-­‐affinity	  binding	  of	  
viral	  gB	  and	  gM/gN	  with	  cell	  surface	  heparan	  sulfate	  proteoglycans	  (HSPGs)	  (96,	  
97),	  this	  step	  helps	  to	  concentrate	  viral	  particles	  on	  cell	  surface,	  thus	  may	  increase	  
the	  chance	  that	  viral	  particles	  could	  interact	  with	  downstream	  receptors	  exhibiting	  
lower	  avidity.	  A	  subsequent	  quick	  switch	  to	  a	  more	  stable	  docking	  occurs	  by	  
interaction	  between	  gB	  and	  the	  epidermal	  growth	  factor	  receptor	  (EGFR),	  platelet	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derived	  growth	  factor	  receptor	  (PDGFR-­‐alpha)	  or	  integrin	  α2β1,	  α6β1,	  αVβ3	  (98–
100).	  Although	  more	  recent	  studies	  didn’t	  support	  their	  roles	  as	  HCMV	  entry	  
receptors,	  the	  interaction	  with	  them	  probably	  further	  facilitates	  virus	  attachment	  
(101,	  102).	  	  
	  Depending	  on	  the	  cell	  type	  that	  HCMV	  encounters,	  entry	  could	  happen	  directly	  
at	  plasma	  membrane	  or	  from	  within	  the	  endosome	  (Figure.	  1-­‐5).	  Regardless	  of	  
either	  entry	  pathway,	  the	  critical	  event	  is	  viral	  envelope	  fusion	  with	  cellular	  
membranes,	  which	  is	  mediated	  by	  the	  “core	  fusion	  machinery”	  comprised	  of	  gB	  and	  
gH/gL.	  After	  membrane	  fusion,	  HCMV	  deposits	  its	  viral	  components	  into	  the	  
cytoplasm.	  Genome-­‐containing	  capsid,	  facilitated	  by	  some	  tegument	  proteins,	  is	  
transported	  to	  nuclear	  pores	  along	  microtubules	  and	  DNA	  genome	  is	  released	  into	  
nucleus	  afterwards	  (Figure.	  1-­‐5).	  At	  the	  same	  time,	  other	  tegument	  proteins	  diffuse	  
to	  nucleus	  independently	  or	  stay	  in	  different	  subcellular	  locations	  to	  either	  regulate	  
viral	  gene	  expression	  or	  inhibit	  host	  cell	  anti-­‐viral	  immune	  response.	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Figure	  1-­‐5	  Schematic	  of	  HCMV	  replication	  cycle.	  
(Modified	  from	  (103)).	  Detailed	  description	  of	  the	  diagram	  is	  given	  in	  the	  text.	  
2)	  Gene	  expression	  
The	  expression	  of	  HCMV	  viral	  proteins	  is	  finely	  regulated,	  and	  falls	  into	  a	  
cascade	  of	  events,	  which	  are	  divided	  into	  three	  main	  temporal	  classes:	  immediate	  
early	  (IE),	  delayed	  early	  (DE)	  and	  late	  (L)	  (Figure.	  1-­‐5).	  IE	  genes	  are	  immediately	  
expressed	  following	  nuclear	  entry,	  in	  absence	  of	  any	  de	  novo	  protein	  synthesis.	  
Their	  expression	  can	  be	  detected	  within	  a	  few	  hours	  in	  HCMV	  infected	  cells	  (104).	  IE	  
genes	  are	  transcribed	  by	  RNA	  polymerase	  II	  of	  the	  host	  cell	  under	  the	  control	  of	  
major	  immediate	  early	  promoter	  (MIEP).	  The	  most	  abundant	  IE	  proteins	  are	  IE1-­‐72	  
kDa	  (pUL123),	  and	  IE2-­‐86	  kDa	  (pUL122)	  (39,	  104).	  IE1-­‐72	  kDa	  is	  necessary	  for	  
efficient	  viral	  replication	  after	  low	  MOI	  infection	  (105).	  IE2-­‐86	  kDa	  is	  critical	  for	  
viral	  DE	  genes	  expression	  and	  it	  can	  negatively	  regulate	  the	  transcription	  of	  IE1	  and	  
IE2	  genes	  (106,	  107).	  Together	  they	  act	  as	  trans-­‐activators	  to	  stimulate	  the	  
transcription	  of	  various	  viral	  and	  host	  genes,	  which	  are	  important	  for	  the	  efficiency	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of	  viral	  replication	  (108).	  The	  progression	  of	  IE	  gene	  expression	  is	  very	  important	  in	  
deciding	  virus	  fate	  of	  productive	  infection	  versus	  latent	  infection.	  
Expression	  of	  DE	  genes	  depends	  on	  IE	  gene	  expression.	  The	  products	  of	  DE	  
genes	  are	  often	  directly	  involved	  in	  viral	  DNA	  replication	  (e.g.,	  DNA	  polymerase)	  or	  
priming	  the	  cellular	  environment	  ready	  for	  viral	  DNA	  replication	  (e.g.,	  up-­‐regulation	  
of	  cellular	  genes	  exhibited	  in	  S-­‐phase).	  And	  the	  kinetics	  of	  DE	  gene	  expression	  varies	  
from	  as	  early	  as	  after	  IE	  gene	  expression	  to	  as	  late	  as	  before	  viral	  DNA	  synthesis.	  	  
Expression	  of	  L	  genes	  is	  largely	  dependent	  on	  viral	  DNA	  replication.	  There	  are	  
two	  groups	  of	  L	  genes:	  leaky-­‐late	  and	  true-­‐late	  genes.	  Leaky-­‐late	  genes	  are	  
expressed	  at	  very	  low	  level	  at	  early	  times	  and	  the	  levels	  are	  tremendously	  increased	  
at	  late	  times.	  True-­‐late	  genes	  are	  exclusively	  after,	  and	  dependent	  on	  viral	  DNA	  
replication.	  	  L	  genes	  are	  expressed	  about	  24-­‐48	  hours	  after	  infection,	  the	  products	  of	  
which	  are	  often	  structure	  proteins	  that	  are	  required	  for	  viral	  assembly	  and	  egress.	  
3)	  Gene	  replication	  
Soon	  after	  deposited	  into	  the	  nucleus,	  HCMV	  linear	  DNA	  genome	  is	  rapidly	  
circularized	  and	  serves	  as	  the	  template	  for	  transcription	  and	  replication.	  The	  
initiation	  position	  of	  DNA	  replication	  resides	  at	  a	  defined	  region	  on	  the	  genome,	  the	  
so-­‐called	  lytic	  origins	  of	  replication,	  oriLyt.	  The	  oriLyt	  for	  HCMV	  is	  identified	  in	  the	  
middle	  of	  the	  UL	  segment,	  upstream	  of	  the	  gene	  (UL57)	  that	  encodes	  the	  single-­‐
stranded	  DNA	  binding	  protein	  (109,	  110).	  Approximately	  at	  16	  hours	  post	  infection,	  
DNA	  synthesis	  takes	  place	  in	  the	  vicinity	  of	  oriLyt	  as	  soon	  as	  essential	  viral	  proteins	  
are	  present.	  The	  core	  DNA	  replication	  proteins	  include	  helicase-­‐primase	  complex	  
(formed	  by	  pUL105,	  pUL70	  and	  pUL102),	  DNA	  polymerase	  (pUL54),	  polymerase	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accessory	  protein	  (pUL44)	  and	  single-­‐stranded	  DNA	  binding	  protein	  (pUL57).	  
Another	  protein,	  gene	  product	  of	  UL84,	  is	  also	  essential.	  pUL84	  is	  thought	  to	  trans-­‐
activate	  a	  responsive	  promoter	  within	  the	  oriLyt	  through	  interaction	  with	  IE2-­‐
86KDa,	  the	  process	  of	  which	  might	  partly	  initiate	  DNA	  replication	  (111).	  Moreover,	  
study	  also	  showed	  that	  pUL84	  has	  UTPase	  activity,	  which	  may	  help	  generate	  energy	  
needed	  for	  helicase	  activity	  in	  the	  initiation	  of	  DNA	  replication	  (112).	  	  
The	  initiation	  of	  DNA	  replication	  for	  alpha-­‐herpesviruses	  is	  thought	  to	  involve	  
an	  origin-­‐binding	  protein	  (OBP),	  which	  binds	  to	  specific	  origin	  sequences	  to	  provide	  
the	  initial	  unwinding	  spot	  with	  its	  intrinsic	  helicase	  activity.	  Since	  HCMV	  lacks	  the	  
homologue	  to	  OBP,	  the	  mechanism	  of	  initiation	  is	  less	  clear.	  One	  interesting	  model	  is	  
that	  RNA-­‐DNA	  hybrid	  formed	  during	  transcription	  may	  yield	  an	  open	  region	  that	  
could	  be	  used	  as	  the	  initial	  spot.	  This	  hypothesis	  is	  in	  concert	  with	  the	  trans-­‐
activator	  property	  of	  the	  replication	  essential	  protein	  pUL84.	  An	  alternative	  but	  not	  
mutually	  exclusive	  possibility	  is	  that	  HCMV	  could	  make	  use	  of	  cellular	  initiation	  
machinery.	  	  
While	  alpha-­‐herpesvirus	  DNA	  replication	  is	  believed	  to	  begin	  with	  a	  
bidirectional	  theta-­‐like	  mechanism,	  followed	  by	  a	  unidirectional	  rolling-­‐circle	  
mechanism	  at	  later	  stage	  (1),	  HCMV	  likely	  exclusively	  relies	  on	  the	  rolling-­‐circle	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4)	  Assembly	  and	  egress	  
a) Assembly	  and	  egress	  in	  nucleus	  
The	  first	  step	  in	  HCMV	  assembly	  and	  egress	  involves	  capsid	  assembly	  and	  
genome	  packaging	  in	  the	  nucleus	  (Figure.	  1-­‐5).	  Capsid	  assembly	  initiates	  with	  the	  
formation	  of	  a	  scaffold	  that	  could	  “crystalize”	  the	  capsid.	  There	  are	  two	  scaffolding	  
proteins	  identified	  for	  HCMV,	  pUL80	  and	  pUL80.5	  (113,	  114).	  Both	  proteins	  can	  
interact	  with	  MCP	  through	  carboxyl	  terminus	  and	  lead	  to	  the	  translocation	  of	  MCP	  
from	  cytoplasm	  to	  nucleus.	  The	  amino	  terminus	  of	  pUL80	  and	  pUL80.5	  promotes	  
self-­‐interactions,	  resulting	  in	  the	  generation	  of	  MCP	  multimers	  and	  formation	  of	  
hexons	  and	  pentons	  (115,	  116).	  At	  the	  same	  time,	  mCP	  and	  mc-­‐BP	  translocate	  into	  
nucleus	  to	  form	  triplexes.	  Hexons	  and	  pentons,	  together	  with	  triplexes,	  form	  an	  
immature	  capsid	  shell.	  Next	  step	  is	  genome	  packaging.	  Two	  conserved	  sequence	  
motifs,	  pac-­‐1	  and	  pac-­‐2,	  are	  located	  at	  each	  end	  of	  the	  concatemeric	  HCMV	  DNA	  
sequence.	  Viral	  terminase	  complex	  comprised	  of	  pUL56	  and	  pUL89	  recognizes	  pac-­‐1	  
and	  pac-­‐2	  and	  cleaves	  DNA	  into	  genome-­‐length	  units	  (117,	  118).	  Before	  DNA	  
packaging,	  scaffolding	  protein	  pUL80	  and	  pUL80.5	  is	  disassociated	  from	  MCP	  by	  a	  
protelytic	  cleavage	  at	  the	  carboxyl	  terminus.	  Then,	  insertion	  of	  DNA	  genome	  into	  
capsid	  occurs	  through	  the	  portal	  formed	  by	  pUL104,	  coupled	  with	  the	  extrusion	  of	  
the	  scaffolding	  protein	  remainders.	  It	  is	  worth	  noting	  that	  capsid	  formation	  and	  
DNA	  packaging	  do	  not	  necessarily	  accompany	  each	  other.	  In	  fact,	  there	  are	  three	  
types	  of	  viral	  capsid	  that	  could	  form:	  1)	  A-­‐capsid	  is	  an	  empty	  capsid	  lacking	  genome,	  
which	  is	  a	  result	  of	  failure	  in	  DNA	  packaging;	  2)	  B-­‐capsid	  is	  an	  immature,	  scaffold	  
containing	  capsids	  that	  lacks	  genome,	  probably	  due	  to	  unsuccessful	  proteolytic	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digestion	  of	  scaffolding	  proteins;	  and	  3)	  C-­‐capsid	  is	  the	  mature,	  genome-­‐containing	  
capsid.	  Only	  C	  capsid	  will	  generate	  infectious	  viral	  particles.	  Although	  A-­‐,	  B-­‐capsids	  
are	  not	  infectious,	  they	  might	  affect	  viral	  replication	  cycle	  somehow.	  	  
Nucleocapsid	  will	  then	  go	  through	  a	  process	  known	  as	  nuclear	  egress	  or	  
primary	  envelopment.	  Nuclear	  lamina,	  a	  network	  of	  proteins	  underlying	  the	  
nucleoplasmic	  side	  of	  the	  inner	  nuclear	  membrane	  (INM)	  is	  the	  first	  obstacle.	  
Disruption	  of	  the	  nuclear	  lamina	  is	  essential	  to	  gain	  access	  to	  the	  inner	  nuclear	  
membrane	  (INM).	  HCMV	  cleverly	  finds	  a	  way	  to	  achieve	  that	  by	  mimicking	  the	  
phosphorylation-­‐mediated	  depolymerizaion	  of	  nuclear	  lamina	  occurring	  during	  
cellular	  mitosis.	  Virus	  encodes	  a	  nuclear	  egress	  complex	  (NEC),	  comprised	  of	  pUL50	  
and	  pUL53.	  pUL50	  is	  a	  INM	  protein	  while	  pUL53	  is	  a	  nucleoplasmic	  protein,	  which	  is	  
brought	  to	  INM	  by	  binding	  with	  pUL50	  (42,	  119).	  HCMV	  NEC	  recruits	  cellular	  kinase	  
PKC,	  as	  well	  as	  a	  viral	  kinase	  pUL97,	  to	  phosphorylate	  and	  dissolve	  nuclear	  lamina	  
(120–122).	  The	  disruption	  of	  nuclear	  lamina	  allows	  the	  nucleocapsid	  budding	  into	  
INM,	  resulting	  in	  an	  enveloped	  nucleocapsid	  in	  the	  lumen	  of	  nuclear	  membrane.	  A	  
subsequent	  deenvelopment	  process	  occurs	  by	  fusion	  with	  the	  outer	  nuclear	  
membrane	  (ONM)	  and	  leads	  to	  the	  delivery	  of	  the	  nucleocapsid	  into	  cytoplasm.	  It	  
has	  been	  suggested	  that	  there	  is	  a	  quality	  control	  during	  nuclear	  egress	  to	  
preferentially	  allow	  the	  genome-­‐containing	  capsid	  budding	  through	  INM	  (123,	  124).	  
To	  support	  this	  hypothesis,	  C-­‐capsid	  is	  found	  to	  be	  the	  predominant	  type	  of	  capsid	  
present	  in	  the	  cytoplasm.	  Some	  tegument	  proteins	  are	  acquired	  during	  primary	  
envelopment,,	  probably	  due	  to	  interactions	  with	  capsid	  proteins.	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b) Assembly	  and	  egress	  in	  cytoplasm	  
Nucleocapsid	  acquires	  its	  final	  tegument	  and	  envelope	  by	  budding	  through	  the	  
cytoplasmic	  assembly	  compartment	  (AC),	  the	  process	  of	  which	  is	  also	  called	  
secondary	  envelopment	  (Figure.	  1-­‐5).	  AC	  is	  a	  juxtanuclear	  body	  formed	  by	  
extensively	  reorganization	  of	  cellular	  secretory	  organelles	  (e.g.,	  endoplasmic	  
reticulum	  (ER),	  Golgi,	  trans-­‐Golgi	  and	  endosomes).	  The	  formation	  of	  AC	  is	  a	  unique	  
characteristic	  of	  HCMV	  infected	  cells	  during	  the	  late	  stage	  of	  infection.	  It	  is	  not	  well	  
understood	  how	  nucleocapsid	  is	  directed	  to	  AC	  after	  nuclear	  egress,	  but	  tegument	  
proteins	  are	  suggested	  to	  play	  an	  important	  role	  in	  it.	  Moreover,	  the	  putative	  
intimate	  connection	  between	  nucleus	  and	  AC,	  achieved	  by	  HCMV-­‐mediated	  
remodeling	  of	  nucleus	  shape	  and	  formation	  of	  membranous	  channel	  on	  the	  nucleus-­‐
AC	  interface,	  might	  also	  facilitate	  nucleocapsid	  trafficking	  to	  AC	  (125).	  Some	  of	  the	  
tegument	  proteins	  and	  almost	  all	  envelope	  glycoproteins	  are	  located	  in	  AC,	  which	  
are	  finally	  incorporated	  into	  mature	  viral	  particle	  when	  nucleocapsid	  buds	  into	  the	  
endosomal	  and/or	  trans-­‐Golgi	  derived	  membranes.	  Enveloped	  viral	  particle	  is	  
secreted	  to	  the	  extracellular	  environment	  by	  cellular	  exocytic-­‐associated	  pathways.	  
Together	  with	  mature	  viral	  particle,	  infected	  cells	  also	  produce	  noninfectious	  
enveloped	  particles	  (NIEPs)	  and	  dense	  bodies	  (DBs)	  (126).	  NIEPs	  are	  viral	  particles	  
that	  lack	  genome	  (i.e.,	  formed	  by	  A-­‐	  and	  B-­‐	  capsid).	  DBs	  are	  viral	  particles	  that	  
contain	  tegument	  proteins	  (mainly	  pp65)	  instead	  of	  capsid	  (therefore	  also	  lacking	  
genome),	  thus	  they	  are	  noninfectious	  as	  well.	  The	  relative	  proportions	  of	  NIEPs	  and	  
DBs	  to	  infectious	  virus	  particles	  may	  vary	  due	  to	  differences	  in	  genetic	  background	  
of	  the	  virus	  and/or	  in	  cell	  types	  where	  progenies	  are	  produced.	  Although	  being	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replication	  defective,	  it	  is	  possible	  that	  NIEPs	  and	  DBs	  could	  act	  like	  “decoy”	  to	  wear	  
out	  host	  immune	  response	  (e.g.,	  the	  humoral	  antibody	  attack),	  thus	  giving	  infectious	  
particles	  higher	  chance	  to	  survive	  and	  establish	  infection	  in	  a	  new	  cell.	  	  
HCMV	  latent	  infection	  
HCMV	  infection	  of	  a	  host	  for	  the	  first	  time	  is	  considered	  as	  the	  “primary	  
infection”.	  Primary	  infection	  generally	  has	  two	  outcomes:	  1)	  the	  virus	  enters	  the	  
lytic	  replication	  cycle,	  where	  viral	  gene	  expression	  and	  replication	  successfully	  
proceed,	  leading	  to	  production	  and	  release	  of	  infectious	  progeny	  virions;	  2)	  
Alternatively,	  under	  some	  conditions	  or	  in	  certain	  cell	  types,	  the	  virus	  enters	  a	  latent	  
infection	  state,	  where	  the	  viral	  gene	  expression	  is	  largely	  limited	  and	  progeny	  
production	  is	  shut	  off.	  The	  current	  consensus	  is	  that	  HCMV	  is	  never	  cleared	  away	  
after	  primary	  infection	  and	  it	  coexists	  with	  the	  host	  through	  latency	  for	  a	  lifetime,	  
with	  reactivation	  happening	  periodically.	  While	  shedding	  of	  the	  virions	  from	  body	  
fluids	  peaks	  at	  a	  few	  months	  after	  primary	  infection,	  persistent	  virus	  shedding	  at	  
low	  levels	  could	  be	  detected	  for	  years,	  and	  intermittently	  virus	  shedding	  due	  to	  
reactivation	  continues	  for	  the	  rest	  of	  the	  life,	  all	  of	  which	  could	  contribute	  to	  the	  
horizontal	  transmission	  of	  the	  virus.	  Surprisingly,	  a	  large	  portion	  (up	  to	  40%)	  of	  an	  
individual’s	  T	  cell	  repertoire	  is	  directed	  against	  epitopes	  on	  HCMV	  viral	  proteins	  
that	  are	  expressed	  at	  all	  stages	  of	  replication	  cycle	  (64),	  suggesting	  a	  continual	  
exposure	  of	  host	  immunity	  to	  HCMV	  antigen.	  This	  observation	  implies	  there	  is	  a	  
relatively	  huge	  immune	  burden	  added	  from	  HCMV	  due	  to	  persistent	  infection	  
and/or	  frequent	  reactivation	  from	  latency.	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Latency	  is	  a	  common	  feature	  of	  herpesvirus	  family.	  While	  alpha-­‐herpesviruses	  
and	  gamma-­‐herpesviruses	  establish	  latency	  mainly	  in	  neurons	  and	  lymphocytes,	  
respectively,	  beta-­‐herpesviruses	  establish	  latency	  in	  myeloid	  lineage	  cells	  (Table.	  1-­‐
2).	  CD34+	  myeloid	  progenitor	  cells	  and	  CD14+	  monocytes	  are	  the	  main	  latency	  sites	  
for	  HCMV	  (127–131).	  The	  prevailing	  view	  for	  establishment	  of	  latency	  and	  
triggering	  of	  reactivation	  is	  that	  HCMV	  major	  immediate	  early	  promoter	  (MIEP)	  is	  
silenced	  by	  cellular	  transcriptional	  repressor	  in	  those	  myeloid	  cells,	  and	  the	  
repression	  of	  MIEP	  hampers	  the	  IE	  gene	  expression	  thus	  prevents	  lytic	  infection,	  
leading	  to	  the	  establishment	  of	  latency.	  During	  latency,	  HCMV	  genome	  exists	  in	  the	  
nucleus	  like	  an	  episome,	  coupled	  with	  limited	  transcription	  of	  specific	  viral	  genes,	  
which	  are	  thought	  to	  be	  important	  for	  latency	  maintenance.	  Following	  
differentiation	  of	  myeloid	  cells	  into	  macrophages	  or	  dendritic	  cells,	  the	  cellular	  
environment	  changes	  in	  a	  way	  that	  the	  repression	  on	  MIEP	  is	  relieved,	  which	  
induces	  IE	  gene	  expression	  and	  reactivation	  of	  the	  virus	  (reviewed	  in	  (132,	  133)).	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HCMV	  genetic	  diversity	  
When	  considering	  about	  HCMV	  genetic	  diversity,	  cautions	  need	  to	  be	  taken	  with	  
some	  important	  terminologies.	  An	  “isolate”	  refers	  to	  HCMV	  recovered	  from	  a	  human	  
specimen	  and	  passaged	  in	  tissue	  culture	  for	  a	  limited	  number	  of	  times.	  Generally	  an	  
isolate	  is	  not	  plaque	  purified,	  suggesting	  that	  several	  genomically	  different	  viruses	  
might	  present	  in	  one	  isolate.	  A	  “strain”	  refers	  to	  a	  passaged	  derivative	  of	  an	  isolate	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acquired	  by	  plaque	  purification.	  Strains	  of	  HCMV	  differ	  in	  the	  pattern	  of	  viral	  DNA	  
fragments	  generated	  by	  restriction	  enzyme	  digestion,	  which	  is	  later	  confirmed	  with	  
genome-­‐wide	  sequencing	  techniques.	  A	  “variant”	  refers	  to	  a	  derivative	  of	  a	  strain	  
that	  expresses	  a	  phenotypic	  or	  genotypic	  characteristic	  different	  from	  the	  parental	  
strain	  (134).	  	  
About	  third-­‐quarter	  of	  HCMV	  genome	  shows	  polymorphisms,	  while	  one-­‐quarter	  
is	  highly	  conserved.	  The	  most	  conserved	  regions	  of	  the	  genome	  are	  localized	  to	  
genes	  encoding	  DNA-­‐processing	  enzymes,	  capsid,	  and	  tegument	  proteins,	  while	  the	  
variable	  regions	  are	  genes	  encoding	  envelope	  glycoproteins	  and	  immune	  evasion	  
proteins	  (135,	  136).	  Several	  variable	  regions	  of	  the	  genome	  have	  been	  selected	  to	  
define	  distinct	  genotype	  based	  on	  the	  clustering	  of	  polymorphisms,	  including	  genes	  
that	  encode	  for	  glycoprotein	  gB	  (5	  genotypes),	  gH	  (2	  genotypes),	  gN	  (7	  genotypes),	  
and	  gO	  (8	  genotypes)	  (87,	  89,	  137,	  138).	  	  
	  It	  has	  been	  appreciated	  for	  decades	  that	  HCMV	  exhibits	  significant	  levels	  of	  
genetic	  diversity	  between	  individuals	  (inter-­‐host	  diversity)	  (139–141).	  However,	  
more	  recent	  research	  work	  has	  showed	  that	  this	  virus	  also	  exhibited	  high	  level	  of	  
genetic	  diversity	  within	  a	  single	  individual	  (intra-­‐host	  diversity)	  (reviewed	  in	  (142)).	  
Quite	  surprisingly,	  this	  intra-­‐host	  diversity	  could	  be	  comparable	  to	  what	  has	  been	  
observed	  for	  RNA	  viruses,	  a	  benchmark	  of	  highly	  diverse	  viral	  populations	  (7).	  Then	  
the	  intriguing	  question	  is	  what	  source	  contributes	  to	  the	  high	  levels	  of	  HCMV	  intra-­‐
host	  diversity.	  Currently,	  there	  is	  no	  clear	  answer	  to	  explain	  the	  observed	  diversity,	  
though	  several	  hypotheses	  could	  be	  proposed:	  1)	  High	  levels	  of	  replication	  during	  
primary	  infection	  could	  contribute	  to	  the	  generation	  of	  de	  novo	  mutations	  in	  each	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host,	  albeit	  the	  total	  numbers	  of	  mutations	  may	  be	  limited	  by	  the	  proof	  reading	  of	  
HCMV	  DNA	  polymerase.	  2)	  Reinfections	  may	  offer	  a	  way	  for	  introducing	  diversity	  
into	  virus	  intra-­‐host	  population.	  Indeed,	  mixed	  infection	  of	  multiple	  strains	  of	  HCMV	  
happens	  in	  a	  wide	  variety	  of	  hosts,	  including	  immunocompetent,	  immunocomprised	  
and	  congenital	  infected	  individuals	  (2–7).	  3)	  Recombination	  and	  natural	  selections	  
within	  a	  host	  could	  also	  alter	  the	  pattern	  of	  HCMV	  intra-­‐host	  diversity.	  	  
The	  high	  levels	  of	  HCMV	  intra-­‐host	  diversity	  probably	  would	  help	  us	  rethink	  the	  
evolution	  of	  the	  virus	  within	  a	  host.	  Given	  the	  high	  level	  of	  genetic	  diversity,	  HCMV	  
should	  be	  considered	  more	  as	  a	  “swarm”-­‐heterogeneous	  population.	  In	  line	  with	  
this	  notion,	  recent	  work	  also	  showed	  that	  different	  genotypes	  were	  detected	  from	  
different	  compartments	  within	  the	  body	  (e.g.,	  plasma	  and	  urine)	  (143),	  suggesting	  
that	  during	  virus	  dissemination	  to	  distal	  compartments,	  the	  viral	  population	  can	  
rapidly	  evolve,	  either	  due	  to	  natural	  selection	  or	  stochastic	  mutations,	  and	  can	  lead	  
to	  populations	  of	  virus	  colonized	  in	  distal	  organs	  or	  tissues	  genetically	  different	  
from	  the	  ones	  present	  in	  peripheral	  blood.	  Meanwhile,	  research	  also	  suggests	  that	  
HCMV	  is	  genetically	  stable	  over	  time,	  as	  shown	  by	  that	  while	  mixed	  genotypes	  were	  
detected	  in	  patients,	  the	  compositions	  of	  the	  mixed	  populations	  remains	  nearly	  
constant	  over	  time	  (144,	  145).	  Thus,	  HCMV	  can	  be	  diverse	  but	  yet	  stable	  within	  its	  
host.	  The	  intra-­‐host	  diversity	  may	  provide	  a	  mechanism	  for	  the	  virus	  to	  gain	  overall	  
fitness	  by	  rapidly	  adapting	  to	  the	  changing	  environment,	  like	  new	  host	  organ/tissue,	  
immune	  surveillance,	  and	  antiviral	  therapy.	  However,	  once	  settled	  down,	  the	  virus	  
population	  tends	  to	  remain	  stable	  probably	  due	  to	  its	  low	  mutation	  rate.	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HCMV	  cell	  tropism	  and	  entry	  
HCMV	  in	  vivo	  cell	  tropism	  and	  viral	  dissemination	  	  
One	  of	  the	  fundamental	  questions	  in	  virology	  has	  been	  that	  why	  a	  given	  virus	  
will	  particularly	  infect	  one	  host	  species	  but	  not	  the	  other,	  or	  at	  a	  cellular	  level,	  why	  a	  
given	  virus	  will	  specifically	  infect	  one	  cell	  type	  while	  failing	  to	  infect	  others.	  The	  
above-­‐mentioned	  phenomena	  have	  been	  referred	  to	  as	  viral	  “host	  range”	  or	  “cell	  
tropism”.	  Natural	  infections	  with	  most	  herpesviruses	  are	  restricted	  to	  a	  single	  
species,	  although	  some	  can	  infect	  other	  species	  experimentally.	  In	  general,	  alpha-­‐
herpesvirues	  have	  a	  relatively	  broader	  host	  range	  (excepting	  VZV)	  but	  restricted	  
cell	  tropism.	  Beta-­‐herpesviruses	  have	  a	  restricted	  host	  range	  but	  a	  wide	  cell	  tropism.	  
Gamma-­‐herpesviruses	  have	  both	  restricted	  host	  range	  and	  cell	  tropism	  (reviewed	  in	  
(146))	  (Table.	  1-­‐2).	  HCMV,	  a	  human-­‐specific	  virus,	  is	  able	  to	  virtually	  infect	  all	  cell	  
types	  in	  human	  body,	  including	  endothelial	  cells,	  epithelial	  cells,	  fibroblasts,	  smooth	  
muscle	  cells,	  placental	  trophoblasts,	  hepatocyte,	  polymorphonuclear	  leukocyte	  
(PMNL),	  monocyte,	  dendritic	  cells,	  macrophages,	  lymphocyte	  and	  neuronal	  cells	  
(147–157).	  HCMV	  infection	  in	  PMNL,	  monocyte	  and	  lymphocyte	  is	  blocked	  at	  the	  IE	  
gene	  expression	  stage,	  thus	  those	  cells	  are	  considered	  to	  be	  susceptible	  but	  not	  fully	  
permissive	  to	  HCMV	  infection.	  It	  is	  worthwhile	  to	  point	  out	  that	  monocyte	  will	  turn	  
into	  full	  permissiveness	  to	  HCMV	  when	  it	  is	  differentiated	  into	  macrophages	  or	  
dendritic	  cells	  (154,	  158).	  With	  this	  extremely	  wide	  range	  of	  cell	  tropism	  in	  vivo,	  
HCMV	  can	  acquire	  systemic	  dissemination	  and	  cause	  pathology	  in	  multiple	  organs,	  
e.g.,	  lung,	  kidney,	  liver,	  spleen,	  intestine,	  heart,	  brain	  and	  bone	  marrow	  (159).	  
Several	  cell	  types,	  of	  significant	  roles	  in	  viral	  dissemination,	  will	  be	  described	  below.	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Epithelial	  cell	  
	  	  Epithelial	  cell,	  lining	  the	  major	  cavities	  of	  the	  body,	  could	  be	  the	  first	  cell	  that	  
HCMV	  infects	  if	  the	  transmission	  route	  is	  through	  oral	  or	  genital	  contact.	  It	  is	  the	  
main	  target	  of	  HCMV	  in	  lung,	  gastrointestinal	  tract,	  kidney,	  and	  secretory	  glands	  
(147,	  160).	  Since	  epithelial	  cell	  is	  permissive	  for	  HCMV	  infection,	  it	  mainly	  involves	  
in	  virus	  shedding	  into	  body	  fluids.	  In	  addition,	  infected	  epithelial	  cells	  have	  been	  
reported	  to	  detach	  from	  the	  basal	  membrane,	  thus	  might	  contribute	  to	  infectivity	  in	  
body	  fluids	  as	  well	  (159).	  	  
Endothelial	  cell	  
Endothelial	  cell,	  lining	  the	  inner	  wall	  of	  blood	  and	  lymphatic	  vessel,	  could	  be	  the	  
first	  cell	  that	  HCMV	  infects	  if	  transmission	  happens	  by	  blood	  transfusion.	  This	  cell	  
type	  is	  believed	  to	  be	  involved	  in	  HCMV	  haematogenous	  dissemination	  for	  the	  
following	  two	  reasons:	  1)	  endothelial	  cell	  is	  permissive	  for	  HCMV	  infection	  and	  2)	  
infected	  endothelial	  cells	  may	  detach	  from	  vessel	  wall	  and	  circulate	  in	  peripheral	  
blood	  (160,	  161).	  Transmission	  of	  the	  virus	  from	  infected	  endothelial	  cells	  to	  
leukocytes	  has	  been	  reported	  in	  tissue	  culture	  model	  (162).	  Moreover,	  evidence	  also	  
suggests	  that	  endothelial	  cell	  can	  also	  be	  a	  site	  for	  HCMV	  latent	  infection	  (reviewed	  
in	  (163)).	  	  
Monocyte/Macrophage	  
Monocyte	  is	  also	  found	  to	  be	  the	  key	  contributor	  for	  HCMV	  haematogenous	  
dissemination.	  Although	  complete	  replication	  cycle	  is	  blocked,	  HCMV	  could	  promote	  
monocyte	  migration	  into	  organ	  tissues	  and	  ensuing	  its	  differentiation	  into	  the	  
permissive	  macrophage	  cell.	  Infected	  macrophage	  could	  then	  migrate	  into	  bone	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marrow	  and	  infect	  myeloid	  progenitor	  cells,	  where	  latency	  is	  usually	  established	  
(164).	  
Taken	  together,	  a	  putative	  model	  for	  HCMV	  in	  vivo	  dissemination	  is	  that	  
epithelial	  cells	  or	  endothelial	  cells	  are	  first	  infected	  by	  HCMV	  at	  mucosal	  epithelium	  
or	  in	  the	  blood	  vessel.	  HCMV	  then	  replicates	  and	  spreads	  to	  monocytes	  in	  the	  
peripheral	  blood	  by	  some	  unresolved	  mechanisms,	  where	  HCMV	  enters	  a	  temporary	  
latent	  state.	  Infection	  by	  HCMV	  increases	  monocyte	  migration	  into	  different	  organs,	  
and	  differentiation	  into	  permissive	  macrophages.	  Infected	  macrophages	  could	  either	  
enter	  bone	  marrow	  to	  establish	  latency	  in	  CD34+	  myeloid	  progenitor	  cells	  or	  keep	  
migrating	  and	  infect	  mucosal	  epithelial	  cells	  at	  a	  different	  site,	  where	  virus	  shedding	  
and	  transmission	  take	  place.	  
HCMV	  in	  vitro	  cell	  tropism	  and	  associated	  adaptive	  genetic	  changes	  
Historically,	  HCMV	  in	  vitro	  isolation	  and	  propagation	  has	  been	  heavily	  
dependent	  on	  primary	  human	  fibroblast	  cultures	  (e.g.,	  primary	  human	  foreskin	  
fibroblasts,	  HFF)	  because	  those	  cells	  supported	  high	  titer	  replications	  of	  HCMV.	  
Based	  on	  the	  extent	  of	  passage	  on	  fibroblast	  cultures,	  strains	  of	  HCMV	  were	  
conventionally	  divided	  into	  two	  categories:	  “lab	  strain”	  (high-­‐passaged)	  and	  “clinical	  
strain”	  (low-­‐passaged).	  Two	  prototypic	  lab	  strains	  are	  AD169	  and	  Towne.	  Strain	  
AD169,	  isolated	  from	  the	  adenoid	  culture	  of	  a	  7-­‐year-­‐old	  girl,	  was	  developed	  as	  an	  
attenuated	  vaccine	  candidate	  by	  extensively	  propagation	  on	  fibroblasts	  and	  was	  
then	  used	  by	  laboratories	  worldwide	  for	  over	  50	  years	  (165);	  Strain	  Towne,	  isolated	  
from	  the	  urine	  of	  a	  congenitally	  infected	  infant,	  was	  also	  developed	  as	  an	  attenuated	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vaccine	  candidate	  by	  passaging	  on	  fibroblasts	  for	  over	  128	  times	  (166).	  In	  contrast,	  
strains	  like	  Toledo,	  isolated	  from	  the	  urine	  of	  a	  congenitally	  infected	  child	  (167),	  and	  
TR,	  an	  ocular	  isolate	  from	  an	  AIDS	  patient	  with	  retinitis	  (168)	  are	  considered	  
clinical	  strains	  due	  to	  their	  more	  limited	  propagations	  on	  fibroblast	  cells.	  	  
Lab	  strains	  and	  clinical	  strains	  exhibit	  different	  competencies	  in	  tropism.	  Lab	  
strains	  are	  able	  to	  replicate	  on	  fibroblasts	  with	  high	  efficiency,	  but	  show	  restricted	  
tropisms	  by	  failing	  to	  infect	  epithelial	  cells,	  endothelial	  cell,	  and	  some	  types	  of	  
leukocytes	  (134,	  169,	  170).	  Clinical	  strains	  show	  broader	  cell	  tropism	  and	  replicate	  
in	  cells	  types	  in	  addition	  to	  fibroblast	  cells	  (171),	  although	  unexpectedly,	  the	  clinical	  
strain	  Toledo	  was	  later	  found	  to	  be	  negative	  in	  endothelial	  cells	  tropism	  (170,	  172).	  
Accordingly,	  the	  tissue	  culture	  tropism	  model	  for	  HCMV	  involves	  fibroblasts	  versus	  
endothelial/epithelial	  cells,	  and	  other	  cell	  types	  in	  the	  body	  tend	  to	  fall	  into	  this	  
dichotomy.	  
Initial	  genome	  comparative	  studies	  of	  lab	  strains	  AD169,	  Towne,	  and	  clinical	  
strain	  Toledo	  found	  that	  both	  lab	  strains	  A169	  and	  Towne	  had	  suffered	  dramatic	  
genetic	  deletions,	  missing	  15,	  and	  13	  Kb	  sequence	  from	  the	  right	  end	  of	  the	  UL	  
region	  respectively	  (173).	  Perhaps	  in	  order	  to	  keep	  intact	  genome	  length,	  both	  
AD169	  and	  Towne	  also	  exhibit	  genetic	  rearrangement	  by	  replacing	  the	  missing	  
region	  with	  an	  inverted	  version	  (b’a’	  or	  also	  called	  IRL)	  of	  the	  terminal	  repeated	  
block	  (ab	  or	  also	  called	  TRL),	  which	  is	  otherwise	  lacking	  in	  clinical	  strains	  (Figure.	  1-­‐
3)	  (41).	  Thus	  the	  missing	  region	  is	  designated	  the	  UL/b’,	  which	  is	  predicted	  to	  
encode	  19	  ORFs	  (UL133-­‐151)	  or	  14	  ORFs	  (UL133-­‐146)	  in	  AD169	  or	  Towne	  
respectively	  and	  many	  of	  those	  ORFs	  are	  predicted	  to	  be	  glycoproteins	  (41,	  173).	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Some	  of	  the	  ORFs	  missing	  in	  lab	  strains	  are	  displayed	  in	  an	  inverted	  orientation	  in	  
clinical	  strain	  Toledo	  as	  compared	  to	  other	  clinical	  strains	  (41,	  134).	  UL128-­‐131	  
gene	  locus	  on	  the	  UL/b’	  was	  later	  shown	  to	  be	  indispensable	  for	  virus	  infection	  in	  
epithelial/endothelial	  cells	  and	  transmission	  to	  leukocytes	  (78).	  This	  was	  confirmed	  
by	  genome-­‐wide	  sequencing	  showing	  that	  AD169	  contains	  a	  single	  nucleotide	  
insertion	  in	  UL131;	  Towne	  contains	  a	  frameshift	  mutation	  in	  UL130,	  and	  Toledo	  
contains	  an	  inverted	  site	  disrupting	  UL128	  (41,	  78,	  174,	  175).	  Therefore	  the	  so-­‐
called	  clinical	  strain	  Toledo	  behaves	  more	  like	  lab	  strain	  with	  respect	  to	  the	  
mutations	  acquired	  in	  the	  UL/b’.	  	  
Recently,	  Dargan	  et	  al.	  demonstrated	  that	  genetic	  changes	  inevitably	  occurred	  
when	  clinical	  viruses	  were	  serially	  passaged	  in	  tissue	  cultures,	  including	  epithelial	  
and	  endothelial	  cells	  (176).	  These	  authors	  passaged	  HCMV	  on	  fibroblasts,	  epithelial	  
and	  endothelial	  cells	  in	  parallel	  and	  showed	  that	  in	  all	  three	  cultures,	  mutations	  
were	  first	  selected	  in	  gene	  RL13,	  and	  then	  in	  genes	  UL128-­‐131	  (specifically	  
associated	  with	  fibroblasts	  as	  described	  above	  for	  AD169,	  Towne	  and	  Toledo),	  and	  
in	  some	  cases,	  eventually	  in	  UL/b’	  region	  (as	  what	  happened	  to	  AD169	  and	  Towne).	  
RL13	  encodes	  a	  glycoprotein	  that	  tracks	  to	  the	  virion	  assembly	  site,	  suggesting	  it	  
might	  be	  a	  virion	  envelope	  protein	  (177).	  Although	  the	  function	  of	  the	  RL13	  protein	  
is	  currently	  unknown,	  the	  rapid	  negative	  selection	  against	  it	  suggests	  that	  it	  is	  likely	  
a	  potent	  inhibitor	  for	  HCMV	  in	  vitro	  replication	  and	  the	  loss	  of	  function	  in	  RL13	  may	  
also	  contribute,	  at	  least	  in	  part,	  to	  the	  less	  cell-­‐associated	  phenotype	  observed	  in	  lab	  
strains	  (177–180).	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The	  overall	  picture	  is	  that	  HCMV	  strains	  that	  have	  been	  propagated	  in	  vitro	  tend	  
to	  harbor	  mutation(s)	  resulted	  from	  selection	  pressure	  in	  all	  cell	  culture	  systems.	  
And	  the	  appearance	  of	  the	  mutants	  is	  not	  only	  inevitable	  but	  also	  prone	  to	  emerge	  at	  
early	  stages	  of	  the	  passage	  (43,	  176).	  Therefore,	  even	  the	  less	  propagated	  “clinical	  
strain”	  could	  contain	  mutations	  that	  we	  are	  not	  aware	  of,	  thus	  might	  not	  truly	  
represent	  its	  clinical	  ancestor.	  Recently	  Wilkinson	  et	  al.	  suggested	  a	  more	  adequate	  
terminology	  system,	  where	  HCMV	  strains	  are	  divided	  into	  “low-­‐passage”	  and	  “high-­‐
passage”	  groups,	  with	  low-­‐passage	  strains	  being	  more	  genome	  intact	  than	  high-­‐
passage	  strains	  (181).	  
Bacterial	  Artificial	  Chromosome	  (BAC)	  (E.	  coli.	  fertility	  plasmid)	  cloning	  
technology	  was	  introduced	  to	  preserve	  HCMV	  genome	  from	  further	  mutations	  and	  
also	  allowed	  for	  intentional	  mutagenesis	  manipulation	  of	  the	  virus	  genome	  (182,	  
183).	  Virus	  can	  be	  recovered	  from	  transfection	  of	  permissive	  cells	  with	  BAC.	  High-­‐
passage	  strains	  AD169	  and	  Towne	  as	  well	  as	  low-­‐passage	  strains	  TR,	  TB40/E,	  
Merlin	  (ME),	  PH	  all	  have	  been	  cloned	  into	  BACs	  (41,	  177,	  184),	  and	  are	  used	  for	  
research	  in	  this	  dissertation.	  	  
HCMV	  entry	  and	  membrane	  fusion	  event	  
Viral	  tropism	  can	  be	  determined	  at	  any	  replication	  step,	  beginning	  with	  the	  
entry	  into	  cells	  and	  ending	  with	  the	  production	  of	  progeny.	  It	  has	  been	  well	  
appreciated	  that	  viral	  tropism	  can	  be	  greatly	  influenced	  by	  virus	  entry.	  Different	  cell	  
types	  vary	  a	  lot	  in	  their	  physical	  morphologies	  as	  well	  as	  surface	  protein,	  
carbohydrate	  and	  lipid	  compositions.	  Thus	  virus	  entry	  is	  largely	  governed	  by	  how	  
	   34	  
the	  virus	  particle	  overcomes	  the	  barriers	  on	  cell	  surface	  and	  accomplishes	  
interactions	  with	  their	  receptors.	  The	  broad	  cell	  tropism	  of	  HCMV	  reflects	  its	  
flexibility	  at	  entry,	  suggesting	  that	  the	  virus	  might	  either	  bind	  to	  a	  ubiquitous	  
receptor	  shared	  with	  all	  cell	  types	  or	  a	  number	  of	  specific	  ones	  on	  different	  cell	  
types.	  On	  the	  other	  hand,	  HCMV	  broad	  tropism	  correlates	  well	  with	  its	  envelope	  
complexity.	  This	  virus	  is	  remarkable	  because	  it	  contains	  more	  than	  20	  different	  
kinds	  of	  glycoproteins	  on	  the	  envelope.	  It’s	  almost	  like	  HCMV	  has	  a	  chain	  of	  “keys”	  to	  
readily	  open	  different	  “locks”.	  	  
As	  an	  enveloped	  virus,	  entry	  has	  to	  happen	  through	  membrane	  fusion	  event	  
between	  viral	  envelope	  and	  cellular	  membranes.	  Depending	  on	  the	  cell	  types	  that	  
the	  virus	  encounters,	  the	  site	  of	  fusion	  can	  be	  at	  either	  the	  plasma	  membrane	  or	  
from	  within	  the	  endosomes.	  Moreover,	  the	  types	  of	  endosomes	  can	  vary	  depending	  
on	  what	  kind	  of	  endocytosis	  that	  the	  virus	  triggers,	  thus	  the	  requirement	  for	  low-­‐pH	  
can	  vary	  as	  well.	  For	  HCMV,	  it	  has	  been	  reported	  that	  the	  virus	  enters	  fibroblasts	  
through	  pH-­‐independent	  fusion	  at	  the	  plasma	  membrane.	  Although	  more	  recent	  
research	  suggested	  that	  the	  virus	  utilizes	  macropinocytosis	  pathway	  to	  enter	  
fibroblasts	  in	  a	  pH-­‐independent	  manner.	  Meanwhile,	  entry	  into	  
epithelial/endothelial	  cells	  requires	  endocytosis	  and	  depends	  on	  low-­‐pH	  (79,	  185,	  
186).	  	  
Although	  thermodynamically	  favorable,	  fusion	  of	  two	  membranes	  must	  
overcome	  a	  repulsive	  “hydration	  force”,	  which	  increases	  steeply	  as	  the	  two	  
membranes	  come	  closer	  than	  20	  angstrom	  (187).	  Because	  of	  that,	  membrane	  fusion	  
requires	  a	  source	  of	  free	  energy	  to	  bring	  them	  together,	  for	  example,	  a	  chemical	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called	  polyethylene	  glycol	  (PEG)	  could	  induce	  membrane	  fusion	  by	  dehydration	  of	  
the	  inter-­‐membrane-­‐space	  to	  overcome	  the	  repulsive	  “hydration	  force”	  and	  bring	  
apposing	  membranes	  closer	  than	  20	  angstrom.	  Essentially,	  enveloped	  viruses	  
encode	  a	  “fusogen”	  to	  achieve	  this	  end,	  which	  is	  defined	  as	  viral	  fusion	  protein.	  Viral	  
fusion	  protein	  is	  held	  in	  a	  “prefusion	  conformation”	  on	  the	  virion	  envelope	  by	  
constraints	  that	  either	  come	  from	  another	  part	  of	  the	  same	  protein	  or	  from	  another	  
viral	  protein.	  Usually	  two	  events	  have	  to	  happen	  before	  fusion	  protein	  
conformational	  change:	  1)	  “priming”	  of	  fusion	  protein	  to	  make	  the	  transition	  
possible,	  e.g.,	  proteolytic	  cleavage;	  2)	  “triggering”	  of	  fusion	  protein	  to	  initiate	  the	  
transition,	  e.g.,	  ligand	  binding.	  The	  ligand	  can	  be	  a	  receptor	  (e.g.,	  receptor-­‐mediated	  
fusion	  of	  HIV	  virus)	  or	  a	  proton	  (e.g.,	  low-­‐pH	  induced	  fusion	  of	  influenza	  virus).	  
Upon	  the	  triggering,	  the	  constraints	  that	  hold	  the	  fusion	  protein	  in	  the	  “prefusion	  
conformation”	  is	  released,	  leading	  to	  a	  dramatic	  conformational	  change	  and	  
exposure	  of	  the	  hydrophobic	  “fusion	  peptide”	  or	  “fusion	  loop”,	  which	  then	  inserts	  
into	  the	  apposing	  cellular	  membrane.	  This	  state	  of	  the	  fusion	  protein	  is	  “metastable”,	  
and	  favors	  to	  fold	  back	  to	  the	  more	  energetic	  stable	  “postfusion	  conformation”.	  Thus,	  
the	  collapse	  of	  the	  intermediate	  conformation	  draws	  two	  membranes	  together	  
(review	  in	  (188)).	  
Fusion	  proteins	  fall	  into	  three	  categories.	  (1)	  Class	  I	  fusion	  proteins,	  
represented	  by	  influenza	  virus	  hemagglutinin	  (HA)	  or	  HIV-­‐1	  gp160,	  are	  mainly	  
composed	  of	  alpha-­‐helices	  and	  contain	  a	  “fusion	  peptide”	  located	  closed	  to	  the	  N-­‐
terminus.	  The	  postfusion	  structure	  of	  it	  is	  a	  trimeric	  alpha-­‐helical	  coiled	  coil.	  (2)	  
Class	  II	  fusion	  proteins,	  represented	  by	  flavivirus	  envelope	  protein	  E,	  are	  mostly	  
	   36	  
comprised	  of	  beta-­‐sheets.	  Unlike	  class	  I	  fusion	  proteins	  being	  perpendicular	  to	  viral	  
envelope,	  class	  II	  fusion	  proteins	  form	  a	  parallel	  lattice	  on	  the	  envelope.	  Upon	  
triggering,	  the	  proteins	  flip	  up	  to	  insert	  internal	  “fusion	  loop”	  to	  cellular	  membrane.	  
(3)	  Class	  III	  fusion	  proteins,	  represented	  by	  vesicular	  stomatitis	  virus	  glycoprotein	  G	  
(VSV-­‐G),	  combine	  the	  feature	  of	  both	  class	  I	  and	  class	  II.	  They	  contain	  a	  central	  
trimeric	  coiled	  coil	  domain	  just	  like	  class	  I	  fusion	  proteins	  in	  their	  postfusion	  state,	  
but	  other	  domains	  are	  mostly	  made	  up	  by	  beta-­‐sheets,	  and	  the	  “fusion	  loop”	  is	  
buried	  internally,	  typical	  feature	  of	  class	  II	  fusion	  proteins	  (reviewed	  in	  (188)).	  
HCMV	  core	  fusion	  machinery	  and	  accessory	  glycoproteins	  
All	  herpesviruses	  share	  conserved	  core	  fusion	  machinery	  comprised	  of	  gB	  and	  
gH/gL	  complexes	  (146,	  189,	  190).	  All	  three	  glycoproteins	  are	  essential	  for	  virus	  
entry,	  for	  example,	  HCMV	  gB-­‐null,	  gH-­‐null	  and	  gL-­‐null	  mutants	  all	  fail	  to	  infect	  cells	  
unless	  treated	  with	  the	  chemical	  fusogen	  PEG,	  suggesting	  that	  the	  defect	  is	  at	  fusion	  
(191–193).	  	  
HCMV	  gB	  (pUL55)	  is	  a	  160~170	  kDa	  transmembrane	  protein.	  It	  contains	  a	  
cleavage	  motif	  R-­‐X-­‐K/R-­‐R	  recognized	  by	  intracellular	  endoprotease	  furin	  and	  is	  
cleaved	  into	  a	  116	  kDa	  N-­‐terminal	  fragment	  and	  a	  55	  kDa	  C-­‐terminal	  fragment,	  
which	  are	  hold	  together	  by	  disulfide	  bonds.	  The	  proteolytic	  cleavage	  probably	  
occurs	  in	  the	  TGN-­‐derived	  assembly	  compartment	  during	  virus	  maturation,	  thus	  gB	  
incorporated	  into	  virion	  envelope	  is	  a	  disulfide-­‐linked	  complex	  of	  the	  two	  fragments	  
(194,	  195).	  Several	  gB	  homologues	  across	  the	  three	  herpesvirus	  families	  share	  this	  
cleavage	  feature,	  including	  gB	  of	  pseudorabies	  virus	  (PRV),	  VZV,	  EBV,	  KSHV,	  and	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other	  betaherpesviruses	  (e.g.,	  HHV-­‐6	  and	  HHV-­‐7)	  (196–201).	  In	  contrast,	  gB	  of	  some	  
members	  of	  herpesviruses	  do	  not	  harbor	  the	  cleavage	  site,	  including	  HSV-­‐1	  and	  
HSV-­‐2	  (202,	  203).	  The	  influence	  of	  gB	  cleavage	  on	  virus	  replication	  has	  been	  
variable	  depending	  on	  different	  viruses.	  There	  are	  reports	  showing	  that	  for	  HCMV,	  
PRV	  and	  VZV,	  the	  cleavage	  site	  of	  gB	  is	  dispensable	  for	  virus	  growth	  in	  tissue	  culture,	  
while	  for	  EBV,	  the	  proteolytic	  cleavage	  seems	  to	  be	  required	  for	  gB	  function	  in	  cell-­‐
cell	  fusion	  (197,	  204–206).	  The	  fact	  that	  cleavage	  of	  gB	  in	  HCMV	  is	  not	  necessarily	  
needed	  during	  replication	  suggests	  that	  this	  furin	  cleavage	  is	  not	  required	  for	  the	  
activation	  of	  fusion	  potential,	  as	  in	  the	  case	  of	  influenza	  virus	  HA	  or	  HIV	  gp160.	  
Moreover,	  posttranslational	  glycosylation	  adds	  both	  N-­‐linked	  and	  O-­‐linked	  
polysaccharides	  to	  gB,	  contributing	  to	  one	  third	  of	  the	  total	  molecular	  weight	  (122,	  
207,	  208).	  Recent	  research	  found	  that	  antigenic	  sites	  that	  elicit	  neutralizing	  
antibodies	  are	  more	  glycosylated	  than	  those	  eliciting	  non-­‐neutralizing	  antibodies,	  
suggesting	  that	  the	  glycans	  might	  help	  shielding	  the	  neutralizing	  epitopes	  on	  gB	  
(67).	  Crystal	  structure	  of	  HCMV	  gB	  ectodomain	  has	  been	  resolved	  and	  has	  revealed	  
structural	  homology	  to	  HSV-­‐1	  and	  EBV	  gB,	  all	  of	  which	  resemble	  the	  structure	  of	  
class	  III	  fusion	  protein	  VSV-­‐G	  (67,	  209,	  210).	  However,	  unlike	  VSV-­‐G	  being	  necessary	  
and	  sufficient	  in	  mediating	  membrane	  fusion,	  herpesvirus	  gB	  is	  not	  sufficient	  on	  its	  
own	  and	  it	  needs	  a	  partner	  gH/gL.	  	  
HCMV	  gH	  (pUL75)	  is	  a	  97-­‐kDa	  transmembrane	  protein,	  and	  gL	  (pUL115)	  is	  a	  
37-­‐kDa	  soluble	  protein.	  Together	  they	  form	  a	  disulfide-­‐linked	  heterodimer	  (211,	  
212).	  Crystal	  structures	  have	  revealed	  the	  overall	  similar	  but	  slightly	  different	  
structures	  between	  HSV	  and	  EBV	  gH/gL.	  HSV	  gH/gL	  adopts	  a	  boot-­‐like	  
	   38	  
configuration	  whereas	  EBV	  gH/gL	  is	  more	  linear	  and	  elongated.	  In	  both	  cases,	  
gH/gL	  heterodimer	  is	  intimately	  integrated	  with	  each	  other,	  with	  gL	  binding	  to	  the	  
N-­‐terminal	  of	  gH,	  suggesting	  the	  two	  proteins	  require	  one	  another	  for	  proper	  
folding	  (213,	  214).	  Although	  HCMV	  gH/gL	  crystal	  structure	  has	  not	  been	  resolved	  
yet,	  cryo-­‐EM	  analysis	  suggested	  a	  more	  similar	  structure	  to	  HSV	  gH/gL	  (215).	  HCMV	  
gB	  and	  gH/gL	  together	  are	  necessary	  and	  sufficient	  to	  mediate	  cell-­‐cell	  fusion	  in	  a	  
transient	  expression	  system	  (216),	  with	  gH/gL	  provides	  an	  essential	  regulatory	  role	  
for	  gB’s	  fusion	  function.	  However,	  the	  mechanisms	  by	  which	  gH/gL	  regulates	  gB-­‐
fusion	  are	  still	  largely	  unknown.	  
Besides	  the	  core	  fusion	  machinery,	  each	  herpesvirus	  employs	  accessory	  
proteins	  to	  regulate	  the	  action	  of	  the	  gB	  and	  gH/gL.	  Accessory	  proteins	  usually	  
interact	  with	  gH/gL	  transiently	  or	  stably,	  and	  influence	  viral	  tropism	  through	  
receptor	  binding.	  HSV	  encodes	  gD	  to	  bind	  to	  cell	  surface	  receptors	  like	  herpesvirus	  
entry	  mediator	  (HVEM),	  nectin,	  or	  heparan	  sulfate	  (217).	  Upon	  receptor	  binding,	  gD	  
experiences	  conformational	  changes,	  which	  leads	  to	  transient	  interaction	  with	  
gH/gL,	  followed	  by	  gB-­‐mediated	  fusion	  (218–220).	  EBV	  encodes	  gp42,	  which	  forms	  
a	  trimeric	  complex	  with	  gH/gL.	  	  Thus	  EBV	  gH/gL	  exists	  in	  two	  forms,	  gH/gL/gp42	  
or	  unbound	  gH/gL.	  	  gH/gL/gp42	  promotes	  virus	  entry	  into	  B	  cells	  through	  
interaction	  between	  gp42	  and	  MHC	  II	  molecules	  on	  B	  cell	  surface.	  gH/gL	  promotes	  
virus	  entry	  into	  epithelial	  cells	  through	  interaction	  between	  gH/gL	  and	  specific	  
integrins	  on	  epithelial	  cell	  surface.	  Binding	  of	  gp42	  blocks	  gH/gL	  interaction	  with	  
integrins,	  thus	  gp42	  acts	  like	  a	  tropism	  switch	  adaptor	  (74,	  221–224).	  HCMV	  gH/gL	  
can	  be	  bound	  by	  gO	  or	  the	  small	  set	  of	  proteins	  UL128-­‐131,	  forming	  gH/gL/gO	  or	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gH/gL/UL128-­‐131	  complex.	  Both	  complexes	  could	  influence	  HCMV	  entry	  and	  
tropism.	  	  
HCMV	  gH/gL/UL128-­‐131	  and	  gH/gL/gO	  complexes	  in	  entry	  and	  tropism	  
gH/gL/UL128-­‐131	  
The	  gene	  locus	  of	  UL128,	  UL130,	  and	  UL131	  (collectively	  designated	  the	  UL128	  
locus,	  UL128L)	  encodes	  three	  small	  soluble	  proteins	  UL128	  (15	  kDa),	  UL130	  (35	  
kDa),	  and	  UL131	  (18	  kDa).	  It	  has	  been	  shown	  that	  an	  upstream	  promoter	  drives	  a	  
long	  transcript	  that	  expresses	  UL131,	  UL130	  and	  UL128,	  at	  the	  same	  time,	  there	  
might	  be	  a	  UL128	  specific	  promoter	  overlapping	  the	  UL131-­‐UL130	  region	  to	  
independently	  express	  UL128	  (78,	  175).	  Both	  UL130	  and	  UL131	  are	  modified	  by	  N-­‐
linked	  glycosylations,	  while	  UL128	  are	  not	  (80,	  225,	  226).	  UL128	  and	  UL130	  have	  
also	  been	  predicted	  to	  contain	  chemokine	  domains.	  UL128	  potentially	  has	  a	  CC	  
chemokine	  domain	  near	  the	  N	  terminus,	  while	  UL130	  might	  contain	  a	  central	  CXC	  
chemokine	  domain	  (78,	  175,	  226).	  Whether	  those	  chemokine	  domains	  functions	  in	  
vivo	  has	  not	  been	  convincingly	  determined	  yet.	  	  
UL128	  is	  covalently	  bound	  to	  gH/gL	  through	  disulfide	  linkage	  to	  gL,	  while	  
UL130/UL131	  are	  disulfide	  linked	  to	  each	  other	  but	  are	  noncovalently	  bound	  to	  
gH/gL	  (Figure.	  1-­‐6).	  Together	  UL128-­‐131	  proteins	  bind	  to	  gH/gL,	  forming	  a	  
pentameric	  gH/gL/UL128-­‐131	  complex.	  Incomplete	  complexes	  lacking	  any	  of	  the	  
UL128-­‐131	  proteins	  would	  not	  be	  transported	  to	  assembly	  compartment	  (AC)	  to	  be	  
incorporated	  into	  the	  mature	  virion	  envelope	  (77–80,	  215,	  225,	  227).	  UL128-­‐131	  
sequences	  from	  different	  HCMV	  strains	  are	  highly	  conserved	  (>92.3%	  at	  nucleotide	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level	  and	  >91.1%	  at	  amino	  acid	  level)	  (11,	  228),	  suggesting	  the	  pentameric	  complex	  
likely	  provides	  an	  important	  function	  for	  HCMV	  replication.	  
The	  consensus	  now	  is	  that	  gH/gL/UL128-­‐131	  is	  necessary	  for	  HCMV	  entry	  into	  
endothelial/epithelial	  cells,	  but	  is	  dispensable	  on	  fibroblasts.	  Several	  lines	  of	  
evidences	  support	  this	  conclusion:	  (1)	  Natural	  selection	  on	  fibroblasts	  leads	  to	  
spontaneous	  loss-­‐of-­‐function	  mutations	  within	  UL128L.	  Historically,	  HCMV	  was	  
mainly	  propagated	  on	  fibroblasts,	  and	  as	  a	  result,	  the	  high-­‐passage	  viruses	  were	  
associated	  with	  restricted	  tropism	  on	  epithelial	  and	  endothelial	  cells.	  The	  high-­‐
passage	  strains	  AD169	  and	  Towne	  were	  found	  to	  contain	  a	  single	  nucleotide	  
insertion	  in	  UL131,	  and	  a	  frameshift	  mutation	  in	  UL130	  respectively.	  Relatively	  less	  
passaged	  strain	  Toledo	  contains	  an	  inverted	  UL/b’	  region,	  with	  the	  site	  of	  inversion	  
within	  UL128	  (41,	  43,	  78,	  173–175).	  More	  recently	  Dargan	  et	  al.	  took	  isolates	  of	  
HCMV	  from	  clinical	  samples	  and	  intentionally	  passaged	  them	  on	  various	  tissue	  
cultures,	  and	  found	  that	  mutations	  in	  UL128L	  inevitably	  happened	  and	  were	  
exclusively	  limited	  to	  fibroblasts	  (176).	  (2)	  Reversions	  of	  the	  natural	  
epithelial/endothelial	  loss-­‐of–tropism	  mutants	  are	  all	  associated	  with	  reversal	  in	  
UL128L.	  Similarly,	  when	  UL131	  is	  intentionally	  repaired,	  AD169	  recovers	  infectivity	  
on	  endothelial/epithelial	  cells.	  (3)	  Introductions	  of	  targeted	  deletions	  into	  UL128L	  
result	  in	  loss	  of	  endothelial/epithelial	  tropism.	  (4)	  Trans-­‐complementation	  with	  
individual	  UL128,	  UL130,	  and	  UL131	  could	  also	  partially	  rescue	  
endothelial/epithelial	  tropism	  (41,	  77–79,	  225).	  Furthermore,	  antibodies	  against	  
UL128,	  UL130,	  or	  UL131	  efficiently	  blocks	  virus	  entry	  into	  endothelial/epithelial	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cells,	  but	  not	  fibroblasts	  (77),	  confirming	  that	  gH/gL/UL128-­‐131	  is	  required	  for	  
HCMV	  entry	  into	  endothelial/epithelial	  cells	  but	  not	  fibroblasts.	  	  
Trans-­‐expression	  of	  gH,	  gL,	  UL128-­‐131	  renders	  epithelial	  cell	  resistant	  to	  HCMV	  
infection,	  indicating	  gH/gL/UL128-­‐131	  facilitates	  HCMV	  entry	  into	  epithelial	  cells	  
through	  interactions	  with	  a	  specific,	  yet	  unknown,	  receptor	  (229).	  This	  putative	  
receptor	  interaction	  likely	  triggers	  a	  signaling	  cascade	  (e.g.,	  Src/paxillin	  pathway),	  
which	  leads	  to	  internalization	  of	  viral	  particle	  through	  endocytosis	  (230).	  
Subsequent	  virus	  entry	  happens	  by	  fusion	  from	  within	  the	  endosome	  in	  a	  low-­‐pH	  
dependent	  manner	  (79).	  Interestingly,	  viruses	  lacking	  gH/gL/UL128-­‐131	  can	  still	  be	  
efficiently	  internalized	  into	  endothelial/epithelial	  cells,	  although	  productive	  
infection	  is	  not	  observed	  (79,	  231),	  suggesting	  that	  subsequent	  fusion	  from	  within	  
the	  endosome	  is	  not	  allowed.	  This	  implies	  two	  possibilities:	  1)	  gH/gL/UL128-­‐131	  is	  
also	  required	  for	  the	  subsequent	  fusion	  event,	  or	  2)	  when	  lacking	  the	  “right”	  
gH/gL/UL128-­‐131-­‐specific	  endocytosis,	  virus	  gets	  internalized	  through	  a	  “wrong”	  
signaling	  pathway,	  from	  which	  escape	  into	  cytoplasm	  via	  membrane	  fusion	  is	  simply	  
impossible.	  If	  the	  first	  possibility	  were	  true,	  it	  would	  suggest	  that	  HCMV	  
internalization	  on	  epithelial	  cells	  is	  promiscuous	  and	  not	  entirely	  dependent	  on	  
gH/gL/UL128-­‐131.	  And	  gH/gL/UL128-­‐131	  is	  required	  specifically	  for	  the	  fusion	  
events,	  indicating	  that	  gH/gL/UL128-­‐131	  is	  sufficient	  for	  entry	  into	  
epithelial/endothelial	  cells.	  However,	  this	  view	  is	  challenged	  by	  gO-­‐null	  mutant	  
phenotype	  (descrided	  later	  in	  gH/gL/gO	  section),	  thus	  favors	  the	  second	  possibility.	  
In	  line	  with	  this,	  Vanarsdall	  et	  al.	  reported	  that	  while	  wild	  type	  HCMV	  can	  be	  
internalized	  into	  epithelial	  cells	  through	  endocytosis	  (i.e.,	  macropinocytosis)	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followed	  by	  low-­‐pH	  fusion	  with	  endosome,	  gH/gL/UL128-­‐131-­‐null	  virus	  can	  be	  
internalized	  as	  well,	  although	  via	  a	  different	  pathway	  (i.e.,	  dynamin-­‐dependent	  
endocytosis),	  however	  virus	  particles	  were	  not	  capable	  of	  fusion	  with	  endosome,	  
and	  were	  probably	  degraded	  in	  lysosome	  instead	  (102).	  
gH/gL/gO	  
gO	  is	  an	  approximately	  55	  kDa	  protein	  encoded	  by	  UL74	  gene.	  Posttranslational	  
modifications,	  including	  N-­‐link	  glycosylation,	  result	  in	  gO	  glycoforms	  ranging	  from	  
100~130	  kDa.	  gO	  is	  among	  the	  most	  diverse	  proteins	  encoded	  by	  HCMV.	  
Phylogenetic	  analysis	  showed	  that	  there	  are	  at	  least	  eight	  families	  of	  gO	  in	  nature,	  
varying	  by	  10~30%	  at	  amino	  acid	  level	  (89).	  gO	  forms	  a	  complex	  with	  gH/gL	  
through	  a	  disulfide	  linkage	  to	  gL	  (Figure.	  1-­‐	  6)	  (73,	  74,	  76,	  215,	  232).	  The	  binding	  of	  
gO	  promotes	  gH/gL	  trafficking	  from	  ER	  to	  Golgi-­‐derived	  assembly	  compartment,	  
resulting	  in	  the	  incorporation	  of	  gH/gL/gO	  complex	  into	  virion	  envelope	  (232,	  233).	  	  
The	  functions	  of	  gH/gL/gO	  have	  been	  mostly	  studied	  by	  deletion	  mutants.	  gO-­‐
null	  mutants	  on	  the	  background	  of	  several	  strains	  have	  exhibited	  a	  “small	  plaque”	  
phenotype	  on	  fibroblasts.	  Similar	  phenotype	  is	  also	  observed	  with	  the	  deletion	  
mutants	  of	  gO	  homologues	  in	  murine	  cytomegalovirus	  and	  guinea	  pig	  
cytomegalovirus	  (42,	  234–237).	  It	  has	  been	  suggested	  that	  the	  “small	  plaque”	  
phenotype	  is	  due	  to	  less	  production	  of	  cell-­‐free	  progeny	  virions,	  as	  a	  result	  of	  
deficiency	  in	  secondary	  envelopment	  (235,	  236).	  However,	  a	  more	  recent	  study	  by	  
Wille	  et	  al.	  demonstrated	  that	  the	  gO-­‐null	  virus	  released	  comparable	  amount	  of	  
progeny	  virions	  as	  wild	  type	  virus,	  arguing	  that	  gO-­‐null	  mutant	  was	  not	  defective	  in	  
secondary	  envelopment	  and	  egress,	  instead	  the	  “small	  plaque”	  phenotype	  was	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probably	  due	  to	  poor	  infectivity	  of	  the	  progeny.	  In	  line	  with	  this	  hypothesis,	  cell-­‐free	  
gO-­‐null	  viruses	  fail	  to	  enter	  fibroblasts	  (238),	  indicating	  gH/gL/gO	  is	  required	  for	  
entry	  into	  fibroblasts.	  Trans-­‐expression	  of	  gH/gL/gO	  renders	  fibroblasts	  resistant	  to	  
virus	  infection	  (239),	  further	  suggesting	  that	  gH/gL/gO	  probably	  engages	  specific	  
receptor	  on	  fibroblasts	  to	  mediate	  virus	  entry.	  Phenotypes	  of	  gO-­‐null	  virus	  on	  
epithelial/endothelial	  cells	  have	  not	  been	  looked	  carefully	  until	  a	  more	  recent	  
analysis	  of	  gO-­‐null	  virus	  published	  by	  Wille	  et	  al.	  Compared	  to	  wild	  type	  virus,	  the	  
mutant	  virus	  contained	  drastically	  less	  total	  gH/gL,	  probably	  due	  to	  loss	  of	  gO,	  but	  
had	  increasing	  amount	  of	  gH/gL/UL128-­‐131.	  However	  the	  mutant	  virus	  failed	  to	  
enter	  endothelial/epithelial	  cells	  in	  the	  presence	  of	  elevated	  level	  of	  gH/gL/UL128-­‐
131	  (238).	  Thus,	  it	  seems	  unlikely	  that	  gH/gL/UL128-­‐131	  is	  sufficient	  for	  virus	  
entry	  into	  endothelial/epithelial	  cells;	  instead	  infection	  of	  epithelial/endothelial	  
cells	  requires	  both	  gH/gL/gO	  and	  gH/gL/UL128-­‐131	  complexes.	  Taken	  together,	  
gO-­‐null	  mutagenesis	  studies	  seem	  to	  suggest	  that	  gH/gL/gO	  is	  required	  for	  HCMV	  
entry	  into	  both	  fibroblasts	  and	  epithelial/endothelial	  cells.	  	  
	   	  









Figure	  1-­‐6	  Schematic	  of	  gH/gL/gO	  and	  gH/gL/UL128-­‐131	  complexes.	  	  
S-­‐S	   represents	   disulfide	   linkage.	   Most	   of	   the	   disulfide	   bonds	   are	   not	   resolved,	   except	   recently	  
characterized	  gO-­‐gL-­‐cys144	  in	  gH/gL/gO,	  and	  UL128-­‐gL-­‐cys144	  in	  gH/gL/UL128-­‐131.	  
Focus	  of	  the	  dissertation	  
	  The	  central	  focus	  of	  this	  dissertation	  is	  to	  study	  the	  entry	  mechanisms	  of	  HCMV	  
into	  different	  cell	  types.	  Interaction	  between	  gH/gL	  and	  the	  fusion	  protein	  gB	  is	  a	  
conserved	  feature	  of	  the	  entry	  mechanism	  for	  all	  herpesviruses.	  HCMV	  gH/gL	  can	  be	  
bound	  by	  gO,	  or	  by	  the	  set	  of	  proteins	  UL128,	  UL130,	  and	  UL131,	  forming	  gH/gL/gO	  
and	  gH/gL/UL128-­‐131	  complexes	  in	  the	  virion	  envelope.	  	  
Studies	  in	  Chapter	  2	  showed	  that	  gO	  and	  UL128-­‐131	  competed	  for	  binding	  to	  
gH/gL,	  and	  that	  the	  ratio	  of	  the	  two	  complexes	  in	  the	  virion	  envelope	  can	  vary	  
dramatically	  among	  strains.	  This	  result	  was	  quite	  surprising	  and	  provided	  an	  
opportunity	  to	  address	  the	  functions	  and	  mechanisms	  of	  the	  gH/gL	  complexes.	  The	  
prevailing	  view	  has	  been	  that	  gH/gL/gO	  promotes	  gB-­‐fusion	  on	  fibroblast	  cells	  
while	  gH/gL/UL128-­‐131	  does	  the	  same	  thing	  on	  epithelial/endothelial	  cells.	  This	  
model	  is	  supported	  by	  the	  phenotype	  of	  UL128-­‐131	  deletion	  mutants,	  where	  the	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mutants	  fail	  to	  infect	  epithelial/endothelial	  cells	  but	  can	  infect	  fibroblast	  cells	  as	  
efficiently	  as	  wild	  type	  viruses.	  However,	  analysis	  of	  gO	  deletion	  mutants	  seems	  to	  
be	  inconsistent	  with	  this	  model.	  gO	  mutants	  fail	  to	  enter	  any	  cell	  type,	  suggesting	  
that	  gH/gL/UL128-­‐131	  is	  not	  sufficient	  on	  epithelial/endothelial	  cells,	  and	  entry	  
into	  that	  cell	  type	  requires	  both	  complexes.	  However,	  further	  analysis	  is	  largely	  
limited	  due	  to	  the	  severe	  growth	  defect	  of	  the	  gO	  mutants	  and	  the	  lack	  of	  a	  
complementation	  system.	  Studies	  in	  Chapter	  3	  bypassed	  this	  problem	  by	  utilizing	  
viruses	  that	  contain	  different	  amount	  of	  gH/gL/gO	  and	  gH/gL/UL128-­‐131	  on	  the	  
virion	  envelope,	  and	  showed	  that	  entry	  into	  of	  both	  fibroblasts	  and	  epithelial	  cells	  
was	  positively	  correlated	  with	  the	  abundance	  of	  gH/gL/gO,	  but	  not	  with	  
gH/gL/UL128-­‐131,	  indicating	  a	  new	  model	  where	  gH/gL/gO	  provides	  the	  
conserved	  herpesvirus	  “gH/gL	  entry	  function”	  of	  promoting	  gB	  fusion	  for	  entry	  into	  
all	  cell	  types,	  whereas	  gH/gL/UL128-­‐131	  provides	  a	  distinct,	  yet	  necessary	  function	  
on	  select	  cell	  types	  (i.e.	  epithelial/endothelial	  cells)	  (Figure.	  1-­‐7).	  Studies	  in	  Chapter	  
4	  underpinned	  multiple	  viral	  factors	  involving	  in	  the	  regulation	  of	  HCMV	  gH/gL	  
complexes	  assembly.	  	  
In	  conclusion,	  these	  findings	  stressed	  the	  importance	  of	  until	  now	  
underappreciated	  HCMV	  strain	  variation	  in	  the	  level	  of	  gH/gL	  glycoprotein	  
complexes.	  	  The	  resultant	  distinct	  function	  model	  highlighted	  that	  the	  fusion-­‐
competent	  complex	  gH/gL/gO	  could	  serve	  as	  a	  potential	  vaccine	  target,	  and	  the	  
non-­‐fusion	  complex	  gH/gL/UL128-­‐131	  may	  provide	  an	  unique	  opportunity	  to	  
characterize	  the	  fundamental	  mechanisms	  by	  which	  gH/gL	  regulates	  gB-­‐fusion.	  


















Figure	  1-­‐7	  HCMV	  distinct-­‐function	  tropism	  model.	  	  
gH/gL/gO	   provides	   the	   core-­‐fusion	   function	   by	   promoting	   gB-­‐fusion	   on	   all	   cell	   types,	   whereas	  
gH/gL/UL128-­‐131	   broadens	   virus	   tropism	   by	   providing	   a	   non-­‐fusion,	   yet	   necessary	   function	   for	  
entry	  into	  select	  cell	  types,	  like	  endothelial/	  epithelial	  cells.	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CHAPTER	  2. COMPARATIVE	  ANALYSIS	  OF	  
gO	  ISOFORMS	  REVEALS	  THAT	  STRAINS	  OF	  
HUMAN	  CYTOMEGELOVIRUS	  DIFFER	  IN	  THE	  
RATIO	  OF	  gH/gL/gO	  AND	  gH/gL/UL128-­‐131	  
IN	  THE	  VIRION	  ENVELOPE	  
This	  chapter	  is	  a	  modified	  version	  of	  the	  manuscript	  published	  in	  Journal	  of	  Virology	  
in	  September	  2013;	  87(17),	  9680-­‐9690	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INTRODUCTION	  	  
Human	  cytomegalovirus	  (HCMV)	  is	  a	  ubiquitous	  human	  pathogen	  that	  
contributes	  to	  significant	  disease	  throughout	  the	  world	  (16,	  240–242).	  	  Infections	  of	  
immunocompetent	  adults	  are	  generally	  mild,	  but	  like	  other	  herpesviruses,	  HCMV	  
establishes	  a	  persistent,	  or	  latent	  infection.	  	  Immunosuppression	  resulting	  from	  HIV	  
infection	  or	  post-­‐transplantation	  chemotherapy	  can	  allow	  reactivation	  of	  latent	  
HCMV,	  leading	  to	  a	  wide	  range	  of	  pathologies,	  including	  gastroenteritis,	  encephalitis,	  
retinitis,	  pneumonitis,	  and	  in	  the	  case	  of	  transplant	  recipients,	  graft	  rejection.	  In	  
pregnant	  women,	  HCMV	  can	  cross	  the	  placental	  barrier,	  and	  is	  associated	  with	  
several	  types	  of	  birth	  defects.	  The	  pleomorphic	  manifestation	  of	  HCMV-­‐associated	  
disease	  likely	  relates	  to	  the	  ability	  of	  the	  virus	  to	  infect	  a	  diverse	  spectrum	  of	  cell	  
types	  in	  the	  human	  body,	  including	  epithelial	  and	  endothelial	  cells,	  fibroblasts,	  
monocyte/macrophages,	  dendritic	  cells,	  hepatocytes,	  neurons	  and	  leukocytes	  (147,	  
148).	  The	  broad	  cell	  tropism	  of	  HCMV	  may	  reflect	  the	  abundance	  of	  distinct	  
glycoprotein	  complexes	  in	  the	  virion	  envelope.	  	  Computer	  predictions	  and	  mass	  
spectrometry	  analysis	  of	  purified	  virions	  have	  suggested	  that	  HCMV	  envelope	  may	  
contain	  more	  than	  20	  different	  glycoproteins	  (41,	  49).	  	  	  
Homologues	  of	  gB	  and	  gH/gL	  are	  found	  in	  all	  herpesviruses,	  and	  they	  represent	  
the	  core	  entry	  machinery	  for	  the	  family.	  	  Extensive	  studies	  of	  herpes	  simplex	  virus	  
(HSV)	  and	  Epstein	  -­‐	  Barr	  virus	  (EBV)	  have	  shown	  that	  gB	  is	  the	  fusion	  protein,	  and	  
that	  the	  gH/gL	  provides	  a	  regulatory	  role,	  likely	  requiring	  direct	  interaction	  with	  gB	  
(209,	  210,	  213,	  214,	  219).	  	  In	  addition,	  each	  of	  the	  different	  herpesviruses	  encodes	  
glycoproteins	  that	  appear	  to	  modify,	  or	  regulate	  the	  activity	  of	  the	  gB-­‐gH/gL	  core	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fusion	  machinery.	  	  For	  example	  HSV,	  EBV,	  and	  human	  herpesvirus	  6	  (HHV-­‐6)	  
encode	  gD,	  gp42	  and	  gQ1/gQ2	  respectively.	  Each	  of	  these	  glycoproteins	  interacts	  
transiently,	  or	  stably	  with	  gH/gL,	  and	  each	  engages	  cell	  surface	  proteins	  as	  entry-­‐
mediating	  receptors	  (reviewed	  in	  (189,	  243))	  (244).	  	  For	  EBV,	  the	  accessory	  protein	  
gp42	  has	  a	  well-­‐characterized	  effect	  on	  tropism.	  Unmodified	  gH/gL	  can	  bind	  to	  
integrin	  molecules	  to	  mediate	  entry	  into	  epithelial	  cells	  (222,	  223).	  When	  bound	  to	  
gH/gL,	  gp42	  likely	  blocks	  engagement	  of	  integrin	  by	  gH/gL,	  and	  instead	  gp42	  
engages	  MHC	  II	  molecules	  on	  the	  surfaces	  of	  B	  cells,	  thus	  acting	  like	  an	  adaptor	  to	  
switch	  viral	  tropism	  from	  epithelial	  cells	  to	  B	  cells	  (214,	  245,	  246).	  Importantly,	  
entry	  of	  EBV	  into	  epithelial	  or	  B	  cells	  requires	  either	  gH/gL	  (epithelial	  cells)	  or	  
gH/gL/gp42	  (B	  cells),	  not	  both	  (221,	  247).	  This	  indicates	  that,	  given	  the	  proper	  cell	  
receptors,	  either	  complex	  can	  make	  the	  necessary	  interactions	  with	  gB	  to	  mediate	  
fusion.	  
Because	  entry	  into	  all	  cell	  types	  requires	  membrane	  fusion	  mediared	  by	  gB,	  the	  
regulation	  of	  gB	  through	  direct	  interactions	  may	  be	  considered	  the	  core	  entry	  
function	  of	  the	  herpesvirus	  gH/gL.	  In	  a	  reduced	  system	  involving	  expression	  of	  
HCMV	  proteins	  by	  replication-­‐defective	  adenovirus	  (Ad)	  vectors,	  gH/gL	  and	  gB	  
were	  sufficient	  to	  induce	  cell-­‐cell	  fusion,	  indicating	  that	  the	  HCMV	  gH/gL	  provides	  
the	  direct	  interaction	  surfaces	  involved	  in	  the	  regulation	  of	  gB	  fusion	  activity	  (216).	  
However,	  like	  EBV,	  HCMV	  encodes	  a	  set	  of	  proteins	  that	  bind	  to	  gH/gL,	  i.e.,	  gO	  and	  
the	  set	  of	  UL128,	  UL130,	  and	  UL131	  proteins	  (73,	  74,	  77,	  227).	  	  Trafficking	  of	  HCMV	  
gH/gL	  from	  the	  endoplasmic	  reticulum	  (ER)	  to	  the	  Golgi-­‐derived	  viral	  envelopment	  
compartment	  depends	  on	  interactions	  with	  either	  the	  UL128-­‐131	  or	  gO,	  but	  the	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specific	  effects	  of	  these	  accessory	  proteins	  on	  the	  entry-­‐mediating	  function(s)	  of	  
gH/gL	  are	  not	  well	  understood	  (80,	  233).	  
UL128	  binds	  to	  gH/gL	  through	  disulfide	  bond,	  while	  UL130/UL131	  are	  not	  
(215).	  The	  binding	  of	  UL128-­‐131	  proteins	  promotes	  gH/gL	  trafficking	  to	  trans-­‐Golgi	  
derived	  assembly	  compartment,	  leading	  to	  a	  pentameric	  complex	  gH/gL/UL128-­‐
131	  present	  in	  virion	  envelope	  (80).	  UL128-­‐131	  deleion	  mutants	  failed	  to	  enter	  
epithelial	  or	  endothelial	  cells,	  but	  replicated	  well	  in	  primary	  fibroblasts	  (77–79,	  
248),	  and	  epithelial	  cells	  expressing	  gH/gL/UL128-­‐131	  from	  replication-­‐defective	  
adenovirus	  (Ad)	  vectors	  were	  resistant	  to	  infection	  with	  HCMV	  (229).	  	  These	  data	  
suggest	  that	  the	  gH/gL/UL128-­‐131	  facilitates	  entry	  by	  engaging	  molecules	  on	  the	  
surfaces	  of	  specific	  cell	  types.	  	  	  
The	  role	  of	  gO	  as	  an	  interaction	  partner	  of	  HCMV	  gH/gL	  is	  complicated	  by	  the	  
fact	  that	  it	  is	  among	  the	  most	  diverse	  proteins	  encoded	  by	  the	  virus.	  Rasmussen	  et	  
al.	  performed	  a	  phylogenetic	  analysis	  of	  the	  predicted	  gO	  sequences	  of	  more	  than	  40	  
clinical	  isolates	  of	  HCMV,	  and	  found	  eight	  groups,	  or	  families	  (89).	  	  Within	  each	  
group,	  the	  gO	  amino	  acid	  sequences	  were	  98-­‐100%	  identical,	  whereas	  differences	  
between	  groups	  ranged	  from	  about	  10-­‐30%.	  Stanton	  et	  al.	  analyzed	  HCMV	  from	  
clinical	  specimens	  collected	  from	  donors	  over	  10	  years,	  and	  found	  gO	  sequences	  
that	  fit	  within	  the	  families	  described	  by	  Rassmussen	  et	  al.	  Remarkably,	  the	  gO	  
sequences	  within	  individual	  donors	  were	  stable	  over	  time	  (145).	  Similar	  results	  
were	  also	  reported	  by	  Gorzer	  et	  al.	  (249).	  	  The	  tight	  grouping	  of	  gO	  sequences	  into	  
families,	  and	  their	  relative	  stability	  suggests	  that	  they	  represent	  alleles	  of	  the	  same	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gene,	  fixed	  in	  nature.	  	  Thus,	  the	  gO	  proteins	  encoded	  by	  different	  strains	  or	  isolates	  
of	  HCMV	  may	  be	  considered	  different	  gO	  isoforms.	  	  
Only	  limited	  isoforms	  of	  gO	  have	  been	  studied	  in	  detail.	  Huber	  et	  al.	  first	  
characterized	  gO	  as	  an	  approximately	  55	  kDa	  protein	  encoded	  by	  the	  UL74	  gene	  of	  
the	  fibroblast-­‐adapted	  strain	  AD	  169	  (AD)	  (75).	  Posttranslational	  modifications,	  
including	  extensive	  N-­‐linked	  glycosylation,	  result	  in	  gO	  glycoforms	  that	  range	  from	  
about	  100	  to	  130	  kDa,	  and	  interactions	  with	  gH/gL	  involve	  disulfide	  bonds	  such	  that	  
a	  trimer	  of	  gH/gL/gO	  is	  present	  in	  the	  AD	  virion	  envelope	  (73,	  74,	  76).	  More	  recent	  
analyses	  of	  the	  low-­‐passage	  clinical	  strain	  TR	  failed	  to	  detect	  gO	  in	  the	  virion	  
envelope,	  and	  several	  lines	  of	  evidence	  supported	  the	  conclusion	  that	  TRgO	  might	  
act	  as	  a	  true	  chaperone,	  promoting	  trafficking	  of	  gH/gL	  lacking	  UL128-­‐131	  from	  the	  
ER	  to	  the	  Golgi-­‐derived	  envelopment	  compartment,	  and	  then	  disassociating	  from	  
the	  complex,	  leaving	  unmodified	  gH/gL	  in	  the	  virion	  envelope	  (233).	  	  Because	  HCMV	  
strains	  encoding	  other	  gO	  isoforms	  were	  not	  analyzed,	  it	  was	  not	  clear	  if	  the	  
observed	  difference	  between	  AD,	  and	  TR	  reflected	  the	  diversity	  of	  gO,	  or	  the	  
fibroblast-­‐adaptation	  of	  AD.	  	  Regardless,	  gO	  mutants	  on	  the	  background	  of	  several	  
strains	  have	  exhibited	  extensive	  replication	  defects	  in	  a	  wider	  range	  of	  cell	  types	  
than	  were	  observed	  for	  UL128-­‐131	  mutants	  (42,	  234,	  235,	  238).	  	  Wille	  et	  al.	  found	  
that	  a	  gO	  null	  mutant	  TR,	  released	  normal	  numbers	  of	  DNA-­‐containing	  viral	  
particles	  to	  the	  culture	  supernatants,	  but	  these	  particles	  were	  defective	  for	  entry	  
into	  fibroblasts.	  	  Surprisingly,	  gO-­‐null	  TR	  was	  also	  unable	  to	  enter	  epithelial	  or	  
endothelial	  cells,	  despite	  elevated	  levels	  of	  the	  pentameric	  gH/gL/UL128-­‐131	  
complex	  in	  the	  virion	  envelope.	  	  In	  sum,	  these	  observations	  suggest	  a	  model	  in	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which	  there	  are	  different	  requirements	  for	  entry	  of	  HCMV	  into	  different	  cells	  types.	  	  
Entry	  into	  every	  cell	  type	  likely	  requires	  interactions	  between	  a	  gH/gL	  molecule	  and	  
the	  fusion	  protein	  gB.	  	  The	  failure	  of	  gO	  null	  TR	  to	  enter	  any	  cell	  type	  suggests	  that	  
this	  function	  is	  performed	  by	  gH/gL/gO	  or	  gH/gL,	  and	  not	  the	  pentameric	  
gH/gL/UL128-­‐131.	  	  This	  is	  markedly	  different	  from	  the	  model	  of	  EBV	  tropism,	  in	  
which	  either	  gH/gL	  or	  gH/gL/gp42	  is	  sufficient	  as	  a	  “core	  gH/gL	  complex”	  for	  entry	  
in	  epithelial	  or	  B	  cells,	  respectively.	  	  
The	  aim	  of	  the	  studies	  reported	  this	  chapter	  was	  to	  further	  explore	  gO	  
function(s)	  through	  comparative	  analysis	  of	  a	  wider	  set	  of	  gO	  isoforms.	  	  
Experiments	  involving	  reconstruction	  of	  gH/gL	  –	  gO	  interactions	  by	  replication-­‐
defective	  adenovirus	  (Ad)	  vector	  expression	  suggested	  that	  despite	  the	  sequence	  
diversity,	  all	  isoforms	  of	  gO	  form	  stable	  disulfide-­‐linked	  trimers	  with	  gH/gL.	  	  
Analyses	  of	  extracellular	  HCMV	  virions	  indicated	  that	  unlike	  previously	  reported,	  all	  
HCMV	  strains,	  including	  TR,	  likely	  contain	  gH/gL/gO	  and	  gH/gL/UL128-­‐131,	  and	  
little	  if	  any	  unbound	  gH/gL.	  	  Furthermore,	  strains	  of	  HCMV	  differ	  dramatically	  in	  the	  
ratio	  of	  gH/gL/gO	  to	  gH/gL/UL128-­‐131	  incorporated	  into	  the	  virion	  envelope,	  
which	  may	  relate	  to	  the	  pleomorphic	  tropism,	  and	  clinical	  pathology	  observed	  in	  
HCMV	  infections.	  
MATERIALS	  AND	  METHODS	  
Cell	  lines.	  	  Primary	  human	  foreskin	  fibroblasts	  (HFF;	  LifeTechnologies),	  and	  
U373-­‐MG	  human	  microglial	  cells	  (American	  Type	  Culture	  Collection;	  Manassas,	  VA,	  
USA)	  were	  grown	  in	  Dulbecco’s	  modified	  Eagle’s	  medium	  (DMEM;	  LifeTechnologies)	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supplemented	  with	  12%,	  heat-­‐inactivated	  fetal	  bovine	  serum	  (FBS;	  HyClone),	  or	  
10%	  bovine	  growth	  serum	  (BGS;	  HyClone).	  	  239(IQ)	  cells	  (Microbix,	  Toronto,	  
Canada)	  were	  grown	  in	  minimum	  essential	  medium	  (MEM;	  LifeTechnologies)	  plus	  
10%	  FBS.	  	  HFFtet	  cells,	  which	  express	  the	  tetracycline	  repressor	  protein,	  were	  
provided	  by	  Richard	  Stanton	  (Cardiff	  Univ.,	  Cardiff,	  UK),	  and	  were	  propagated	  in	  
DMEM	  supplemented	  with	  12%	  FBS	  (177).	  	  
Human	  cytomegalovirus	  (HCMV).	  	  All	  HCMV	  were	  derived	  from	  bacterial	  
artificial	  chromosome	  (BAC)	  clones.	  	  BAC	  clone	  TR	  was	  provided	  by	  Jay	  Nelson	  
(Oregon	  Health	  and	  Sciences	  Univ.,	  Portland	  OR,	  USA.)	  (41).	  	  BAC	  clone	  TB40/e	  
(BAC-­‐4;TB)	  was	  provided	  by	  Christian	  Sinzger	  (Univ.	  of	  Tübingen,	  Tübingen,	  
Germany)	  (184).	  	  BAC	  clones	  PH,	  and	  AD169	  (AD)	  were	  provided	  by	  Tom	  Shenk	  
(Princeton	  Univ.,	  Princeton,	  NJ,	  USA)	  (41).	  	  BAC	  clone	  Merlin	  (ME)	  (pAL1393),	  which	  
harbors	  tetracycline	  operator	  sequences	  within	  the	  transcriptional	  promoter	  of	  
UL130,	  and	  UL131,	  was	  provided	  by	  Richard	  Stanton	  (Cardiff	  Univ.,	  Cardiff,	  UK)	  
(177).	  	  Infectious	  HCMV	  was	  recovered	  by	  electroporation	  of	  BAC	  DNA	  into	  MRC-­‐5	  
fibroblasts	  as	  described	  by	  Wille	  et	  al.	  (238).	  	  HCMV	  stocks	  were	  produced	  by	  
infecting	  HFF	  (or	  HFFtet	  for	  ME)	  using	  0.1	  plaque-­‐forming	  units	  (PFU)	  per	  cell	  for	  
10-­‐16	  days.	  	  Cell-­‐associated	  virus	  was	  prepared	  by	  sonic	  disruption	  of	  infected	  cells,	  
and	  clearing	  large	  cellular	  debris	  by	  centrifugation	  at	  1500	  x	  g	  for	  10	  min.	  	  	  
Extracellular	  virus	  was	  concentrated	  from	  culture	  supernatants	  by	  centrifugation	  at	  
50,000	  x	  g	  for	  1	  h,	  and	  pellets	  were	  resuspended	  in	  DMEM	  plus	  10%	  FBS.	  	  PFU	  were	  
determined	  by	  plaque	  assay,	  or	  by	  TCID50	  on	  replicate	  HFF	  cultures.	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Phylogenetic	  and	  sequence	  alignment	  analyses.	  	  DNA	  sequences	  of	  the	  UL74	  
genes	  of	  clinical	  HCMV	  isolates,	  and	  HCMV	  BAC	  clones	  have	  been	  reported	  along	  
with	  Genbank	  accession	  numbers	  (41,	  43,	  89).	  	  Alignment,	  and	  phylogenetic	  
analyses	  were	  performed	  using	  the	  default	  parameters	  of	  the	  online	  MAFFT	  (v.7)	  
tool	  offered	  by	  the	  Computational	  Biology	  Research	  Center	  (CBRC),	  National	  
Institute	  of	  Advanced	  Industrial	  Science	  and	  Technology	  (AIST),	  Japan.	  	  
	  Antibodies.	  	  Monoclonal	  antibodies	  (MAb)	  specific	  for	  HCMV	  gH	  (14-­‐4b)	  were	  
provided	  by	  Bill	  Britt	  (Univ.	  of	  Alabama,	  Birmingham,	  AL)	  (250).	  	  Anti-­‐HA	  MAb	  were	  
obtained	  from	  Sigma	  Aldrich	  (St	  Louis,	  MO,	  USA).	  	  Anti-­‐UL128	  MAb,	  4B10	  was	  
provided	  by	  Tom	  Shenk	  (77).	  	  Rabbit,	  polyclonal	  anti-­‐peptide	  antibodies	  directed	  
against	  HCMV	  gH,	  gL,	  TRgO,	  UL130	  and	  UL131	  were	  provided	  by	  David	  Johnson	  
(Oregon	  Health	  and	  Sciences	  Univ.,	  Portland	  OR,	  USA)	  (80,	  233).	  	  Additional	  rabbit	  
polyclonal	  antisera	  were	  raised	  against	  synthetic	  peptides	  corresponding	  to	  
residues	  258-­‐277	  of	  MEgO,	  250-­‐269	  of	  TBgO,	  252-­‐271	  of	  ADgO,	  and	  248-­‐267	  of	  
TNgO.	  	  Peptide	  synthesis,	  rabbit	  immunization,	  and	  serum	  collection	  was	  performed	  
by	  GenScript	  (Piscataway,	  NJ,	  USA.).	  	  
Replication	  defective	  Ad	  vectors.	  	  Nonreplicating	  (E1-­‐)	  Ad	  vectors	  for	  
expression	  of	  HCMV	  TR	  gH,	  gL,	  and	  gO,	  MEgO,	  TBgO,	  ADgO	  and	  TNgO	  were	  
generating	  using	  a	  commercial	  (Microbix)	  modification	  of	  the	  method	  of	  Matthews	  
et	  al.	  (251).	  	  Briefly,	  HCMV	  genes	  (gH:	  UL75,	  gL:	  UL115,	  gO:	  UL74)	  were	  synthesized,	  
and	  codon	  optimized	  by	  GeneArt/Invitrogen	  (Regensburg,	  Germany).	  	  Coding	  
sequence	  corresponding	  to	  the	  influenza	  HA	  epitope	  was	  added,	  in	  frame	  with	  the	  C-­‐
terminus	  of	  UL74	  constructs.	  	  HCMV	  genes	  were	  ligated	  into	  shuttle	  plasmid	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pDC316	  (io)	  (Microbix),	  and	  shuttle	  plasmids	  were	  transfected	  into	  293IQ	  cells	  
along	  with	  the	  Ad	  genomic	  plasmid,	  pBHGloxΔE1,	  3Cre	  (Microbix).	  	  Cre-­‐lox	  
recombination	  resulted	  in	  Ad	  vectors	  that	  were	  subsequently	  propagated	  on	  293IQ	  
cells,	  which	  express	  the	  lac	  repressor	  protein.	  	  The	  lac	  repressor	  protein	  binds	  to	  lac	  
operator	  sequences	  between	  the	  promoter,	  and	  the	  HCMV	  transgene,	  reducing	  
expression	  of	  the	  transgene	  in	  293IQ	  cells.	  	  Ad	  vector	  PFU	  counts	  were	  determined	  
using	  293IQ	  cells.	  	  Multiplicities	  of	  infection	  (MOI)	  for	  experiments	  on	  U373	  or	  HFF	  
cells	  were	  determined	  empirically	  for	  each	  Ad	  vector	  to	  give	  appropriate	  
expression,	  and	  ranged	  from	  3	  -­‐	  30	  PFU/cell.	  	  There	  was	  little	  production	  of	  Ad	  
proteins,	  and	  little	  or	  no	  cytopathic	  effect	  was	  observed.	  	  
Radiolabeling	  of	  Ad	  vector	  transduced	  cells,	  and	  immunoprecipitation	  (IP)	  
analysis	  of	  expressed	  proteins.	  	  Cells	  were	  transduced	  with	  Ad	  vectors	  for	  12-­‐24	  
hours,	  washed	  extensively	  in	  labeling	  medium	  (DMEM	  lacking	  methionine	  and	  
cysteine)	  then	  incubated	  in	  this	  medium	  for	  45	  min	  at	  37	  C.	  	  Cells	  were	  then	  
incubated	  for	  5	  min	  in	  labeling	  medium	  supplemented	  with	  [35S]-­‐
methionine/cysteine	  (500-­‐1000	  µCi/ml;	  Perkin	  Elmer).	  	  Radioactivity	  was	  chased	  
by	  incubating	  cells	  in	  DMEM	  containing	  10-­‐fold	  excess	  nonradioactive	  methionine	  
and	  cysteine	  for	  indicated	  times.	  	  Cell	  proteins	  were	  extracted	  with	  1%	  Triton	  X-­‐
100,	  0.5%	  sodium	  deoxycholate	  in	  20mM	  tris	  (pH	  6.8),	  100	  mM	  NaCl;	  (TBS-­‐
TX/DOC),	  supplemented	  with	  0.5%	  bovine	  serum	  albumin	  (BSA),	  and	  1mM	  
phenylmethylsulfonyl	  fluoride	  (PMSF).	  	  Extracts	  were	  clarified	  by	  centrifugation	  at	  
16000	  x	  g	  for	  30	  min,	  and	  incubation	  with	  protein	  A-­‐agarose	  beads	  (Invitrogen)	  for	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1	  –	  2	  h.	  	  Proteins	  were	  IP’ed	  by	  the	  addition	  of	  MAb,	  or	  rabbit	  polyclonal	  antiserum	  
as	  indicated	  for	  2	  h	  followed	  by	  protein	  A-­‐agarose	  for	  an	  additional	  2	  h.	  Agarose	  
beads	  were	  collected	  by	  centrifugation,	  and	  washed	  3	  times	  in	  TBS-­‐TX/DOC.	  	  For	  
endo	  H	  and	  PNGase	  F	  treatment,	  IP’ed	  proteins	  bound	  to	  protein	  A-­‐agarose	  were	  
incubated	  with	  endo	  H	  or	  PNGase	  F	  in	  the	  buffer	  specified	  by	  the	  enzyme	  
manufacturer	  (New	  England	  Biolabs).	  	  Proteins	  were	  eluted	  from	  protein	  A-­‐agarose	  
by	  boiling	  in	  2%	  SDS,	  and	  2%	  2-­‐mercaptoethanol,	  and	  separated	  by	  electrophoresis	  
using	  SDS-­‐polyacrylamide	  gels.	  	  For	  sequential	  IP	  experiments,	  proteins	  were	  eluted	  
from	  protein	  A-­‐agarose	  beads	  by	  incubation	  in	  2%	  SDS,	  30mM	  dithiothreitol	  (DTT),	  
in	  100	  mM	  tris	  (pH	  7.4),	  100mM	  NaCl	  at	  95	  C	  for	  5min.	  The	  samples	  were	  diluted	  
35-­‐fold	  with	  solution	  of	  50	  mM	  tris	  (pH	  7.4),	  300mM	  NaCl,	  10mM	  iodoacetamide,	  
1%TX100,	  0.5%	  DOC,	  5mM	  EDTA,	  0.02%	  sodium	  azide.	  	  Then,	  the	  secondary	  IP	  
antibody	  was	  added,	  and	  samples	  analyzed	  as	  described	  above.	  	  	  
Western	  blot	  analysis	  of	  Ad	  vector	  -­‐	  or	  HCMV-­‐	  infected	  cells,	  and	  HCMV	  
extracellular	  virus	  particles.	  	  HFF	  cells	  were	  transduced	  with	  Ad	  vectors	  for	  12-­‐24	  
days,	  and	  proteins	  were	  extracted	  in	  TBS-­‐TX/DOC.	  	  For	  HCMV	  experiments,	  HFF	  or	  
HFFtet	  cells	  were	  infected	  with	  an	  MOI	  of	  3	  of	  different	  strains	  of	  HCMV.	  	  At	  5-­‐10	  
days	  post	  infection	  (depending	  on	  the	  strain)	  proteins	  were	  extracted	  from	  infected	  
cells,	  and	  extracellular	  virus	  collected	  from	  the	  culture	  supernatant	  by	  
centrifugation	  as	  described	  in	  (233)	  in	  the	  same	  volume	  of	  TBS-­‐TX/DOC.	  	  Extracts	  
were	  clarified	  by	  centrifugation	  at	  16000	  x	  g	  for	  30	  min,	  and	  adjusted	  to	  2%	  SDS	  
with,	  or	  without	  2%	  2-­‐ME,	  and	  boiled	  for	  10	  min.	  	  Proteins	  were	  separated	  by	  SDS-­‐
PAGE	  and	  transferred	  to	  polyvinylidine	  fluoride	  membranes	  (Whatman)	  in	  a	  buffer	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containing	  10mM	  NaHCO3	  and	  3mM	  Na2CO3	  (pH	  9.9),	  plus	  10%	  methanol.	  	  
Transferred	  proteins	  were	  probed	  with	  rabbit	  polyclonal	  antibodies,	  or	  MAbs	  
specific	  for	  HCMV	  proteins,	  or	  the	  HA	  epitope,	  followed	  by	  horseradish	  peroxidase-­‐
conjugated	  secondary	  antibodies,	  and	  chemiluminescence	  was	  detected	  using	  a	  
Fujifilm	  LAS-­‐3000	  luminescent	  image	  analyzer.	  
RESULTS	  
Diversity	  of	  HCMV	  gO	  among	  laboratory	  strains,	  and	  clinical	  isolates	  of	  
HCMV.	  	  A	  meta-­‐analysis	  of	  the	  gO	  sequences	  reported	  by	  Rasmussen	  et	  al.	  was	  
performed	  using	  modern	  phylogeny	  software,	  and	  included	  several	  commonly	  
studied	  low-­‐passage,	  “clinical”	  BAC-­‐cloned	  strains	  of	  HCMV	  that	  were	  not	  available	  
at	  the	  time	  of	  the	  prior	  studies	  (89)	  (Figure.	  2-­‐1).	  	  The	  gO	  isoforms	  encoded	  by	  
HCMV	  TR,	  Merlin	  (ME),	  TB40/e	  (TB)	  and	  PH	  fit	  well	  into	  the	  groups	  described	  by	  
Rasmussen	  et	  al.	  	  TRgO,	  MEgO,	  and	  TBgO	  were	  each	  identical	  to	  at	  least	  one	  of	  the	  
other	  sequences	  from	  the	  same	  group,	  whereas	  PHgO	  differs	  from	  its	  closest	  family	  
members,	  (540,	  1176,	  and	  1736)	  by	  two	  amino	  acid	  substitutions	  (G280V	  and	  
S398P).	  	  Strains	  AD169	  (AD),	  and	  Towne	  (TN)	  were	  extensively	  propagated	  in	  
cultured	  fibroblasts,	  and	  are	  known	  to	  harbor	  many	  genetic	  mutations,	  deletions	  
and	  rearrangements	  compared	  to	  the	  low-­‐passage	  strains,	  such	  as	  TR,	  ME,	  TB	  and	  
PH	  (41,	  43,	  173).	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Figure	  2-­‐1	  Phylogenetic	  relationships	  of	  predicted	  gO	  amino	  acid	  sequences	  encoded	  
by	  lab	  strains	  and	  clinical	  isolates	  of	  HCMV.	  
HCMV	  BAC	  clones	  used	  in	  the	  current	  studies	  (bold)	  and	  clinical	  isolates	  described	  in	  Rasmussen	  et	  
al.	  (89)	  were	  included,	  and	  the	  phylogeny	  was	  estimated	  using	  Neighbour-­‐joining	  with	  the	  JTT	  codon	  
model	   implemented	   in	  MAFFT	   v.7.	   	  Horizontal	   bar	   represents	   the	   expected	   number	   of	   amino	   acid	  
substitutions	  per	  site	  according	  to	  the	  indicated	  scale.	  
	  
However	  the	  gO	  sequence	  of	  TN	  is	  identical	  to	  that	  of	  the	  clinical	  isolate	  DM13,	  and	  
ADgO	  differs	  from	  the	  gO	  of	  clinical	  isolates	  298,	  6444,	  SW1,	  and	  SW3	  by	  only	  one	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amino	  acid	  located	  within	  the	  predicted	  signal	  peptide.	  	  Thus,	  the	  gO	  isoforms	  
encoded	  by	  these	  lab	  and	  clinical	  strains	  are	  reflective	  of	  the	  diversity	  of	  this	  protein	  
in	  nature.	  	  It	  is	  important	  to	  note	  that	  given	  the	  limited	  number	  of	  sequences	  
available,	  and	  the	  lack	  of	  understanding	  of	  gO	  function(s),	  no	  conclusions	  can	  be	  
made	  concerning	  potential	  adaptive	  evolution	  of	  gO	  isoforms	  along	  lineages	  from	  a	  
common	  ancestor.	  	  Despite	  this,	  there	  clearly	  exists	  extensive	  diversity	  in	  gO	  
encoded	  by	  strains	  of	  HCMV	  in	  nature,	  and	  it	  is	  a	  compelling	  hypothesis	  that	  these	  
differences	  may	  affect	  the	  function(s)	  of	  gO,	  and	  the	  biology	  of	  the	  virus.	  
Sequence	  alignments	  of	  representative	  gO	  isoforms	  revealed	  regions	  of	  high	  
diversity,	  and	  regions	  of	  conservation	  (Figure.	  2-­‐2).	  	  Sequence	  diversity	  was	  found	  
in	  the	  N-­‐terminal	  100	  residues,	  of	  which	  approximately	  70	  are	  predicted	  to	  remain	  
following	  cleavage	  of	  the	  signal	  peptide.	  	  The	  region	  corresponding	  to	  
approximately	  270-­‐340	  of	  the	  alignment	  also	  harbored	  notable	  diversity.	  	  Six	  
conserved	  cysteine	  (cys)	  residues	  were	  identified	  at	  aligned	  positions	  31,	  152,	  160,	  
178,	  229,	  and	  354.	  	  Cys	  31	  is	  located	  within	  the	  predicted	  signal	  peptide,	  suggesting	  
that	  it	  is	  not	  relevant	  to	  the	  function	  of	  gO.	  	  The	  remaining	  five	  cys	  are	  also	  found	  in	  
the	  gO	  homologues	  encoded	  by	  other	  beta-­‐herpesviruses	  such	  as	  HHV-­‐6,	  rhesus	  
CMV,	  and	  murine	  CMV,	  suggesting	  the	  importance	  of	  disulfide	  bonds	  for	  the	  
structure,	  and	  function	  of	  the	  gO	  interactions	  with	  gH/gL	  complex	  (252–254).	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Figure	  2-­‐2	  Comparisons	  of	  amino	  acid	  sequences	  of	  gO	  encoded	  by	  laboratory	  strains,	  
and	  clinical	  isolates	  of	  HCMV.	  
Top:	  MAFFT	  alignment	  of	  one	  representative	  gO	  sequence	  from	  each	  of	  the	  eight	  groups	  indicated	  in	  
Figure.	   2-­‐1.	   	   Darker	   shading	   indicates	   sequence	   conservation.	   	   The	   approximate	   location	   of	   6	  
conserved	   cysteine	   residues	   is	   indicated.	   Middle:	   Kyte/Doolittle	   hydrophilicity	   analysis	   of	   TRgO.	  	  
Bottom.	   Sequences	  of	   synthetic	  peptides	  used	   to	   raise	   anti-­‐gO	  antibodies.	   	  Asterisks	   at	   the	  bottom	  
indicate	   conserved	   residues,	   and	   shaded	   boxes	   highlight	   the	   position	   of	   a	   proline	   in	   each	   peptide	  
sequence.	  
Construction	  of	  replication-­‐defective	  Ad	  vectors	  to	  express	  gO	  isoforms.	  To	  
study	  the	  effects	  of	  gO	  sequence	  diversity	  on	  interactions	  with	  gH/gL,	  we	  
constructed	  Ad	  vectors	  to	  express	  the	  gO	  isoforms	  encoded	  by	  strains	  TR,	  ME,	  TB,	  
AD,	  and	  TN,	  each	  with	  a	  C-­‐terminal	  HA-­‐epitope	  tag.	  	  These	  Ad	  vectors	  represent	  the	  
HCMV	  strains	  for	  which	  there	  are	  published	  mutational	  analyses	  of	  gO,	  and/or	  
represent	  the	  commonly	  studied	  fibroblast-­‐adapted,	  and	  low-­‐passage	  clinical	  
strains	  (42,	  234,	  235,	  238).	  	  
	  















Figure	  2-­‐3	  Expression	  of	  HCMV	  gO	  isoforms	  by	  replication-­‐defective	  adenovirus	  (Ad)	  
vectors.	  
U373	  cells	  were	  transduced	  with	  Ad	  vectors	  expressing	  gO	  isoforms	  (HA-­‐tagged)	  derived	  from	  HCMV	  
TR	  (TRgO),	  Merlin	  (MEgO),	  TB40	  (TBgO),	  AD169	  (ADgO),	  and	  Towne	  (TNgO).	  	  Cells	  were	  labeled	  for	  
5	  min	  with	   [35S]	  methionine/cysteine,	   and	   then	   the	   label	  was	   chased	   for	   0	   or	   180	  min.	   	   Proteins	  
were	  immunoprecipitated	  with	  anti-­‐HA	  antibodies,	   left	  untreated	  (-­‐),	  or	  treated	  with	  endo	  H	  (H)	  or	  
PNGaseF	  (F),	  and	  separated	  by	  SDS-­‐PAGE	  (8%)	  under	  reducing	  conditions.	  	  Arrows,	  and	  arrowheads	  
mark	  untreated,	  and	  deglycosylated	  forms	  of	  gO,	  respectively.	  
	  
	  
For	  initial	  characterization	  of	  gO	  isoforms,	  cells	  were	  transduced	  with	  Ad	  
vectors,	  and	  proteins	  were	  pulse-­‐radiolabeled,	  and	  then	  chased	  for	  0	  or	  180	  min.	  	  
Cell	  extracts	  were	  then	  analyzed	  by	  immunoprecipitation	  (IP)	  with	  anti-­‐HA	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antibodies	  followed	  by	  treatment	  with	  endoglycosidase	  H	  (endo	  H),	  which	  removes	  
the	  high-­‐mannose	  N-­‐linked	  glycans	  added	  to	  proteins	  in	  ER,	  or	  PNGase	  F,	  which	  can	  
remove	  all	  types	  of	  N-­‐linked	  glycans,	  including	  those	  that	  have	  been	  modified	  by	  
enzymes	  present	  only	  in	  the	  Golgi	  complex.	  	  Proteins	  were	  then	  separated	  by	  SDS-­‐
PAGE	  under	  reducing	  conditions	  (Figure.	  2-­‐3).	  	  Each	  gO	  isoform	  migrated	  with	  an	  
apparent	  molecular	  weight	  of	  approximately	  100	  kDa.	  	  	  Slight	  differences	  in	  mobility	  
likely	  related	  to	  differences	  in	  polypeptide	  length	  among	  these	  isoforms	  (predicted	  
gO	  amino	  acids,	  including	  signal	  peptide:	  TR;	  462,	  ME;	  472,	  TB;	  464,	  AD;	  466,	  and	  
TN;	  456),	  as	  well	  as	  differences	  in	  N-­‐linked	  glycosylation,	  or	  other	  post	  translation	  
modifications.	  Faster	  migrating	  bands	  were	  also	  observed	  in	  the	  untreated	  lanes	  of	  
the	  0	  min	  chase	  samples.	  	  Since	  these	  bands	  were	  absent	  following	  glycosidase	  
treatment,	  and	  were	  not	  apparent	  after	  3	  hours	  of	  chase,	  they	  were	  likely	  
glycosylation	  intermediates	  of	  gO	  present	  in	  the	  cells	  after	  the	  pulse	  labeling.	  	  The	  
N-­‐linked	  glycans	  on	  each	  gO	  isoform	  remained	  sensitive	  to	  endo	  H	  treatment	  for	  at	  
least	  3	  h	  of	  chase	  time,	  as	  indicated	  by	  the	  decrease	  in	  apparent	  molecular	  weight	  to	  
approximately	  55	  kDa.	  	  These	  data	  indicate	  that	  gO	  isoforms	  share	  the	  
characteristics	  of	  being	  highly	  modified	  with	  N-­‐linked	  glycans,	  and	  being	  retained	  in	  
the	  ER	  when	  expressed	  in	  the	  absence	  of	  other	  HCMV	  proteins.	  	  	  
Cross-­‐reactivity	  of	  antibodies	  raised	  against	  distinct	  gO	  isoforms.	  	  
Kyte/Doolittle	  analysis	  of	  TRgO	  indicated	  one	  prominent	  hydrophilic	  stretch	  	  














Figure	  2-­‐4	  Western	  blot	  detection	  of	  gO	  isoforms	  by	  anti-­‐peptide	  rabbit	  sera.	  	  
Primary	   human	   fibroblasts	   (HFF)	   were	   transduced	   with	   Ad	   vectors	   expressing	   the	   indicated	   gO	  
isoforms	  (HA-­‐tagged).	   	  Cell	  extracts	  were	  analyzed	  by	  western	  blot	  using	  anti-­‐HA	  antibodies	  (A),	  or	  
antibodies	  raised	  against	  peptides	  derived	  from	  gO	  of	  HCMV	  TR	  (A),	  Merlin	  (B),	  TB40	  (C),	  or	  AD169	  
(E).	  	  	  For	  detection	  with	  anti-­‐peptide	  antibodies	  (A	  –	  E),	  long,	  and	  short	  chemiluminescent	  detections	  
(top	  and	  bottom,	  respectively)	  were	  performed	  in	  parallel,	  allowing	  comparison	  of	  signal	  intensities.	  
	  
	  
including	  amino	  acids	  245-­‐271	  (Figure.	  2-­‐2).	  	  A	  synthetic	  peptide	  corresponding	  to	  
these	  residues	  was	  used	  to	  raise	  anti-­‐TRgO	  antibodies	  in	  rabbits	  that	  reacted	  well	  
with	  TRgO,	  but	  not	  other	  gO	  isoforms	  (233).	  	  Kyte/Doolittle	  analysis	  of	  other	  gO	  
isoforms	  indicated	  the	  presence	  of	  a	  similar	  hydrophilic	  region	  at	  the	  aligned	  
location	  (data	  not	  shown).	  	  However,	  there	  are	  some	  amino	  acid	  differences	  in	  this	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region	  that	  may	  explain	  the	  lack	  of	  cross-­‐reactivity	  of	  the	  TRgO	  antiserum	  with	  
other	  gO	  isoforms.	  	  	  
To	  allow	  more	  comprehensive	  comparative	  analyses	  of	  gO	  isoforms,	  antibodies	  
were	  raised	  against	  peptides	  corresponding	  to	  the	  aligned	  hydrophilic	  region	  of	  the	  
gO	  isoforms	  encoded	  by	  strains	  ME,	  TB,	  AD,	  and	  TN,	  and	  including	  conserved	  lysine,	  
and	  leucine	  residues	  (Figure.	  2-­‐2).	  	  These	  antibodies	  were	  characterized	  by	  western	  
blot	  analysis	  using	  extracts	  from	  cells	  transduced	  with	  Ad	  vectors	  expressing	  the	  
HA-­‐tagged	  gO	  isoforms	  (Figure.	  2-­‐4A).	  	  The	  previously	  characterized	  anti-­‐TRgO	  
antibodies	  cross-­‐reacted	  with	  TBgO,	  but	  failed	  to	  detect	  MEgO	  or	  ADgO	  (Figure.	  2-­‐
4B).	  	  Both	  the	  anti-­‐TBgO,	  and	  anti-­‐ADgO	  antibodies	  showed	  overall	  stronger	  
reactivity,	  and	  unexpected	  cross-­‐reactivity	  with	  other	  isoforms	  of	  gO,	  detecting	  
TRgO	  better	  than	  the	  TRgO-­‐specific	  antiserum	  (Figure.	  2-­‐4	  compare	  panel	  B,	  with	  D	  
and	  E).	  	  In	  contrast,	  anti-­‐MEgO	  antibodies	  were	  highly	  specific	  for	  MEgO	  (Figure.	  2-­‐
4C).	  	  The	  specificity	  of	  the	  anti-­‐MEgO	  antibodies	  may	  be	  related	  to	  the	  unique	  
position	  a	  proline	  residue	  in	  the	  aligned	  peptide	  sequences	  (Figure.	  2-­‐2).	  	  The	  TNgO	  
peptide	  sequence	  is	  less	  hydrophilic	  than	  the	  others	  (data	  not	  shown).	  	  Consistent	  
with	  this,	  antibodies	  raised	  against	  TNgO	  peptides	  failed	  to	  react	  with	  any	  isoform	  of	  
gO,	  and	  other	  antibodies	  failed	  to	  detect	  TNgO	  (data	  not	  shown).	  	  Thus,	  strain	  TN	  
was	  not	  included	  in	  the	  comparative	  analyses	  of	  gO	  in	  the	  HCMV	  envelope	  described	  
below.	  	  However,	  the	  TBgO	  and	  ADgO	  antibodies	  detected	  the	  gO	  isoform	  expressed	  
by	  the	  low-­‐passage	  strain,	  PH	  (data	  not	  shown).	  
Reconstruction	  of	  gH/gL/gO	  complexes	  by	  Ad	  vector	  expression.	  	  Unlike	  
gO,	  gH/gL	  is	  highly	  conserved	  among	  strains	  of	  HCMV,	  differing	  by	  <5%	  of	  amino	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acids	  among	  strains,	  but	  it	  is	  possible	  that	  gO	  diversity	  reflects	  coevolution	  with	  
specific	  gH/gL	  isoforms.	  	  To	  test	  whether	  or	  not	  distinct	  gO	  isoforms	  could	  bind	  to	  a	  
common	  isoform	  of	  gH/gL,	  Ad	  vectors	  were	  used	  to	  express	  TRgH/gL	  along	  with	  the	  
different	  gO	  isoforms.	  	  Cells	  were	  pulse-­‐chase	  labeled,	  and	  analyzed	  by	  IP	  with	  anti-­‐
gH	  antibodies	  followed	  by	  treatment	  with	  endo	  H	  or	  PNGaseF,	  and	  separation	  by	  
reducing	  SDS-­‐PAGE	  (Figure.	  2-­‐5).	  	  In	  the	  absence	  of	  gO,	  gH/gL	  remained	  endo	  H	  
sensitive	  for	  at	  least	  3	  h,	  indicative	  of	  ER	  retention.	  This	  was	  consistent	  with	  
previous	  results	  (233).	  	  Coexpression	  of	  any	  of	  the	  gO	  isoforms	  resulted	  in	  
conversion	  of	  the	  majority	  of	  the	  labeled	  gH/gL	  to	  an	  endo	  H	  resistant	  form,	  
indicating	  transit	  from	  the	  ER	  to	  the	  trans-­‐Golgi	  network	  (TGN).	  It	  was	  also	  of	  
interest	  to	  determine	  whether	  gO	  isoforms	  remain	  bound	  to	  gH/gL	  during	  transit	  to	  
the	  TGN.	  	  Previous	  analyses	  of	  extracellular	  AD	  virions	  demonstrated	  that	  some	  of	  
the	  N-­‐linked	  glycans	  on	  virion-­‐associated	  gO	  remain	  (partially)	  endo	  H	  sensitive	  
(i.e.,	  high	  mannose	  content)	  despite	  transit	  through	  the	  TGN	  during	  virion	  
morphogenesis	  (233,	  255).	  	  This	  would	  result	  in	  comigration	  of	  post-­‐Golgi	  gO	  with	  
ER-­‐associated	  gH,	  precluding	  direct	  observation	  of	  gO	  glycoforms	  in	  the	  experiment	  
described	  in	  Figure.	  2-­‐5.	  	  Thus,	  a	  modified	  version	  of	  the	  experiment	  was	  performed	  
in	  which	  pulse-­‐chase	  labeled	  proteins	  were	  IP’ed	  with	  anti-­‐gH	  antibodies,	  and	  heat	  
denatured	  in	  the	  presence	  of	  SDS,	  and	  reducing	  agents.	  	  The	  SDS,	  and	  reducing	  
agents	  in	  the	  samples	  were	  then	  diluted,	  and	  gO	  isoforms	  were	  analyzed	  by	  IP	  using	  
anti-­‐HA	  antibodies,	  treatment	  with	  endo	  H	  or	  PNGaseF,	  and	  separation	  by	  reducing	  
SDS-­‐PAGE	  (Figure.	  2-­‐6).	  	  
	   	  


































Figure	  2-­‐5	  Effects	  of	  distinct	  gO	  isoforms	  on	  the	  intracellular	  trafficking	  of	  a	  common	  
isoform	  of	  gH/gL.	  	  
U373	  cells	  were	  transduced	  with	  Ad	  vectors	  expressing	  gH/gL	  (derived	  from	  TR)	  alone,	  or	  together	  
with	   Ad	   vectors	   expressing	   gO	   isoforms	   derived	   from	   TR	   (TRgO),	   Merlin	   (MEgO),	   TB40	   (TBgO),	  
AD169	  (ADgO),	  and	  Towne	  (TNgO).	   	  Cells	  were	  pulse-­‐labeled	  with	  [35S]	  methionine/	  cysteine,	  and	  
then	  the	  label	  was	  chased	  for	  0	  or	  180	  min.	   	   	  Proteins	  were	  immunoprecipitated	  with	  anti-­‐gH	  MAb	  
14-­‐4b,	   left	   untreated	   (-­‐),	   or	   treated	  with	   endo	  H	   (H)	   or	   PNGaseF	   (F),	   and	   separated	   by	   SDS-­‐PAGE	  
under	   reducing	   conditions.	   Arrows	  mark	   untreated,	   or	   resistant	   forms	   of	   gH	   and	   gL.	   	   Arrowheads	  
mark	  deglycosylated	  forms	  of	  gH	  and	  gL.	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Figure	   2-­‐6	   Detection	   of	   Golgi-­‐associated	   glycoforms	   of	   gO	   isoforms	   during	  
coexpression	  with	  gH/gL.	  	  	  
U373	   cells	  were	   transduced	  with	  Ad	   vectors	   expressing	   gH/gL	   (derived	   from	  HCMV	  TR)	   alone,	   or	  
together	   with	   Ad	   vectors	   expressing	   gO	   isoforms	   derived	   from	   TR	   (TRgO),	   Merlin	   (MEgO),	   TB40	  
(TBgO),	  AD169	   (ADgO),	   and	  Towne	   (TNgO).	   	   Cells	  were	   labeled	   for	   5	  min	  with	   [35S]	  methionine/	  
cysteine,	  and	  then	  the	  label	  was	  chased	  for	  180	  min.	  	  	  Proteins	  were	  immunoprecipitated	  with	  anti-­‐
gH	   MAb	   14-­‐4b,	   denatured	   with	   SDS,	   and	   reducing	   agents,	   and	   then	   gO	   isoforms	   were	  
immunoprecipitated	   with	   anti-­‐HA	   antibodies,	   treated	   with	   endo	   H	   or	   PNGaseF	   as	   indicated,	   and	  
analyzed	  by	  SDS-­‐PAGE	  under	  reducing	  conditions.	  Diffuse	  bands	  corresponding	   to	  glycosylated	  gO,	  
and	   endo	   H	   resistant	   gO	   glycoforms	   (gO(H))	   are	   indicated	   with	   vertical	   lines.	   Forms	   of	   gO	  
deglycosylated	  by	  endo	  H,	  or	  PNGaseF	  are	  indicted	  by	  the	  arrow,	  and	  the	  arrowhead.	  
	  
	  
In	  the	  absence	  of	  endo	  H,	  or	  PNGaseF	  treatment,	  each	  gO	  isoform	  resolved	  into	  two	  
bands	  migrating	  at	  approximately	  100~120	  kDa.	  	  After	  endo	  H	  treatment,	  these	  
bands	  were	  replaced	  with	  a	  diffuse	  band	  of	  approx.	  80-­‐90	  kDa	  that	  likely	  
represented	  gO	  glycoforms	  bearing	  mostly	  endo	  H	  resistant	  N-­‐linked	  glycans	  (i.e.,	  
Golgi-­‐associated),	  and	  a	  tighter	  band	  of	  approx.	  55	  kDa	  that	  likely	  represented	  
glycoforms	  bearing	  exclusively	  endo	  H	  sensitive	  glycans	  (i.e.,	  ER-­‐associated).	  	  
PNGase	  F	  treatment	  yielded	  a	  similar	  55	  kDa	  band,	  as	  well	  as	  a	  slightly	  more	  slowy	  
migrating,	  more	  diffuse	  band,	  and	  a	  faint	  band	  at	  approximately	  75-­‐80	  kDa.	  	  The	  
presence	  of	  the	  latter	  band	  was	  inconsistent	  in	  these	  experiments,	  and	  given	  its	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apparently	  molecular	  weight,	  it	  likely	  represented	  residual	  gH–gO	  interactions	  
recaptured	  in	  the	  second	  IP	  reaction.	  	  The	  55	  kDa	  band	  produced	  by	  PNGase	  F	  likely	  
represented	  the	  same	  fraction	  of	  gO	  that	  resolved	  at	  55	  kDa	  following	  endo	  H	  
treatment	  (i.e.	  ER-­‐associated),	  whereas	  the	  slower	  migrating	  species	  produced	  by	  
PNGase	  F	  likely	  corresponded	  to	  the	  fraction	  of	  gO	  that	  was	  endo	  H	  resistant	  (Golgi-­‐
associated).	  	  This	  suggests	  the	  acquisition	  of	  modifications,	  in	  addition	  to	  N-­‐linked	  
oligosaccharides,	  such	  as	  O-­‐linked	  glycans	  (76).	  	  Also,	  extracts	  from	  cells	  
coexpressing	  gH/gL	  and	  any	  of	  the	  gO	  isoforms	  contained	  a	  proteins	  species	  that	  
migrated	  at	  approximately	  240-­‐260	  kDa	  under	  non-­‐reducing	  conditions	  that	  were	  
detected	  by	  both	  anti-­‐gL	  antibodies	  (Figure.	  2-­‐7A),	  anti-­‐HA	  (gO)	  antibodies	  (Figure.	  
2-­‐7B)	  and	  anti-­‐gH	  antibodies	  (data	  not	  shown).	  	  Together,	  these	  data	  strongly	  
suggest	  that	  the	  assembly	  of	  all	  gH/gL/gO	  complexes	  involves	  disulfide	  interactions,	  
and	  the	  conserved	  sequences	  of	  gO.	  	  However,	  it	  is	  important	  to	  note	  that	  these	  Ad	  
vector	  expression	  experiments	  were	  not	  well	  suited	  to	  compare	  how	  efficiently	  each	  
gO	  isoform	  interacts	  with	  gH/gL	  (i.e.,	  binding	  affinity).	  	  
	   	  












Figure	   2-­‐7	   Analysis	   of	   disulfide	   bonds	   in	   the	   interactions	   between	   gH/gL	   and	   gO	  
isoforms.	  
U373	  cells	  were	  transduced	  with	  Ad	  vectors	  expressing	  gH/gL	  (derived	  from	  TR)	  alone,	  or	  together	  
with	   Ad	   vectors	   expressing	   gO	   isoforms	   derived	   from	   TR	   (TRgO),	   Merlin	   (MEgO),	   TB40	   (TBgO),	  
AD169	  (ADgO),	  and	  Towne	  (TNgO).	  	  Cell	  extracts	  were	  separated	  under	  non-­‐reducing	  conditions	  and,	  
analyzed	   by	   western	   blot	   using	   anti-­‐gL	   (A),	   or	   HA	   (B)	   antibodies.	   The	   predicted	   migration	   of	  
gH/gL/gO	  trimers,	  gH/gL	  dimers,	  and	  gO	  monomers	  are	  indicated	  to	  the	  right	  of	  both	  panels.	  
	  
HCMV	  strains	  differ	  in	  the	  ratio	  of	  gH/gL/gO,	  and	  gH/gL/UL128-­‐131	  in	  the	  
virion	  envelope.	  	  The	  results	  of	  the	  Ad	  vector	  expression	  experiments	  described	  
above	  indicated	  that	  all	  isoforms	  of	  gO	  can	  form	  a	  disulfide-­‐linked	  complex	  with	  
gH/gL.	  	  Previous	  comparative	  analysis	  of	  gO	  from	  strains	  TR	  and	  AD	  did	  not	  address	  
disulfide	  interactions	  (233).	  	  Thus,	  using	  the	  new	  gO	  antibodies	  described	  in	  Figure.	  
2-­‐4,	  we	  analyzed	  cell-­‐free	  TR,	  ME,	  TB,	  AD	  and	  PH	  virions,	  and	  infected	  cells	  by	  
reducing,	  and	  non-­‐reducing	  western	  blot	  (Figure.	  2-­‐8).	  	  Under	  reducing	  conditions,	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and	  probing	  for	  gO,	  two	  bands	  were	  detected	  in	  TR-­‐infected	  cell	  extracts,	  a	  
prominent	  100	  kDa	  band,	  and	  a	  fainter,	  more	  diffuse	  band	  of	  approximately	  120	  kDa	  
(Figure.	  2-­‐8A).	  	  These	  bands	  likely	  corresponded	  to	  different	  glycoforms	  of	  gO	  
reflecting	  maturation	  of	  N-­‐linked	  glycans,	  and	  other	  modifications	  acquired	  during	  
transit	  though	  the	  Golgi-­‐derived,	  virion	  assembly	  compartment.	  	  Consistent	  with	  the	  
previous	  report,	  gO	  was	  not	  detected	  in	  extracts	  of	  extracellular	  TR	  virions	  under	  
reducing	  conditions	  (Figure.	  2-­‐8A)	  (233).	  	  However,	  when	  analyzed	  under	  non-­‐
reducing	  conditions,	  a	  band	  was	  detected	  in	  both	  cell,	  and	  virion	  extracts	  that	  
migrated	  slower	  than	  the	  250	  kDa	  marker,	  consistent	  with	  a	  gH/gL/gO	  complex	  
(Figure.	  2-­‐8A).	  	  This	  species	  was	  also	  detected	  with	  anti-­‐gL	  (Figure.	  2-­‐8B)	  and	  anti-­‐
gH	  (not	  shown)	  antibodies,	  confirming	  its	  identity	  as	  gH/gL/gO.	  	  	  Analysis	  of	  4	  other	  
strains	  of	  HCMV,	  each	  encoding	  a	  different	  gO	  isoform,	  yielded	  similar	  results	  
(Figure.	  2-­‐8A	  and	  B).	  	  Since	  these	  experiments	  involved	  detection	  of	  gO	  isoforms	  
using	  different	  antibodies,	  and	  separate	  chemiluminescent	  detections,	  only	  the	  
fraction	  of	  gO	  detected	  as	  gH/gL/gO	  versus	  gO	  monomer	  can	  be	  compared	  between	  
strains.	  Note	  that	  on	  non-­‐reducing	  gels,	  a	  greater	  fraction	  of	  the	  total	  gO	  migrated	  at	  
the	  expected	  monomeric	  size	  in	  ME	  infected	  cells	  than	  in	  cells	  infected	  with	  other	  























Figure	   2-­‐8	   Comparative	   analysis	   of	   gH/gL/gO	   complexes	   from	   different	   strains	   of	  
HCMV.	  
Extracts	  of	  HFF	  cells	  infected	  with	  BAC-­‐derived	  HCMV	  TR,	  Merlin,	  TB40/e,	  AD169,	  or	  PH,	  or	  virions	  
collected	   from	   the	   culture	   supernatant	   were	   separated	   by	   non-­‐reducing	   or	   reducing	   SDS-­‐PAGE	  
transferred	  to	  PVDF	  membranes	  and	  probed	  with	  anti-­‐gO	  (A)	  or	  anti-­‐gL	  (B)	  antibodies.	  	  For	  gO	  blots,	  
anti-­‐TBgO	   antibodies	   were	   used	   for	   TR,	   TB	   and	   PH	   samples,	   anti-­‐MEgO	   antibodies	   used	   for	   ME	  
samples,	   and	   anti-­‐ADgO	   antibodies	   were	   used	   for	   AD	   samples.	   	   Arrowheads	   mark	   bands	  
corresponding	   to	   the	   disulfide-­‐linked	   gH/gL/gO	   trimer,	   and	   vertical	   lines	   indicate	   bands	   that	  
correspond	  to	  gO,	  gL	  or	  the	  disulfide-­‐linked	  gH/gL/UL128.	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The	  detection	  of	  gO	  in	  TR	  virions	  when	  bound	  to	  gH/gL,	  but	  not	  when	  liberated	  
from	  the	  complex	  by	  reduction	  of	  disulfide	  bonds	  is	  difficult	  to	  explain	  since	  the	  
anti-­‐peptide	  epitopes	  are	  generally	  more	  accessible	  following	  reduction	  of	  disulfide	  
bonds.	  	  It	  is	  notable	  that	  similar	  results	  were	  observed	  for	  MEgO,	  ADgO	  (Figure.	  2-­‐
8A)	  and	  gL	  (Figure.	  2-­‐8B),	  but	  not	  TBgO	  and	  PHgO	  (Figure.	  2-­‐8A).	  	  While	  we	  cannot	  
fully	  explain	  this	  phenomenon,	  the	  results	  of	  these	  experiments	  clearly	  indicate	  that	  
the	  disulfide-­‐linked	  gH/gL/gO	  complex	  is	  a	  conserved	  feature	  of	  the	  HCMV	  
envelope.	  
Since	  gO	  and	  UL128	  bind	  to	  gH/gL	  through	  disulfide	  bonds	  whereas	  UL130/131	  
associate	  with	  gH/gL	  through	  non-­‐covalent	  interactions,	  (and	  non-­‐covalent	  
interactions	  will	  be	  disrupted	  on	  SDS-­‐PAGE	  gel),	  under	  non-­‐reducing	  condition,	  
gH/gL/gO	  would	  still	  stay	  intact	  while	  UL130/UL131	  dissociate	  from	  the	  the	  
gH/gL/UL128-­‐131	  complex,	  leaving	  gH/gL/UL128	  behind,	  which	  can	  be	  
distinguished	  by	  different	  molecular	  weitght	  from	  gH/gL/gO.	  The	  analyses	  of	  virion,	  
and	  infected	  cell	  extracts	  with	  anti-­‐gL	  antibodies	  revealed	  a	  striking	  difference	  
between	  ME,	  and	  other	  strains	  (Figure.	  2-­‐8B).	  	  For	  each	  of	  the	  strains	  TR,	  TB,	  AD,	  
and	  PH,	  the	  majority	  of	  the	  gL	  detected	  in	  virions	  extracts	  under	  non-­‐reducing	  
conditions	  was	  associated	  with	  gH/gL/gO	  whereas	  for	  ME,	  most	  of	  the	  gL	  was	  
detected	  at	  an	  apparent	  molecular	  weight	  consistent	  with	  gH/gL/UL128	  
heterodimers;	  approx.	  130	  kDa	  (Figure.	  2-­‐8B,	  top	  row).	  	  Similar	  results	  were	  
obtained	  using	  anti-­‐gH	  antibodies	  (not	  shown).	  In	  this	  context,	  these	  results	  suggest	  
that	  TR,	  TB,	  AD	  and	  PH	  virions	  contain	  vastly	  more	  gH/gL/gO	  compared	  to	  
gH/gL/UL128-­‐131,	  whereas	  ME	  virions	  contain	  more	  gH/gL/UL128-­‐131.	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The	  ratio	  of	  gH/gL/gO	  and	  gH/gL/UL128-­‐131	  in	  the	  HCMV	  virion	  envelope	  
is	  influenced	  by	  competition	  between	  gO,	  and	  the	  set	  of	  UL128-­‐131	  proteins	  
for	  binding	  to	  gH/gL.	  To	  confirm	  that	  the	  apparent	  gH/gL/UL128	  detected	  in	  the	  
ME	  virion	  envelope	  was	  used	  to	  be	  gH/gL/UL128-­‐131	  complex,	  and	  to	  test	  the	  
hypotheses	  that	  the	  ratio	  of	  gH/gL	  complexes	  in	  the	  virion	  envelope	  is	  influenced	  by	  
competition	  between	  gO	  and	  UL128-­‐131	  proteins,	  the	  tetracycline	  (Tet)	  expression-­‐
repression	  system	  described	  by	  Stanton	  et	  al.	  was	  used	  (177).	  	  Briefly,	  ME	  is	  highly	  
sensitive	  to	  mutational	  inactivation	  of	  the	  UL128-­‐131	  genes	  during	  serial	  
propagation	  in	  cultured	  fibroblasts,	  making	  it	  difficult	  to	  maintain	  wild-­‐type	  ME	  in	  
culture	  (175,	  176).	  	  To	  overcome	  this,	  Stanton	  et	  al.	  engineered	  a	  ME	  BAC	  with	  Tet	  
operator	  sequences	  inserted	  within	  the	  promoter	  that	  regulates	  expression	  of	  
UL130,	  and	  UL131,	  and	  a	  fibroblast	  cell	  line	  expressing	  the	  Tet	  repressor	  protein	  
(HFFtet).	  	  During	  replication	  in	  HFFtet	  cells,	  transcription	  from	  the	  UL130/131	  
promoter,	  and	  consequently,	  assembly	  of	  the	  gH/gL/UL128-­‐131	  complex	  is	  
suppressed,	  reducing	  selective	  pressure	  against	  UL128-­‐131.	  
Extracts	  of	  ME	  virions	  produced	  in	  HFF,	  and	  HFFtet	  cells	  were	  analyzed	  by	  
reducing	  and	  non-­‐reducing	  western	  blots	  (Figure.	  2-­‐9).	  	  Reducing	  blots	  indicated	  
that	  virions	  produced	  by	  both	  cell	  types	  contained	  comparable	  amounts	  of	  total	  gL	  
(Figure.	  2-­‐9A),	  and	  gB	  (not	  shown).	  	  On	  non-­‐reducing	  gels,	  the	  majority	  of	  gL	  
detected	  in	  ME	  virions	  produced	  by	  HFF	  cells	  was	  in	  the	  form	  of	  gH/gL/UL128,	  
consistent	  with	  the	  results	  of	  the	  previous	  experiment	  (compare	  Figure.	  2-­‐8B	  and	  2-­‐
9A).	  	  Strikingly,	  in	  virions	  produced	  under	  conditions	  of	  suppressed	  UL128-­‐131	  
expression	  (HFFtet	  cells),	  the	  majority	  of	  the	  gL	  corresponded	  to	  the	  slower	  	  




































Figure	   2-­‐9	   Suppression	   of	   UL128-­‐131	   expression	   enhances	   incorporation	   of	  
gH/gL/gO	  into	  the	  Merlin	  virion	  envelope.	  
BAC-­‐derived	   Merlin	   containing	   Tet	   operator	   sequences	   in	   the	   UL130/131	   promoter	   was	   used	   to	  
infect	   HFF	   cells,	   or	   HFF	   cells	   expressing	   the	   Tet	   repressor	   protein	   (HFFtet).	   	   Extracellular	   virions	  
collected	   from	   culture	   supernatants	  were	   analyzed	   by	   reducing	   or	   and	   non-­‐reducing	  western	   blot	  
using	  (A)	  anti-­‐gL,	  (B)	  anti-­‐gO,	  or	  (C)	  anti-­‐UL128,	  anti-­‐UL130,	  or	  UL131	  antibodies	  as	  indicated.	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migrating	  gH/gL/gO	  complex	  (Figure.	  2-­‐9A).	  	  Consistent	  with	  this,	  ME	  virions	  
produced	  from	  HFFtet	  cells	  contained	  more	  gO	  (Figure.	  2-­‐9B),	  and	  less	  UL128-­‐131	  
proteins	  (Figure.	  2-­‐9C).	  	  Note	  that	  due	  to	  the	  increased	  virion-­‐associated	  MEgO	  
under	  conditions	  of	  UL128-­‐131	  suppression,	  much	  shorter	  chemiluminescent	  
exposures	  were	  needed	  for	  detection	  of	  MEgO	  in	  these	  experiments	  than	  for	  those	  
described	  in	  Figure.	  2-­‐8A.	  	  Since	  unbound	  gH/gL	  dimers	  are	  poorly	  transported	  out	  
of	  the	  ER,	  and	  the	  presence	  of	  UL128-­‐131	  in	  the	  virion	  exactly	  correlates	  with	  the	  
detection	  of	  gH/gL/UL128,	  these	  data	  strongly	  support	  the	  conclusion	  that	  the	  
gH/gL/UL128	  remainder	  detected	  in	  ME	  virions	  represented	  the	  gH/gL/UL128-­‐131	  
complex,	  and	  the	  ratio	  of	  the	  two	  gH/gL	  complexes	  in	  the	  virion	  envelope	  is	  
influenced	  by	  competition	  between	  gO	  and	  the	  UL128-­‐131	  proteins	  for	  binding	  to	  
gH/gL.	  	  
	  DISCUSSION	  
Previous	  analyses	  suggested	  that	  some	  gO	  isoforms	  remain	  bound	  to	  gH/gL	  in	  
the	  virion	  envelope,	  and	  others	  behave	  more	  like	  chaperones	  to	  promote	  assembly	  
of	  unbound	  gH/gL	  dimers	  into	  the	  virion	  envelope	  (233).	  	  The	  chaperone	  model	  was	  
based	  largely	  on	  the	  failure	  to	  detect	  gO	  in	  TR	  virions	  by	  reducing	  western	  blots.	  	  
Here,	  we	  used	  non-­‐reducing	  gel	  systems	  to	  compare	  several	  strains	  of	  HCMV.	  	  In	  all	  
cases,	  gO	  clearly	  was	  detected	  as	  part	  of	  a	  disulfide-­‐linked	  complex	  with	  gH/gL	  in	  
the	  virion	  envelope.	  	  	  
The	  discrepancy	  between	  non-­‐reducing	  and	  reducing	  western	  blots	  is	  puzzling.	  	  
As	  noted,	  anti-­‐peptide	  antibodies	  are	  generally	  thought	  to	  react	  better	  with	  proteins	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that	  have	  been	  separated	  under	  denaturing-­‐reducing	  conditions	  because	  continuous	  
epitopes	  should	  be	  more	  accessible.	  	  It	  is	  notable	  that	  virion-­‐associated	  ADgO	  was	  
clearly	  detected	  in	  the	  reducing	  western	  blot	  experiments	  reported	  in	  Ryckman	  et	  
al.	  (233),	  but	  not	  in	  the	  similar	  experiments	  reported	  here.	  	  This	  difference	  might	  be	  
explained	  by	  the	  fact	  that	  in	  the	  previous	  studies,	  ADgO	  was	  detected	  with	  the	  
polyclonal	  serum	  described	  by	  Huber	  et	  al.	  (75),	  which	  was	  raised	  against	  full	  length	  
gO,	  whereas	  in	  the	  current	  studies,	  anti-­‐peptide	  antibodies	  were	  used	  for	  detection	  
of	  all	  gO	  isoforms.	  	  This	  observation	  points	  towards	  specific	  modification	  of	  gO,	  such	  
as	  proteolysis,	  at	  or	  near	  the	  anti-­‐peptide	  antibody	  target	  site	  (the	  conserved	  
hydrophilic	  domain	  shown	  in	  Figure.	  2-­‐2).	  	  If	  this	  were	  the	  case,	  then	  perhaps	  the	  
disulfide	  nature	  of	  the	  gH/gL/gO	  complex	  might	  preserve	  epitope	  recognition	  in	  
western	  blot	  experiments.	  	  Potential	  modifications	  are	  likely	  coincident	  with	  virion	  
morphogenesis,	  and	  release	  because	  intracellular	  gO	  was	  easily	  detected	  with	  the	  
anti-­‐peptide	  antibodies	  on	  reducing	  western	  blots.	  	  Also,	  since	  detection	  of	  some	  gO	  
isoforms	  was	  less	  affected	  by	  disulfide	  reduction,	  sequence	  differences	  might	  affect	  
these	  potential	  modifications.	  	  It	  is	  also	  important	  to	  note	  that	  a	  similar	  
phenomenon	  was	  observed	  during	  analysis	  of	  gL,	  and	  it	  is	  interesting	  that	  the	  anti-­‐
gL	  antibodies	  used	  were	  also	  raised	  against	  synthetic	  peptides.	  	  In	  order	  to	  
efficiently	  elicit	  antibodies,	  synthetic	  peptides	  are	  conjugated	  to	  a	  carrier	  protein	  
(such	  as	  keyhole	  limpet	  hemocyanin;	  KLH)	  via	  a	  terminal	  cys	  residue	  that	  either	  
represents	  a	  cys	  in	  the	  protein	  of	  interest,	  or	  one	  that	  is	  added	  to	  the	  synthetic	  
peptide	  for	  the	  sole	  purpose	  of	  conjugation	  to	  the	  carrier.	  Thus,	  it	  is	  tempting	  to	  
suggest	  that	  the	  presence	  of	  a	  cys	  in	  the	  peptides	  used	  to	  generate	  the	  antibodies	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might	  contribute	  to	  the	  observed	  phenomenon.	  	  However,	  for	  all	  antibodies	  
described,	  the	  cys	  used	  for	  conjugation	  was	  extraneous,	  and	  not	  present	  in	  the	  
actual	  protein.	  	  Finally,	  it	  is	  possible	  that	  the	  observed	  effects	  relate	  to	  differences	  
between	  cell-­‐associated,	  and	  virion-­‐associated	  proteins	  in	  the	  transfer	  to	  blotting	  
membranes,	  and	  that	  these	  differences	  are	  less	  apparent	  during	  transfer	  of	  the	  
intact	  gH/gL/gO	  complex.	  	  Again,	  this	  explanation	  would	  suggest	  posttranslational	  
modifications	  of	  proteins	  coincident	  with	  virion	  release.	  	  Regardless,	  the	  analyses	  of	  
TR,	  and	  other	  HCMV	  strains	  reported	  here	  clearly	  demonstrate	  that	  disulfide-­‐linked	  
gH/gL/gO	  complexes	  are	  a	  conserved	  feature	  of	  the	  HCMV	  virion	  envelope.	  	  	  
Regulation	  of	  gB	  can	  be	  considered	  the	  “core	  entry	  function”	  of	  the	  herpesvirus	  
gH/gL.	  HCMV	  gH/gL,	  without	  UL128-­‐131	  or	  gO,	  can	  regulate	  gB-­‐mediated	  cell-­‐cell	  
fusion,	  indicating	  that	  the	  necessary	  surfaces	  for	  gB	  interaction	  are	  comprised	  of	  
amino	  acids	  contained	  within	  gH/gL	  alone	  (216).	  	  However,	  data	  presented	  here	  
indicate	  that	  the	  HCMV	  envelope	  contains	  a	  mixture	  of	  gH/gL/UL128-­‐131	  and	  
gH/gL/gO,	  and	  little	  or	  no	  unbound	  gH/gL.	  	  Thus,	  for	  HCMV,	  the	  core	  function	  
involving	  interactions	  with	  gB	  must	  be	  provided	  by	  either	  the	  pentameric	  
gH/gL/UL128-­‐131,	  or	  the	  trimeric	  gH/gL/gO.	  	  EBV	  also	  has	  different	  types	  of	  gH/gL,	  
unmodified	  gH/gL	  or	  a	  trimeric	  gH/gL/gp42,	  and	  either	  can	  perform	  this	  function	  
depending	  on	  the	  cell	  type	  involved	  (221,	  247).	  	  In	  contrast,	  the	  phenotypes	  of	  
HCMV	  gO,	  and	  UL128-­‐131	  mutants	  strongly	  suggest	  that	  gH/gL/gO	  performs	  the	  
core	  gB-­‐interaction	  function	  during	  entry	  into	  all	  cell	  types,	  whereas	  gH/gL/UL128-­‐
131	  serves	  a	  distinct,	  receptor-­‐binding	  function	  that	  is	  an	  additional	  necessity	  for	  
entry	  into	  specific	  cell	  types	  such	  as	  epithelial,	  endothelial,	  and	  dendritic	  cells,	  but	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not	  others,	  such	  as	  fibroblasts	  or	  neurons	  (42,	  77,	  79,	  156,	  227,	  234,	  235,	  238,	  248,	  
256).	  	  The	  receptors	  for	  gH/gL/UL128-­‐131	  are	  unknown,	  but	  engagement	  of	  these	  
molecules	  might	  trigger	  endocytosis,	  actin	  rearrangement	  or	  other	  cell	  surface	  
functions	  that	  then	  allow	  for	  the	  universally	  required	  gH/gL/gO	  -­‐	  gB	  interactions	  
that	  result	  membrane	  fusion	  and	  entry.	  	  An	  important	  prediction	  of	  this	  model	  is	  
that	  the	  surfaces	  on	  gH/gL	  that	  interact	  with	  gB	  are	  inaccessible	  on	  gH/gL/UL128-­‐
131,	  but	  are	  accessible	  on	  gH/gL/gO,	  and	  studies	  to	  test	  aspects	  of	  this	  model	  are	  in	  
progress.	  	  	  
The	  significance	  of	  gO	  sequence	  diversity	  on	  the	  composition	  of	  the	  HCMV	  
envelope,	  and	  the	  function	  of	  the	  gH/gL/gO	  complex	  adds	  a	  layer	  of	  complexity	  to	  
models	  of	  HCMV	  entry	  and	  tropism	  that	  has	  not	  previously	  been	  addressed.	  	  In	  the	  
analyses	  presented	  here,	  all	  isoforms	  of	  gO	  bound	  to	  a	  common	  isoform	  of	  gH/gL	  to	  
form	  a	  disulfide-­‐linked	  trimer	  that	  was	  transported	  from	  the	  ER	  to	  the	  TGN.	  	  This	  
suggests	  that	  gH/gL/gO	  complexes	  share	  a	  similar	  structure	  involving	  the	  
conserved	  sequences	  of	  gO.	  	  This	  conclusion	  is	  consistent	  with	  the	  model	  of	  
gH/gL/gO	  providing	  a	  core	  entry	  function	  since	  all	  gO	  isoforms	  must	  leave	  critical	  
surfaces	  on	  gH/gL	  available	  for	  interaction	  with	  gB.	  	  These	  results	  are	  also	  
consistent	  with	  those	  of	  Rasmussen	  et	  al.,	  who	  investigated	  genetic	  linkages	  of	  
polymorphic	  loci	  in	  clinical	  HCMV	  isolates,	  and	  found	  evidence	  of	  several	  
combinations	  of	  gH/gL	  and	  gO	  isoforms	  (257).	  	  
The	  finding	  that	  virions	  of	  TR,	  TB,	  AD	  and	  PH	  virions	  contained	  vastly	  more	  
gH/gL/gO	  than	  gH/gL/UL128-­‐131,	  whereas	  ME	  contain	  more	  gH/gL/UL128-­‐131	  
than	  gH/gL/gO	  was	  unexpected,	  and	  has	  a	  number	  of	  important	  implications.	  	  First,	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the	  observation	  that	  UL128-­‐131	  suppression	  during	  ME	  replication	  dramatically	  
shifted	  the	  ratio	  of	  gH/gL	  complexes	  in	  the	  virion	  envelope	  towards	  gH/gL/gO	  
indicates	  that	  gO,	  and	  UL128-­‐131	  compete	  for	  binding	  of	  gH/gL	  to	  form	  the	  two	  
complexes,	  and	  the	  relative	  abundance	  of	  unbound	  gO	  in	  ME	  infected	  cells	  suggests	  
that	  MEgO	  may	  be	  less	  able	  to	  compete	  than	  other	  gO	  isoforms.	  	  Thus,	  the	  variable	  
sequences	  of	  gO	  might	  affect	  the	  ratio	  of	  the	  core	  entry	  factor	  gH/gL/gO	  to	  the	  
tropism	  factor	  gH/gL/UL128-­‐131.	  	  However,	  these	  results	  do	  not	  exclude	  the	  
possibility	  that	  differences	  in	  protein	  expression	  levels,	  or	  small	  sequence	  
differences	  in	  gH/gL,	  or	  UL128-­‐131	  also	  contribute	  to	  strain	  variation.	  Wille	  et	  al.	  
showed	  that	  a	  TR	  mutant	  that	  could	  not	  express	  gO	  produced	  virions	  that	  contained	  
elevated	  amounts	  of	  gH/gL/UL128-­‐131,	  but	  drastically	  lower	  total	  amounts	  of	  
gH/gL,	  indicating	  that	  UL128-­‐131	  was	  unable	  to	  bind	  a	  significant	  fraction	  of	  the	  
remaining	  gH/gL	  (238).	  	  This	  might	  indicate	  that	  TR	  expresses	  more	  gH/gL,	  or	  less	  
UL128-­‐131	  than	  ME.	  	  Second,	  it	  is	  well	  appreciated	  that	  there	  is	  a	  selective	  pressure	  
against	  UL128-­‐131	  during	  replication	  in	  fibroblast	  cultures,	  and	  that	  ME	  is	  
especially	  sensitive	  to	  this	  selection	  (175–177).	  If	  the	  assembly	  of	  gH/gL/gO	  and	  
gH/gL/UL128-­‐131	  come	  at	  the	  expense	  of	  one	  another,	  and	  if	  the	  gH/gL/UL128-­‐
131	  cannot	  participate	  in	  the	  interactions	  with	  gB	  that	  are	  necessary	  for	  fusion,	  then	  
mutation	  of	  UL128-­‐131	  would	  be	  expected	  to	  result	  in	  a	  greater	  fibroblast-­‐
replication	  fitness	  advantage	  for	  a	  virus	  like	  ME	  than	  for	  a	  virus	  like	  TR.	  	  This	  model	  
predicts	  an	  evolutionary	  balancing	  act	  requiring	  the	  virus	  to	  express	  enough	  
gH/gL/UL128-­‐131	  for	  broad	  tropism,	  while	  retaining	  enough	  gH/gL/gO	  to	  promote	  
fusion	  on	  all	  cell	  types.	  	  Clearly,	  the	  amounts	  of	  each	  complex	  in	  the	  ME	  virion	  are	  
	   80	  
sufficient	  to	  allow	  infection	  of	  both	  fibroblasts,	  and	  epithelial/endothelial	  cells,	  but	  
the	  relative	  efficiency	  (i.e.	  per	  virion)	  compared	  to	  other	  HCMV	  strains	  with	  
different	  amounts	  of	  the	  complexes	  is	  difficult	  to	  directly	  measure.	  	  As	  noted	  above,	  
it	  is	  possible	  that	  HCMV	  strains	  differ	  in	  the	  total	  amount	  of	  gH/gL,	  and	  this	  could	  
either	  lessen,	  or	  magnify	  the	  importance	  of	  the	  ratio	  of	  the	  two	  complexes.	  Clearly	  
suppression	  of	  UL128-­‐131	  enhances	  the	  replication	  of	  ME,	  but	  the	  effects	  of	  
manipulation	  the	  expression	  of	  gO	  or	  gH/gL	  has	  not	  been	  addressed.	  	  Finally,	  It	  is	  
tempting	  to	  speculate	  that	  adaptive	  evolution	  of	  HCMV	  tropism	  observed	  in	  culture	  
may	  also	  occur	  in	  vivo.	  	  Infection	  of	  neuronal	  cells	  is	  likely	  independent	  of	  
gH/gL/UL128-­‐131	  (156).	  	  Thus,	  it	  is	  conceivable	  that	  the	  ratio	  of	  the	  core	  entry	  
factor	  (gH/gL/gO),	  and	  the	  tropism	  factor	  (gH/gL/UL128-­‐131)	  might	  be	  subject	  to	  
similar	  selective	  pressures	  in	  neuronal	  or,	  other	  tissues	  as	  has	  been	  observed	  in	  
fibroblast	  cultures.	  	  If	  so,	  the	  gO	  genotype	  of	  HCMV	  might	  influence	  viral	  pathology,	  
and	  the	  ability	  of	  the	  virus	  to	  spread	  to	  other	  hosts,	  which	  likely	  involves	  replication	  
in	  epithelial	  and	  endothelial	  tissues.	  	  	  
Host	  cell	  characteristics	  may	  also	  influence	  the	  protein	  composition	  of	  the	  
HCMV	  envelope.	  	  Wang	  et	  al.	  found	  that	  HCMV	  produced	  by	  epithelial	  cells	  entered	  
epithelial	  cells	  though	  fusion	  at	  the	  plasma	  membrane	  rather	  than	  via	  fusion	  
following	  endocytosis,	  as	  had	  been	  described	  for	  fibroblast-­‐produced	  virus.	  	  They	  
suggested	  that	  this	  correlated	  with	  an	  approximately	  2-­‐fold	  increase	  in	  the	  ratio	  of	  
gH/gL/UL128-­‐131	  vs.	  gH/gL/gO	  in	  epithelial	  cell-­‐produced	  virions	  (258).	  	  Scrivano	  
et	  al.	  similarly	  analyzed	  HCMV	  virions	  produced	  by	  fibroblasts	  with	  those	  produced	  
by	  endothelial	  cells,	  and	  suggested	  that	  both	  cell	  types	  produce	  virion	  populations	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that	  are	  heterogeneous	  in	  the	  relative	  levels	  of	  gH/gL/gO	  and	  gH/gL/UL128-­‐131	  
(259).	  	  The	  notion	  of	  heterogeneity	  in	  the	  amounts	  of	  gH/gL	  complexes	  
incorporated	  into	  the	  HCMV	  envelope	  had	  been	  previously	  suggested	  by	  Li	  et	  al.	  
(260).	  	  Our	  results	  linking	  gO	  diversity	  with	  the	  ratio	  of	  the	  two	  gH/gL	  complexes	  
raises	  the	  question	  of	  whether	  all	  strains	  display	  similar	  envelope	  heterogeneity,	  or	  
are	  equally	  sensitive	  to	  producer	  cell.	  	  	  	  
In	  summary,	  the	  data	  presented	  in	  this	  report	  clearly	  indicate	  that	  the	  
gH/gL/gO	  complex	  is	  an	  envelope	  component	  of	  all	  strains	  of	  HCMV,	  and	  suggest	  
that	  the	  sequence	  differences	  between	  gO	  isoforms	  may	  affect	  the	  ratio	  of	  gH/gL	  
complexes	  incorporated	  in	  the	  virion	  envelope.	  	  The	  diverse	  sequences	  of	  gO	  may	  
also	  affect	  other	  functions,	  and	  aspects	  of	  the	  gH/gL/gO	  complex.	  	  For	  example,	  
Vanarsdall	  et	  al.	  provided	  evidence	  from	  receptor	  interference	  experiments	  that	  
suggested	  gH/gL/gO	  might	  act	  as	  a	  receptor-­‐binding	  complex,	  and	  the	  gO	  isoform	  
might	  participate	  in	  these	  interactions	  or	  modulate	  the	  activity	  (239).	  	  Also,	  Jiang	  et	  
al.	  recently	  suggested	  that	  the	  extensive	  array	  of	  N-­‐linked	  glycans	  on	  gO	  might	  act	  to	  
shield	  the	  virus	  from	  the	  effects	  of	  neutralizing	  antibodies	  (261).	  	  Research	  work	  in	  
Chapter	  4	  studied	  the	  possible	  significances	  of	  gO	  diversity	  by	  analyzing	  inter-­‐strain	  
of	  gO	  recombinant	  HCMVs.	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CHAPTER	  3. CHARACTERIZATION	  OF	  
HUMAN	  CYTOMEGALOVIRUS	  gH/gL	  
COMPLEXES	  FUNCTION	  DURING	  VIRUS	  
ENTRY	  AND	  TROPISM	  
This	  chapter	  is	  a	  modified	  version	  of	  the	  manuscript	  published	  in	  Journal	  of	  
Virology	  in	  September	  2015;	  89(17),	  8999-­‐9009	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INTRODUCTION	  
Primary	  infection	  of	  healthy	  adults	  by	  human	  cytomegalovirus	  (HCMV)	  is	  
usually	  subclinical	  or	  mildly	  symptomatic,	  but	  leads	  to	  lifelong	  persistent	  or	  latent	  
infection.	  	  Primary	  infection	  or	  reactivation	  of	  HCMV	  in	  immunocompromised	  hosts,	  
such	  those	  infected	  with	  HIV	  and	  transplant	  recipients	  on	  anti-­‐rejection	  
chemotherapies,	  is	  associated	  with	  significant	  morbidity	  and	  mortality,	  and	  
maternal	  transmission	  of	  HCMV	  to	  the	  developing	  fetus	  across	  the	  placenta	  can	  
result	  in	  severe	  congenital	  birth	  defects	  (16,	  21,	  240).	  The	  diverse	  nature	  of	  HCMV-­‐
associated	  disease	  likely	  relates	  to	  the	  ability	  of	  the	  virus	  to	  infect	  many	  cell	  types	  in	  
vivo,	  including	  epithelial	  and	  endothelial	  cells,	  fibroblasts,	  monocyte-­‐macrophages,	  
dendritic	  cells,	  hepatocytes,	  leukocytes	  and	  neurons	  (147,	  148,	  156).	  	  Much	  research	  
effort	  has	  been	  focused	  on	  understanding	  the	  mechanisms	  by	  which	  HCMV	  initiates	  
infection	  of	  different	  cell	  types	  (reviewed	  in	  (190)).	  	  Most	  studies	  have	  described	  an	  
entry	  mechanism	  dichotomy	  between	  fibroblasts	  and	  epithelial/endothelial	  cells.	  	  
Other	  relevant	  cell	  types,	  though	  more	  difficult	  to	  work	  with	  in	  the	  laboratory,	  likely	  
fit	  to	  one	  side	  or	  the	  other	  of	  the	  fibroblasts	  –	  epithelial/endothelial	  entry	  
dichotomy.	  
Entry	  of	  all	  herpesviruses	  requires	  membrane	  fusion,	  which	  is	  mediated	  by	  a	  
conserved	  core	  fusion	  apparatus	  comprised	  of	  glycoprotein	  B	  (gB)	  and	  gH/gL.	  	  
Extensive	  studies	  of	  herpes	  simplex	  virus	  (HSV)	  and	  Epstein-­‐Barr	  virus	  (EBV)	  have	  
shown	  that	  gB	  has	  characteristics	  of	  a	  class	  III	  viral	  fusion	  protein	  (209,	  210,	  213,	  
214).	  The	  necessary	  role	  of	  gH/gL	  in	  herpesvirus	  membrane	  fusion	  is	  unclear,	  but	  
likely	  involves	  direct	  interaction	  between	  gH/gL	  and	  gB	  (218,	  223,	  262–265).	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Herpesviruses	  also	  encode	  accessory	  glycoproteins	  such	  as	  HSV	  gD	  and	  EBV	  gp42,	  
which	  regulate	  the	  core	  fusion	  apparatus	  through	  receptor-­‐binding,	  and	  stable	  or	  
transient	  interactions	  with	  gH/gL	  (reviewed	  in	  (189)).	  	  	  
HCMV	  shares	  the	  conserved	  features	  of	  herpesviruses	  entry,	  but	  there	  are	  some	  
important	  unique	  aspects,	  especially	  related	  to	  cell	  tropism.	  	  Structural	  analyses	  of	  
HCMV	  gB	  suggest	  general	  mechanistic	  similarities	  with	  other	  herpesvirus	  gB	  
homologues	  (122)	  and	  the	  combination	  of	  HCMV	  gB	  and	  gH/gL	  is	  necessary,	  and	  
sufficient	  for	  membrane	  fusion	  in	  cell-­‐cell	  fusion	  experiments	  (216).	  The	  
ectodomain	  of	  HCMV	  gH/gL	  can	  be	  bound	  by	  either	  gO,	  or	  proteins	  encoded	  by	  
UL128,	  UL130	  and	  UL131	  (UL128-­‐131),	  forming	  the	  gH/gL/gO,	  and	  gH/gL/UL128-­‐
131	  complexes	  on	  the	  virion	  envelope	  (73,	  74,	  77,	  227).	  	  Experiments	  reported	  in	  
Chapter	  2	  indicated	  the	  following:	  1)	  extracellular	  virions	  contain	  little,	  if	  any	  
unbound	  gH/gL,	  2)	  the	  ratio	  of	  gH/gL/gO	  to	  gH/gL/UL128-­‐131	  can	  vary	  
dramatically	  between	  different	  HCMV	  strains,	  and	  3)	  gO	  and	  UL128-­‐131	  compete	  
for	  binding	  of	  gH/gL	  (232).	  	  The	  mutually	  exclusive	  nature	  of	  gH/gL/gO	  and	  
gH/gL/UL128-­‐131	  formation	  is	  consistent	  with	  a	  recent	  structural	  analysis	  showing	  
that	  gO,	  and	  the	  UL128	  protein	  make	  a	  disulfide	  bond	  with	  the	  same	  cysteine	  
residue	  of	  the	  gL	  polypeptide	  (215).	  The	  gH/gL/gO	  and	  gH/gL/UL128-­‐131	  
complexes	  influence	  cell	  tropism	  at	  the	  level	  of	  entry,	  although	  the	  mechanisms	  are	  
not	  well	  understood.	  	  
The	  roles	  of	  HCMV	  gH/gL	  complexes	  have	  mostly	  been	  studied	  with	  deletion	  
mutant	  approaches.	  In	  general,	  mutants	  that	  lack	  gH/gL/UL128-­‐131	  replicate	  as	  
well,	  or	  better	  than	  wild	  type	  strains	  on	  fibroblasts	  (77–79,	  227).	  This	  indicates	  that	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gB-­‐mediated	  fusion	  with	  fibroblast	  membranes	  can	  be	  facilitated	  by	  gH/gL/gO.	  	  In	  
contrast	  gH/gL/UL128-­‐131	  mutants	  fail	  to	  infect	  cell	  types	  such	  as	  epithelial,	  
endothelial	  and	  monocyte/macrophages	  (77,	  79,	  227,	  248,	  266).	  These	  observations	  
have	  generally	  been	  interpreted	  to	  mean	  that	  gB-­‐mediated	  fusion	  with	  membranes	  
of	  epithelial	  cells	  (and	  other	  cell	  types	  for	  which	  gH/gL/UL128-­‐131	  is	  necessary	  for	  
HCMV	  entry)	  is	  facilitated	  by	  gH/gL/UL128-­‐131.	  	  The	  resulting	  model	  suggests	  that	  
both	  gH/gL/gO,	  and	  gH/gL/UL128-­‐131	  provide	  essentially	  the	  same	  function	  for	  
entry	  into	  different	  cell	  types,	  i.e.,	  promoting	  gB-­‐mediated	  membrane	  fusion.	  	  This	  
model	  was	  attractive	  due	  to	  analogy	  with	  the	  well-­‐described	  model	  of	  EBV	  tropism	  
(reviewed	  in	  (189)).	  EBV	  gH/gL	  can	  exist	  in	  the	  virion	  envelope	  as	  unmodified	  
gH/gL,	  or	  bound	  by	  gp42.	  	  For	  entry	  into	  epithelial	  cells,	  gH/gL	  binds	  specific	  
integrins,	  and	  promotes	  gB-­‐mediated	  membrane	  fusion.	  	  The	  presence	  of	  gp42	  on	  
gH/gL	  blocks	  integrin	  binding,	  and	  instead	  gp42	  binds	  MHC	  II,	  which	  facilitates	  
entry	  into	  B-­‐cell.	  	  Presumably,	  both	  gH/gL	  and	  gH/gL/gp42	  promote	  gB-­‐mediated	  
membrane	  fusion	  through	  interactions	  involving	  “pro-­‐fusion”	  surfaces	  of	  gH/gL,	  
with	  gp42	  acting	  as	  a	  receptor-­‐adapter	  to	  switch	  cell	  tropism.	  	  While	  HCMV	  mutants	  
lacking	  gH/gL/UL128-­‐131	  replicate	  well	  on	  fibroblasts,	  mutants	  lacking	  gH/gL/gO	  
are	  severely	  replication	  impaired	  on	  all	  cell	  types	  (42,	  234,	  235,	  238).	  In	  particular,	  
Wille	  et	  al.	  showed	  that	  HCMV	  virions	  lacking	  gH/gL/gO	  were	  impaired	  at	  the	  fusion	  
step	  of	  entry	  into	  fibroblasts,	  epithelial,	  and	  endothelial	  cells,	  despite	  containing	  
elevated	  amounts	  of	  gH/gL/UL128-­‐131	  (238).	  Together,	  the	  results	  of	  deletion	  
mutant	  approaches	  seem	  to	  suggest	  that	  gH/gL/gO	  is	  sufficient	  for	  entry	  into	  
fibroblast,	  but	  that	  entry	  into	  epithelial/endothelial	  cells	  requires	  both	  gH/gL/gO	  
	   86	  
and,	  gH/gL/UL128-­‐131.	  	  
	  Characterization	  of	  the	  mechanisms	  by	  which	  HCMV	  gH/gL/gO	  and	  
gH/gL/UL128-­‐131	  facilitate	  cell	  type	  dependent	  entry	  using	  deletion	  mutants	  has	  
been	  limited	  largely	  due	  to	  the	  severe	  replication	  defects	  associated	  with	  gO	  
deletions,	  and	  the	  lack	  of	  an	  adequate	  complementation	  system.	  	  The	  studies	  
described	  herein,	  capitalize	  on	  our	  previously	  reported	  observations	  that	  the	  
amounts	  of	  gH/gL	  complexes	  in	  the	  HCMV	  virion	  envelope	  can	  vary	  dramatically	  
among	  strains,	  and	  that	  the	  ratio	  of	  the	  two	  gH/gL	  complexes	  can	  be	  manipulated	  
through	  suppression	  of	  the	  UL128-­‐131	  proteins.	  	  Here,	  we	  report	  further	  
characterizations	  of	  strain	  variability	  in	  the	  abundance	  of	  gH/gL	  complexes	  in	  the	  
virion	  envelope,	  and	  relate	  these	  differences	  to	  the	  efficiency	  of	  entry	  on	  different	  
cell	  types.	  Comparisons	  of	  genetically	  identical	  HCMV	  preparations	  either	  enriched	  
in	  gH/gL/gO,	  or	  gH/gL/UL128-­‐131	  suggest	  a	  model	  in	  which	  gH/gL/gO	  provides	  
the	  herpesvirus	  “core-­‐fusion	  gH/gL”	  function	  of	  promoting	  gB-­‐mediated	  membrane	  
fusion	  for	  entry	  into	  all	  cell	  types,	  whereas	  gH/gL/UL128-­‐131	  facilitates	  entry	  into	  
select	  cell	  types,	  such	  as	  epithelial	  cells,	  through	  a	  distinct,	  yet	  necessary	  
mechanism.	  
MATERIALS	  AND	  METHODS	  
	  	  	  	  Cell	  lines.	  Primary	  human	  foreskin	  fibroblasts	  (HFF;	  Life	  Technologies),	  MRC-­‐
5	  fibroblasts	  	  (ATCC	  CCL-­‐171),	  and	  HFFtet	  cells	  (which	  express	  the	  tetracycline	  
(Tet)	  repressor	  protein	  (177);	  provided	  by	  Richard	  Stanton	  (Cardiff	  University,	  
Cardiff,	  United	  Kingdom))	  were	  grown	  in	  Dulbecco’s	  modified	  Eagle’s	  medium	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(DMEM;	  Life	  Technologies)	  supplemented	  with	  6%	  heat-­‐inactivated	  fetal	  bovine	  
serum	  (FBS;	  Rocky	  Mountain	  Biologicals,	  Inc.,	  Missoula,	  Montana,	  USA.)	  and	  6%	  
bovine	  growth	  serum	  (BGS;	  Rocky	  Mountain	  Biologicals,	  Inc.,	  Missoula,	  Montana,	  
USA.).	  	  Retinal	  pigment	  epithelial	  cell	  line,	  ARPE-­‐19	  (American	  Type	  Culture	  
Collection;	  Manassas,	  VA,	  USA)	  was	  grown	  in	  a	  1:1	  dilution	  mix	  of	  DMEM	  and	  Ham’s	  
F-­‐12	  medium	  (DMEM:F-­‐12;	  Life	  Technologies)	  supplemented	  with	  10%	  FBS.	  
HCMV.	  	  All	  HCMV	  were	  derived	  from	  bacterial	  artificial	  chromosome	  (BAC)	  
clones.	  	  BAC	  clone	  TR	  was	  provided	  by	  Jay	  Nelson	  (Oregon	  Health	  and	  Sciences	  
University,	  Portland	  OR,	  USA)	  (41).	  	  BAC	  clone	  TB40/e	  (BAC-­‐4)	  (TB)	  was	  provided	  
by	  Christian	  Sinzger	  (University	  of	  Ulm,	  Germany)	  (184).	  	  BAC	  clone	  Merlin	  (ME)	  
(pAL1393),	  which	  contains	  tetracycline	  operator	  sequences	  within	  the	  
transcriptional	  promoter	  of	  UL130	  and	  UL131,	  was	  provided	  by	  Richard	  Stanton	  
(Cardiff	  University,	  Cardiff,	  United	  Kingdom)	  (177).	  Infectious	  HCMV	  was	  recovered	  
by	  electroporation	  of	  BAC	  DNA	  into	  MRC-­‐5	  fibroblasts	  as	  described	  by	  Wille	  et	  al.	  
(238).	  	  Cell-­‐free	  HCMV	  stocks	  were	  produced	  by	  infecting	  HFF	  or	  HFFtet	  at	  2	  plaque-­‐
forming	  unit	  (PFU)	  per	  cell.	  	  At	  8-­‐10	  days	  post	  infection	  (when	  cells	  were	  still	  
visually	  intact),	  culture	  supernatants	  were	  harvested,	  and	  cellular	  contaminants	  
were	  removed	  by	  centrifugation	  at	  1,000	  X	  g	  for	  10min,	  and	  again	  at	  6,000	  X	  g	  for	  
10min.	  	  Stocks	  were	  judged	  cell-­‐free	  by	  the	  lack	  of	  calnexin,	  and	  actin	  in	  western	  
blot	  analyses,	  stored	  at	  -­‐80°C.	  The	  number	  of	  PFU	  was	  determined	  by	  plaque	  assay	  
on	  triplicate	  HFF	  or	  ARPE-­‐19	  cultures.	  	  Freeze/thaw	  cycles	  were	  avoided.	  	  
Antibodies.	  	  Monoclonal	  antibodies	  (MAbs)	  specific	  for	  HCMV	  major	  capsid	  
protein	  (MCP)	  28-­‐4	  and	  gB	  27-­‐156	  were	  provided	  by	  Bill	  Britt	  (University	  of	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Alabama,	  Birmingham,	  AL,	  USA)	  (45,	  267).	  Anti-­‐UL128	  MAb	  4B10	  was	  provided	  by	  
Tom	  Shenk	  (Princeton	  University,	  Princeton,	  NJ,	  USA)	  (77).	  	  Rabbit	  polyclonal	  
antipeptide	  antibodies	  directed	  against	  HCMV	  gH/gL,	  UL130,	  and	  UL131	  were	  
provided	  by	  David	  Johnson	  (Oregon	  Health	  and	  Sciences	  University,	  Portland,	  OR,	  
USA)	  (80).	  Rabbit	  polyclonal	  antipeptide	  antibodies	  directed	  against	  MEgO	  were	  
described	  in	  (232).	  
Western	  blot.	  	  Cell-­‐free	  virions	  from	  culture	  supernatants	  (as	  described	  above)	  
were	  concentrated	  by	  centrifugation	  at	  50,000	  X	  g	  for	  1	  h,	  and	  resuspended	  in	  2%	  
SDS	  in	  20mM	  tris-­‐buffered	  saline	  (TBS;	  pH	  6.8).	  	  Insoluble	  material	  was	  removed	  by	  
centrifugation	  at	  16,000	  X	  g	  for	  30min,	  cleared	  extracts	  were	  heated	  to	  95	  °C	  for	  
10min.	  	  For	  reducing	  blots,	  extracts	  were	  adjusted	  to	  2%	  DTT.	  	  Proteins	  were	  
separated	  by	  SDS-­‐PAGE	  and	  transferred	  to	  PVDF	  membranes	  (Whatman)	  in	  a	  buffer	  
containing	  10mM	  NaHCO3	  and	  3mM	  Na2CO3	  (PH9.9),	  plus	  10%	  methanol.	  
Transferred	  proteins	  were	  probed	  with	  MAbs	  or	  rabbit	  polyclonal	  antibodies	  
specific	  for	  HCMV	  proteins,	  followed	  by	  horseradish	  peroxidase-­‐conjugated	  
secondary	  antibodies;	  chemi	  luminescence	  was	  detected	  using	  a	  Bio-­‐Rad	  ChemiDoc	  
MP	  imaging	  system.	  Band	  densities	  were	  quantified	  using	  Bio-­‐Rad	  Image	  lab	  v	  5.1	  or	  
ImageJ	  v	  1.48	  software.	  
Quantitative	  PCR	  (qPCR).	  	  200	  μl	  cell-­‐free	  HCMV	  stock	  was	  first	  treated	  with	  
DNase	  I	  to	  remove	  DNA	  not	  protected	  within	  viral	  capsids.	  Capsids	  were	  disrupted	  
by	  using	  the	  viral	  lysis	  buffer,	  and	  proteinase	  K	  provided	  in	  the	  PureLink	  Viral	  
RNA/DNA	  mini	  kit	  (Life	  Technologies).	  Viral	  DNA	  was	  eluted	  in	  50μl	  RNAse-­‐free	  
water.	  A	  conserved	  region	  within	  UL83	  among	  ME,	  TR	  and	  TB	  was	  chosen	  as	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amplicon,	  and	  genomes	  were	  quantified	  by	  real-­‐time	  qPCR	  using	  SYBR	  Green	  dye	  
(Bio-­‐Rad):	  forward	  primer,	  TGGTCACCTATCACCTGCAT;	  reverse	  primer,	  
GAAAGAGCCCGACGTCTACT.	  PCR	  samples	  were	  made	  to	  a	  total	  well	  volume	  of	  20μl	  
with	  1X	  SYBR	  Green	  master	  mix	  (Bio-­‐Rad),	  1:100	  dilution	  of	  viral	  DNA	  and	  500nM	  
forward	  and	  reverse	  primers.	  PCR	  products	  were	  detected	  using	  MyiQ	  real-­‐time	  
PCR	  detection	  system	  (Bio-­‐Rad).	  QPCR	  results	  were	  compared	  to	  a	  plasmid	  
pTRUL83	  standard	  and	  then	  calculated	  into	  genome/ml.	  Efficiency	  of	  DNase	  I	  
treatment	  were	  tested	  in	  independent	  experiments	  by	  spiking	  plasmid	  DNA.	  For	  
each	  experiment,	  two	  independent	  viral	  DNA	  extractions	  and	  three	  independent	  
QPCR	  reactions	  were	  performed.	  	  
Determination	  of	  plaque	  forming	  units	  (PFU).	  	  Cell	  monolayers	  were	  
infected	  with	  cell	  free	  HCMV,	  or	  HCMV	  infected	  cells	  (infectious	  centers),	  and	  cell	  
culture	  medium	  was	  replaced	  with	  a	  1:1	  mixture	  of	  2XDMEM	  and	  1.2%	  SeaPlaque	  
agarose	  to	  prevent	  spread	  of	  progeny	  virus	  by	  diffusion.	  	  Plaques	  were	  counted	  by	  
light	  microscopy	  3	  weeks	  later.	  	  	  	  
Antibody	  neutralization	  of	  HCMV.	  	  1:100	  diluted	  (vol/vol)	  anti-­‐UL130	  and	  
anti-­‐UL131	  rabbit	  serum	  were	  added	  to	  culture	  medium	  containing	  cell-­‐free	  HCMV.	  	  
The	  mixture	  was	  incubated	  for	  at	  room	  temperature	  for	  1	  h,	  and	  then	  added	  to	  HFF	  
or	  ARPE-­‐19	  cultures.	  
Polyethylene	  glycol	  (PEG)	  treatment.	  	  Cell-­‐free	  HCMV	  was	  adsorbed	  to	  cells	  
for	  2	  h	  at	  10°C,	  under	  800	  X	  g	  centrifugation	  or	  at	  37°C	  without	  centrifugation.	  	  
Unbound	  virus	  was	  removed	  by	  two	  cold	  PBS	  washes,	  and	  cells	  were	  subsequently	  
treated	  with	  44%	  PEG	  (pre-­‐warmed	  to	  37°C)	  for	  30s	  followed	  by	  10	  washes	  with	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warm	  culture	  medium	  to	  remove	  PEG.	  	  Cultures	  were	  incubated	  37°C	  until	  
immunofluorescence	  analysis	  was	  performed.	  PEG	  6000	  (Fluka)	  was	  prepared	  as	  a	  
60%	  (wt/wt)	  solution	  in	  PBS,	  and	  diluted	  with	  PBS	  to	  44%.	  
	   Immunofluorescence.	  HCMV	  infected	  cells	  were	  fixed	  with	  2%	  
formaldehyde	  in	  PBS	  for	  15	  min	  followed	  by	  three	  PBS	  washes.	  Fixed	  cells	  were	  
incubated,	  for	  1hr	  in	  immunofluorescence	  (IF)	  buffer	  (0.5%	  Triton	  X-­‐100,	  0.5%	  
deoxycholate,	  1%	  bovine	  serum	  albumin	  [BSA],	  0.05%	  sodium	  azide	  in	  PBS).	  	  To	  
visualize	  HCMV	  infected	  cells,	  anti-­‐IE1/IE2	  MAb	  P63-­‐27	  was	  used	  at	  1:50	  in	  IF	  
buffer,	  and	  Alexa	  488-­‐conjugated	  goat-­‐anti-­‐mouse	  antibodies	  1:1000	  diluted	  in	  IF	  
buffer.	  4’,	  6’-­‐diamidino-­‐2-­‐phenylindole	  dihydrochloride	  (DAPI)	  was	  used	  to	  
visualize	  total	  cells.	  
RESULTS	  
	   HCMV	  strains	  vary	  in	  both	  the	  ratio	  of	  gH/gL/gO	  to	  gH/gL/UL128-­‐131,	  
and	  the	  total	  amount	  of	  gH/gL	  complexes.	  In	  Chapter	  2,	  gH/gL	  complexes	  of	  
different	  HCMV	  strains	  were	  analyzed	  by	  non-­‐reducing	  western	  blot.	  	  Since	  the	  main	  
goal	  of	  those	  experiments	  was	  to	  compare	  the	  ratio	  of	  gH/gL/gO	  to	  gH/gL/UL128-­‐
131	  among	  strains,	  gels	  loads	  were	  adjusted	  to	  equalize	  the	  total	  amount	  of	  gH/gL.	  
TR	  and	  TB40/e	  (TB)	  virions	  were	  found	  to	  contain	  gH/gL	  mostly	  in	  the	  form	  of	  
gH/gL/gO,	  whereas	  Merlin	  (ME)	  had	  mostly	  gH/gL/UL128-­‐131	  (232).	  Those	  
experiments	  made	  use	  of	  recombinant	  ME	  in	  which	  the	  assembly	  of	  gH/gL/UL128-­‐
131	  could	  be	  reduced	  by	  the	  tetracycline-­‐repressor	  protein	  (TetR),	  which	  resulted	  
in	  ME	  virions	  containing	  mostly	  gH/gL/gO	  (denoted	  Merlin-­‐trimer;	  ME-­‐T)	  (177,	  
	   91	  
232).	  To	  further	  characterize	  the	  amounts	  of	  gH/gL	  complexes	  among	  HCMV	  




























Figure	   3-­‐1	   Comparison	   of	   glycoprotein	   concentrations	   in	   the	   virion	   envelope	   of	  
different	  HCMV	  strains.	  
Cell-­‐free	  virions	  of	  HCMV	  TB40/e	  (TB),	  TR,	  Merlin	  (ME)	  or	  Merlin-­‐Trimer	  (ME-­‐T)	  were	  separated	  by	  
reducing	  SDS-­‐PAGE,	  and	  analyzed	  by	  western	  blot	  with	  antibodies	  specific	  for	  major	  capsid	  protein	  
(MCP),	  the	  55-­‐kDa	  portion	  of	  gB,	  gH,	  gL,	  or	  UL131.	  Mass	  markers	  (kDa)	  are	  shown	  on	  the	  left	  of	  each	  
panel.	  	  Gel	  loads	  were	  normalized	  to	  equal	  MCP	  (A),	  or	  to	  5-­‐fold	  less	  MCP	  for	  ME	  (B).	  	  Numbers	  below	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expressing	  cells)	  were	  analyzed	  by	  western	  blot	  under	  reducing	  conditions,	  and	  gel	  
loads	  were	  normalized	  to	  major	  capsid	  protein	  to	  allow	  for	  comparison	  of	  the	  
amounts	  of	  the	  different	  glycoproteins	  per	  virion	  (Figure.	  3-­‐1).	  All	  strains	  contained	  
comparable	  amounts	  of	  gB,	  but	  the	  amounts	  of	  gH/gL	  varied	  dramatically.	  TB	  
contained	  the	  most	  total	  gH/gL,	  followed	  by	  TR,	  ME	  and	  ME-­‐T	  virions	  contained	  the	  
least	  total	  gH/gL	  (Figure.	  3-­‐1A).	  Despite	  the	  low	  amount	  of	  gH/gL,	  ME	  virions	  
contained	  dramatically	  more	  UL131	  (a	  marker	  of	  the	  gH/gL/UL128-­‐131	  complex)	  
(Figure.	  3-­‐1B).	  	  Note	  that	  in	  Figure.	  3-­‐1B,	  gel	  loads	  were	  adjusted	  to	  allow	  
visualization	  of	  the	  lower	  amounts	  of	  UL131	  in	  TB	  and	  TR	  virions,	  suggesting	  that	  
the	  difference	  in	  the	  level	  of	  UL131	  between	  ME	  and	  the	  other	  viruses	  was	  greater	  
then	  10-­‐fold.	  Also	  note	  that	  UL128,	  UL130	  and	  gO	  were	  not	  directly	  analyzed	  in	  
these	  experiments	  because	  amino	  acid	  polymorphisms	  between	  strains	  affect	  cross	  
reactivity	  of	  available	  antibodies	  (232).	  	  
	   	  HCMV	  gH/gL	  complexes	  were	  also	  analyzed	  by	  non-­‐reducing	  western	  blot	  
(loads	  normalized	  to	  MCP)	  (Figure.	  3-­‐2).	  	  Consistent	  with	  analyses	  reported	  in	  
Chapter	  2,	  the	  vast	  majority	  of	  gH/gL	  in	  TB,	  TR	  and	  ME-­‐T	  virions	  migrated	  at	  a	  size	  
indicative	  of	  disulfide-­‐linked	  gH/gL/gO,	  whereas	  most	  of	  the	  gH/gL	  in	  ME	  virions	  
was	  at	  the	  size	  of	  disulfide-­‐linked	  gH/gL/UL128	  (Figure.	  3-­‐2).	  	  Note	  that	  UL130	  and	  
UL131	  are	  not	  disulfide-­‐linked	  to	  gH/gL/UL128-­‐131,	  and	  are	  thus	  removed	  by	  SDS-­‐
PAGE	  (77,	  80).	  	  Unbound,	  or	  free	  gH/gL	  comprised	  a	  very	  small	  fraction	  of	  the	  total	  
gH/gL	  in	  all	  strains.	  Whether	  this	  represents	  spontaneous	  reduction	  of	  disulfide	  
bonds	  in	  the	  extract	  samples,	  or	  is	  indicative	  of	  small	  amounts	  of	  free	  gH/gL	  in	  
virions	  is	  not	  clear.	  	  Band	  density	  analyses	  of	  the	  three	  gH/gL	  species	  on	  non-­‐
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reducing	  blots	  corresponded	  well	  with	  the	  quantitation	  of	  total	  gH	  and	  gL	  on	  








Figure	  3-­‐2	  Comparison	  of	  gH/gL	  complexes	  in	  the	  virion	  envelope	  of	  different	  HCMV	  
strains.	  	  
Cell-­‐free	  virions	  of	  HCMV	  TB40/e	  (TB),	  TR,	  Merlin	  (ME)	  or	  Merlin-­‐Trimer	  (ME-­‐T)	  were	  separated	  by	  
non-­‐reducing	  SDS-­‐PAGE,	  and	  analyzed	  by	  western	  blot	  with	  antibodies	  specific	  for	  gL.	  	  Mass	  markers	  
(kDa)	  are	  shown	  on	  the	  left.	  Gel	  loads	  were	  normalized	  to	  equal	  MCP	  as	  in	  Figure.	  3-­‐1A	  (not	  shown).	  	  
Numbers	  below	  blot	  indicate	  analysis	  of	  band	  density	  for	  each	  species	  of	  gH/gL.	  nd:	  not	  detected.	  
	  
The	  low	  amounts	  of	  gH/gL	  complexes	  in	  ME	  and	  ME-­‐T	  virions	  made	  
quantitation	  in	  these	  viruses	  difficult	  to	  perform	  on	  the	  same	  blots	  as	  TB	  and	  TR.	  	  	  
Thus,	  ME	  and	  ME-­‐T	  virions	  were	  also	  analyzed	  on	  separate	  non-­‐reducing	  gels	  with	  
increased	  gel	  loads	  to	  allow	  detection	  in	  a	  quantifiable	  range	  (Figure.	  3-­‐3).	  
Furthermore,	  since	  ME	  and	  ME-­‐T	  are	  genetically	  identical	  viruses,	  these	  virions	  
could	  be	  directly	  compared	  by	  western	  blots	  using	  anti-­‐MEgO	  and	  anti-­‐UL128	  
antibodies	  (232).	  	  As	  in	  the	  previous	  analyses,	  ME	  virions	  contained	  more	  total	  
gH/gL	  than	  ME-­‐T	  virions,	  although	  at	  these	  increased	  loads,	  the	  difference	  was	  less	  
pronounced.	  	  This	  likely	  reflected	  the	  limitations	  of	  band	  density	  quantitation	  on	  the	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lower	  end	  of	  the	  spectrum	  in	  Figures.	  3-­‐1	  and	  3-­‐2.	  	  Comparison	  of	  the	  amount	  of	  
gH/gL/gO	  and	  gH/gL/UL128-­‐131	  in	  ME	  and	  ME-­‐T	  virions	  by	  probing	  blots	  for	  
either	  the	  common	  antigen	  (gL),	  or	  the	  unique	  antigen,	  (gO	  or	  UL128)	  confirmed	  
that	  ME-­‐T	  virions	  contained	  more	  gH/gL/gO	  than	  ME	  virions,	  whereas	  ME	  virions	  
had	  more	  gH/gL/UL128-­‐131	  than	  ME-­‐T	  virions	  (compare	  analogous	  bands	  in	  
Figure.	  3-­‐3A,	  B,	  and	  C).	  	  Together,	  these	  analyses	  indicated	  that	  strains	  of	  HCMV	  vary	  
widely	  in	  both	  the	  total	  amount	  of	  gH/gL	  complexes	  in	  the	  virion	  envelope,	  and	  also	  
vary	  in	  whether	  that	  gH/gL	  is	  in	  the	  form	  of	  gH/gL/gO	  or	  gH/gL/UL128-­‐131.	  	  	  
	  
	  
Figure	  3-­‐3	  Comparison	  of	  gH/gL	  complexes	  in	  the	  virion	  envelope	  of	  Merlin	  (ME)	  or	  
Merlin-­‐Trimer	  (ME-­‐T).	  
Cell-­‐free	   virions	   were	   separated	   by	   non-­‐reducing	   SDS-­‐PAGE,	   and	   analyzed	   by	   western	   blot	   with	  
antibodies	  specific	  for	  (A)	  gL,	  (B),	  MEgO,	  or	  (C)	  UL128.	  	  Mass	  markers	  (kDa)	  are	  shown	  on	  the	  far	  left.	  	  
Gel	  loads	  were	  normalized	  to	  equal	  MCP	  (not	  shown).	  	  Numbers	  below	  blots	  indicate	  analysis	  of	  band	  
density	  analysis,	  normalized	  to	  the	  more	  intense	  band	  within	  the	  same	  blot.	  	  nd:	  not	  detected.	  
	   	  












Figure	  3-­‐4	  Particle-­‐to-­‐PFU	  analysis	  of	  HCMV.	  
Cell	  free	  stocks	  of	  TB40/e	  (TB),	  TR,	  Merlin	  (ME),	  or	  Merlin-­‐trimer	  (ME-­‐T)	  virions	  were	  analyzed	  by	  
qPCR	  to	  quantitate	  genome-­‐containing	  virions,	  and	  plaque-­‐forming	  units	  (PFU)	  were	  determined	  on	  
fibroblast	  (A)	  or	  epithelial	  (B)	  cell	  cultures.	  	  	  Specific	  infectivity	  was	  calculated	  as	  the	  ratio	  of	  average	  
genomes	  per	  mL	  to	  average	  PFU	  per	  mL.	  	  Averages	  and	  standard	  deviations	  of	  three	  experiments	  are	  
plotted.	  Brackets	  above	  columns	  indicate	  results	  of	  2-­‐tailed,	  unpaired	  Student’s	  T-­‐test.	  P	  values:	  *	  =	  
0.04	  -­‐	  0.05;	  	  **	  <	  0.04.	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Particle-­‐to-­‐PFU	  analysis	  of	  strains	  of	  HCMV	  that	  contain	  different	  amounts	  
of	  gH/gL	  complexes.	  	  One	  model	  of	  HCMV	  tropism	  suggests	  that	  gH/gL/gO	  and	  
gH/gL/UL128-­‐131	  serve	  mechanistically	  analogous	  roles	  for	  entry	  into	  fibroblasts	  
and	  epithelial	  cells,	  respectively.	  	  However,	  that	  model	  is	  inconsistent	  with	  
observations	  that	  a	  gO-­‐null	  mutant	  TR	  was	  impaired	  for	  entry	  into	  fibroblasts	  and	  
epithelial	  cells	  (238).	  	  To	  help	  resolve	  this	  issue,	  we	  reasoned	  that	  specific	  infectivity	  
(particle-­‐to-­‐PFU	  ratio)	  of	  HCMV	  on	  both	  fibroblasts	  and	  epithelial	  cells	  should	  be	  
influenced	  by	  the	  amounts	  of	  the	  gH/gL	  complexes	  in	  the	  virion	  envelope.	  	  Thus,	  cell	  
free	  virions	  of	  TB,	  TR,	  ME,	  and	  ME-­‐T	  were	  quantitated	  by	  real-­‐time	  quantitative	  PCR	  
(qPCR)	  for	  viral	  genomes,	  titered	  by	  plaque	  assay	  on	  both	  fibroblasts	  and	  epithelial	  
cells	  and	  the	  specific	  infectivity	  was	  calculated	  (Figure.	  3-­‐4).	  
Particle-­‐to-­‐PFU	  measurements	  on	  fibroblasts	  varied	  widely	  between	  strains,	  
and	  were	  statistically	  significant	  in	  all	  comparisons	  (Figure.	  3-­‐4A).	  	  The	  extremes	  
were	  TB	  and	  ME	  at	  11,	  and	  5825	  particles-­‐per-­‐PFU	  respectively,	  which	  correlated	  
with	  the	  respectively	  high	  and	  low	  amounts	  of	  gH/gL/gO	  detected	  in	  these	  strains	  
(Figure.	  3-­‐2).	  	  Values	  for	  TR	  and	  ME-­‐T	  were	  intermediate	  (217	  and	  83	  respectively),	  
which	  generally	  correlated	  with	  their	  intermediate	  amounts	  of	  gH/gL/gO	  relative	  to	  
TB	  and	  ME.	  	  Notably	  however,	  TR	  contained	  considerably	  more	  gH/gL/gO	  than	  ME-­‐
T,	  but	  was	  2.6-­‐fold	  less	  infectious	  than	  ME-­‐T.	  It	  is	  possible	  that	  this	  relatively	  
modest	  difference	  might	  indicate	  that	  the	  level	  of	  gH/gL/gO	  in	  ME-­‐T	  represents	  a	  
minimum	  threshold.	  	  Additionally,	  this	  might	  reflect	  other	  genetic	  differences	  
between	  the	  strains.	  	  Thus,	  the	  comparison	  of	  ME	  with	  ME-­‐T	  is	  highly	  informative	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since	  these	  are	  genetically	  identical	  viruses	  that	  likely	  differ	  mostly,	  if	  not	  
exclusively,	  in	  the	  amounts	  of	  gH/gL/gO	  and	  gH/gL/UL128-­‐131.	  	  
	   Particle-­‐to-­‐PFU	  ratios	  were	  generally	  higher	  on	  epithelial	  cells,	  consistent	  
with	  previous	  observations	  that	  these	  cells	  are	  more	  difficult	  to	  infect	  with	  HCMV	  
than	  are	  fibroblasts,	  perhaps	  reflecting	  the	  more	  complicated	  route	  of	  entry	  which	  
involves	  internalization	  followed	  by	  fusion	  from	  within	  endosomes	  (79).	  	  TB	  was	  
the	  most	  infectious	  on	  epithelial	  cells	  (419	  particles/PFU),	  followed	  by	  ME-­‐T	  (1250	  
particles/PFU),	  ME	  (10,529	  particles/PFU),	  and	  TR	  (325,330	  particles/PFU)	  (Figure.	  
3-­‐4B).	  All	  comparisons	  were	  statistically	  significant.	  	  Given	  that	  ME	  virions	  
contained	  dramatically	  more	  gH/gL/UL128-­‐131	  than	  the	  other	  viruses,	  the	  
observation	  that	  ME	  was	  nearly	  10-­‐fold	  less	  infectious	  than	  ME-­‐T,	  and	  25-­‐fold	  less	  
infectious	  than	  TB	  on	  epithelial	  cells	  was	  inconsistent	  with	  the	  model	  that	  
gH/gL/UL128-­‐131	  performs	  the	  conserved	  herpesvirus	  gH/gL	  function	  of	  
promoting	  gB	  mediated	  fusion	  on	  these	  cells.	  	  Rather,	  the	  comparatively	  poor	  
infectivity	  of	  ME	  on	  both	  fibroblast	  and	  epithelial	  cells	  is	  more	  consistent	  with	  the	  
hypothesis	  that	  gH/gL/gO	  provides	  the	  core	  fusion	  function	  for	  entry	  into	  all	  cell	  
types,	  and	  that	  gH/gL/UL128-­‐131	  provides	  a	  mechanistically	  distinct,	  additional	  
function	  necessary	  for	  entry	  into	  epithelial	  cells.	  	  However,	  the	  particle-­‐to-­‐PFU	  ratio	  
of	  TR	  on	  epithelial	  cells	  was	  log-­‐folds	  higher	  than	  any	  of	  the	  other	  viruses,	  despite	  
being	  relatively	  rich	  in	  gH/gL/gO.	  	  This	  discrepancy	  was	  likely	  due	  in	  part	  to	  the	  fact	  
that	  plaque	  formation	  is	  not	  only	  a	  function	  of	  initial	  entry	  of	  cell	  free	  virions,	  but	  
also	  of	  replication	  and	  spread.	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   To	  address	  post-­‐entry	  differences	  in	  plaque	  formation	  between	  these	  viruses	  
(i.e.,	  replication	  and	  spread),	  an	  infectious	  center	  experiment	  was	  performed.	  	  
Fibroblast	  or	  epithelial	  cells	  were	  infected	  with	  TB,	  TR,	  or	  ME,	  and	  at	  2	  dpi.	  cells	  
were	  detached,	  and	  re-­‐plated	  onto	  monolayers	  of	  the	  homologous	  cell	  type,	  and	  
resultant	  plaques	  were	  counted	  (Figure.	  3-­‐5).	  	  Note	  that	  since	  ME-­‐T	  virions	  were	  
produced	  by	  propagating	  ME	  in	  cells	  expressing	  TetR	  to	  repress	  the	  transcription	  
from	  the	  UL128	  locus	  (177,	  232),	  they	  are	  genetically	  identical	  to	  ME	  virions.	  	  Thus,	  
there	  was	  no	  logical	  distinction	  to	  be	  made	  between	  ME	  and	  ME-­‐T	  in	  these	  
infectious	  center	  experiments.	  	  On	  fibroblasts,	  TB,	  TR,	  and	  ME	  were	  all	  comparably	  
efficient	  at	  forming	  plaques	  from	  infectious	  centers	  (40-­‐60	  plaques	  per	  100	  
infectious	  centers	  seeded)	  (Figure.	  3-­‐5A).	  	  On	  epithelial	  cells,	  TB	  and	  ME	  formed	  
plaques	  from	  infectious	  centers	  as	  efficiently	  as	  they	  did	  on	  fibroblasts,	  (approx.	  
50%),	  but	  TR	  was	  notably	  less	  efficient,	  yielding	  only	  10	  plaques	  per	  100	  infectious	  
centers	  (Figure.	  3-­‐5B).	  In	  interpreting	  these	  results,	  it	  is	  important	  to	  note	  that	  gO-­‐
null	  TR	  was	  severely	  impaired	  for	  entry,	  but	  more	  efficient	  at	  cell-­‐cell	  spread	  in	  
these	  epithelial	  cells	  compared	  to	  the	  parental	  wild	  type	  TR	  (238),	  suggesting	  a	  
mechanistic	  distinction	  between	  entry	  and	  spread	  on	  these	  cells.	  	  Thus,	  the	  poor	  
ability	  of	  TR	  to	  form	  plaques	  on	  epithelial	  cells	  from	  infectious	  centers	  helps	  to	  
explain	  the	  apparently	  high	  particle-­‐to-­‐PFU	  ratio	  of	  TR	  on	  these	  cells,	  and	  is	  also	  
consistent	  with	  reports	  indicating	  that	  HCMV	  tropism	  is	  not	  solely	  determined	  at	  
the	  level	  of	  entry	  (268,	  269).	  
	   	  








Figure	  3-­‐5	  HCMV	  plaque	  formation	  from	  infectious	  centers.	  	  	  
Replicate	  cultures	  of	  fibroblasts	  (A),	  or	  epithelial	  cells	  (B)	  were	  infected	  were	  infected	  with	  TB,	  TR	  or	  
ME.	  	  At	  2	  dpi.,	  one	  set	  of	  cultures	  was	  fixed	  and	  the	  fraction	  of	  infected	  cells	  was	  quantified	  for	  each	  
infection	   by	   immunofluorescence	   detection	   of	   immediate	   early	   gene	   expression.	   Cells	   in	   replicate	  
cultures	  were	  detached,	  counted	  and	  an	  amount	  of	  cells	  corresponding	  to	  100	  IE-­‐positive	  cells	  were	  
plated	  onto	  cultures	  of	  the	  homologous	  cell	  type.	  	  Plaques	  were	  allowed	  to	  develop	  and	  then	  counted.	  	  
Averages	  and	  standard	  deviations	  from	  three	  experiments	  are	  plotted.	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Perhaps	  the	  most	  surprising	  result	  of	  the	  particle-­‐to-­‐PFU	  analysis	  presented	  in	  
Figure.	  3-­‐4	  was	  that	  ME-­‐T	  was	  approximately	  10-­‐fold	  more	  efficient	  than	  ME	  on	  
epithelial	  cells	  (Figure.	  3-­‐4B).	  	  Western	  blot	  analysis	  clearly	  demonstrated	  that	  ME-­‐
T	  virions	  contain	  mostly	  gH/gL/gO,	  and	  very	  little	  gH/gL/UL128-­‐131,	  whereas	  ME	  
contains	  abundant	  gH/gL/UL128-­‐131,	  and	  smaller	  amounts	  of	  gH/gL/gO	  (Figure.	  3-­‐
1~3-­‐3).	  	  It	  was	  possible	  that	  these	  differences	  in	  gH/gL	  complexes	  affected	  the	  
fundamental	  mechanism,	  or	  route	  of	  entry	  for	  ME	  and	  ME-­‐T	  into	  these	  cells.	  	  To	  test	  
this,	  antibody	  neutralization	  experiments	  were	  performed	  using	  anti-­‐UL130	  and	  
anti-­‐UL131,	  which	  have	  been	  shown	  previously	  to	  block	  HCMV	  infection	  of	  
epithelial	  cells,	  but	  not	  fibroblasts	  (270)	  (Figure.	  3-­‐6).	  	  Anti-­‐UL130/131	  antibodies	  
blocked	  infection	  of	  both	  ME	  and	  ME-­‐T	  on	  epithelial	  but	  not	  on	  fibroblasts,	  
indicating	  that	  for	  both	  viruses,	  infection	  of	  epithelial	  cells	  but	  not	  fibroblasts	  was	  
gH/gL/UL128-­‐131-­‐dependent.	  	  These	  results	  indicate	  that	  1)	  ME-­‐T	  virions	  were	  not	  
completely	  devoid	  of	  gH/gL/UL128-­‐131,	  and	  2)	  the	  enhanced	  infectivity	  of	  ME-­‐T	  on	  
epithelial	  cells	  was	  not	  due	  to	  an	  aberrant,	  gH/gL/UL128-­‐131-­‐independent	  process.	  
Taken	  together,	  these	  analyses	  strongly	  contradict	  the	  model	  that	  gH/gL/gO	  and	  
gH/gL/UL128-­‐131	  serve	  mechanistically	  analogous	  roles	  for	  entry	  of	  HCMV	  into	  
fibroblasts	  and	  epithelial	  cells,	  respectively.	  	  Instead,	  it	  seems	  more	  likely	  that	  the	  
two	  complexes	  act	  through	  distinct	  mechanisms	  to	  facilitate	  entry	  into	  these	  cell	  
types.	  	  
	   The	  specific	  infectivity	  difference	  between	  ME	  and	  ME-­‐T	  virions	  can	  be	  
overcome	  with	  polyethylene	  glycol.	  	  Since	  ME	  and	  ME-­‐T	  are	  genetically	  identical	  
viruses,	  their	  post	  entry	  replication	  and	  spread	  characteristics	  are	  identical	  in	  cells	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that	  do	  not	  express	  TetR	  (177,	  232).	  	  Thus,	  the	  observed	  differences	  in	  particle-­‐to-­‐
PFU	  ratios	  (Figure.	  3-­‐4)	  were	  likely	  indicative	  of	  differences	  in	  the	  entry	  process	  as	  a	  
direct	  result	  of	  the	  amounts	  of	  gH/gL/gO	  and	  gH/gL/UL128-­‐131	  in	  the	  virion	  
envelope,	  likely	  acting	  on	  the	  ability	  of	  fusion.	  To	  test	  this	  hypothesis,	  equivalent	  
amounts	  of	  ME	  or	  ME-­‐T	  were	  adsorbed	  onto	  fibroblasts,	  or	  epithelial	  cells,	  and	  then	  
both	  viruses	  were	  provided	  with	  an	  equivalent,	  surrogate	  fusion	  mechanism,	  









Figure	  3-­‐6	  Neutralization	  of	  HCMV	  by	  UL130,	  and	  UL131	  specific	  antibodies.	  
Cell	  free	  Merlin	  (ME)	  or	  Merlin-­‐trimer	  (ME-­‐T)	  were	  plated	  on	  fibroblast	  or	  epithelial	  cell	  cultures	  in	  
the	   presence	   of	   anti-­‐UL130	   and	   anti-­‐UL131	   antibodies,	   and	   the	   number	   of	   resultant	   plaques	   was	  
determined.	   The	   average	   number	   of	   plaques	   as	   percent	   of	   control	   (no	   antibody)	   and	   standard	  
deviations	   from	   three	  experiments	   are	  plotted.	   	   For	   each	  experiment,	   the	  number	  of	  plaque	  under	  
control	  conditions	  ranged	  from	  80-­‐120.	  
	  
	   ME-­‐T	  efficiently	  infected	  fibroblast	  cells,	  but	  ME	  did	  not	  (66%	  and	  2.5%,	  
respectively;	  Figure.	  3-­‐7A).	  	  PEG	  treatment	  had	  no	  significant	  effect	  on	  the	  number	  
of	  cells	  infected	  with	  ME-­‐T	  suggesting	  that	  most	  ME-­‐T	  virions	  were	  capable	  of	  
	   102	  
efficient	  entry	  without	  PEG.	  	  This	  was	  consistent	  with	  the	  relatively	  low	  particle-­‐to-­‐
PFU	  ratio	  of	  ME-­‐T	  on	  these	  cells	  (Figure.	  3-­‐4A).	  In	  contrast,	  PEG	  resulted	  in	  an	  
approximately	  20-­‐fold	  increase	  in	  the	  numbers	  of	  cells	  infected	  with	  ME,	  bringing	  
the	  percent	  of	  cells	  infected	  with	  ME	  very	  near	  the	  values	  for	  ME-­‐T.	  	  These	  results	  
confirmed	  that	  ME	  virions	  were	  poorly	  infectious	  on	  fibroblasts	  largely	  due	  to	  an	  
inefficient	  fusion	  mechanism.	  	  	  	  
	   At	  the	  multiplicity	  used	  in	  these	  experiments	  (150	  particles	  per	  cell),	  neither	  
ME	  nor	  ME-­‐T	  infected	  measurable	  numbers	  of	  epithelial	  cells	  (Figure.	  3-­‐7B).	  	  This	  
was	  consistent	  with	  the	  much	  higher	  particle-­‐to-­‐PFU	  ratio	  measured	  on	  these	  cells	  
(Figure.	  3-­‐4B).	  	  PEG	  treatment	  resulted	  in	  a	  similar	  number	  of	  infected	  cells	  for	  both	  
ME	  and	  ME-­‐T,	  consistent	  with	  the	  notion	  that	  the	  high	  particle-­‐to-­‐PFU	  ratio	  of	  ME	  
compared	  to	  ME-­‐T	  (Figure.	  3-­‐4B)	  reflected	  a	  reduced	  ability	  of	  ME	  virus	  to	  
accomplish	  the	  fusion	  step	  of	  entry,	  not	  later	  stages	  of	  the	  replication	  cycle.	  
However,	  because	  of	  the	  relatively	  high	  particle-­‐to-­‐PFU	  ratios	  for	  both	  ME	  and	  ME-­‐T	  
on	  these	  cells	  (1250	  and	  10,529,	  respectively;	  Figure.	  3-­‐4B),	  it	  was	  possible	  that	  the	  
150	  particles	  per	  cell	  used	  in	  these	  experiments	  did	  not	  reflect	  the	  replication-­‐
competent	  virions	  in	  each	  population.	  To	  address	  this	  caveat,	  another	  set	  of	  
experiments	  were	  performed	  in	  which	  10,	  or	  30	  PFU	  were	  plated	  on	  epithelial	  cells,	  
virus	  entry	  was	  induced	  with	  PEG,	  and	  the	  number	  of	  resultant	  plaques	  was	  
determined	  (Figure.	  3-­‐8).	  	  For	  ME,	  PEG	  treatment	  resulted	  in	  plaque	  numbers	  4-­‐5	  
fold	  greater	  than	  the	  inputs,	  but	  PEG	  had	  no	  significant	  effect	  on	  the	  numbers	  of	  ME-­‐
T	  plaques.	  	  The	  lack	  of	  effect	  on	  ME-­‐T	  plaque	  formation	  suggests	  that	  a	  large	  portion	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of	  the	  1250	  particle-­‐to-­‐PFU	  ratio	  may	  represent	  virions	  with	  post-­‐entry	  defects.	  	  





Figure	  3-­‐7	  Effects	  of	  polyethylene	  glycol	  (PEG)	  on	  infection	  by	  gH/gL/UL128-­‐131-­‐rich,	  
and	  gH/gL/gO-­‐rich	  HCMV.	  	  
Cell	  free	  Merlin	  (ME)	  or	  Merlin-­‐trimer	  (ME-­‐T)	  virions	  were	  plated	  on	  fibroblast	  (A)	  or	  epithelial	  cell	  
(B)	  cultures	  at	  150	  particles	  per	  cell,	  and	  then	  treated	  with	  either	  PBS	  (-­‐)	  or	  PEG	  (+).	  	  Cells	  were	  fixed	  
48h	  later,	  and	  analyzed	  by	  immunofluorescence	  to	  detect	  HCMV	  IE	  gene	  expression.	  	  Representative	  
microscopic	   fields	   are	   shown	   (left),	   and	   the	   average	  percent	   of	   cells	   infected	   among	  6	  microscope	  
fields	  (>	  80	  cells	  each)	  are	  plotted	  (right).	  	  Error	  bars	  represent	  standard	  deviations.	  
	  
	  






















Figure	   3-­‐8	   Effects	   of	   polyethylene	   glycol	   (PEG)	   on	   HCMV	   plaque	   formation	   on	  
epithelial	  cells.	  
10	   PFU	   (A),	   or	   30	   PFU	   (B)	   of	  Merlin	   (ME)	   or	  Merlin-­‐trimer	   (ME-­‐T)	  were	   plated	   on	   epithelial	   cell	  
cultures,	   treated	   with	   PEG,	   and	   the	   number	   of	   resultant	   plaques	   was	   determined.	   The	   average	  
number	  of	  plaques	  and	  standard	  deviations	  from	  three	  experiments	  are	  plotted.	  
	  
	  
entry	  events	  that	  progress	  to	  IE	  expression	  fail	  to	  result	  in	  a	  plaque	  on	  these	  cells	  
(Figure.	  3-­‐5B.)	  	  However,	  it	  may	  also	  reflect	  limitations	  in	  PEG-­‐induction	  of	  virus	  
entry.	  	  The	  observed	  enhancement	  of	  ME	  plaque	  formation	  by	  PEG	  strongly	  suggests	  
that	  ME	  virions	  were	  less	  infectious	  on	  epithelial	  cells	  due	  to	  an	  inability	  to	  
accomplish	  the	  fusion	  stage	  of	  entry,	  despite	  their	  elevated	  levels	  of	  gH/gL/UL128-­‐
131.	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DISCUSSION	  
	  	   Specific	  infectivity	  (also	  referred	  to	  as	  “plating	  efficiency”)	  was	  among	  the	  
earliest	  established	  parameters	  of	  virus	  characterization,	  and	  has	  been	  generally	  
expressed	  as	  some	  unit	  of	  physical	  quantitation	  of	  virus	  (e.g.,	  grams	  of	  protein	  or	  
nucleic	  acid,	  number	  of	  capsids,	  number	  of	  genomes,	  etc.)	  per	  unit	  of	  virus	  
infectivity	  (e.g.,	  plaque	  forming	  units	  (PFU),	  lethal/infectious	  dose	  (LD/ID)	  50,	  
tissue	  culture	  infectious	  dose	  (TCID)	  50,	  etc.)	  (271–273).	  	  High	  particle-­‐to-­‐PFU	  
ratios	  are	  common,	  and	  reflect	  the	  fact	  that	  some	  viral	  particles	  in	  a	  given	  
preparation	  are	  defective,	  and	  incapable	  of	  initiating	  or	  completing	  a	  replication	  
cycle.	  	  However,	  irrespective	  of	  bona	  fide	  defective	  virions,	  high	  specific	  infectivity	  
ratios	  also	  reflect	  the	  generally	  low	  probability	  that	  any	  given	  replication-­‐competent	  
virion	  within	  a	  population	  will	  successfully	  accomplish	  a	  measurable	  replication	  
event	  in	  an	  inherently	  time-­‐limited	  assay.	  	  Indeed,	  Thomas	  et	  al.	  reported	  that	  high	  
particle-­‐to-­‐PFU	  ratios	  of	  HIV	  in	  part	  reflect	  the	  poor	  odds	  that	  any	  given	  virion	  will	  
even	  attach	  to	  a	  host	  cell	  (274).	  	  It	  has	  been	  suggested	  that	  the	  envelope	  
composition	  of	  HCMV	  virions	  within	  a	  population	  is	  heterogeneous	  (259,	  260),	  and	  
it	  is	  plausible	  that	  this	  phenomenon	  contributes	  to	  high	  and	  variable	  particle-­‐to-­‐PFU	  
ratios,	  through	  stochastic	  probability	  effects.	  	  
	   Early	  analyses	  of	  the	  specific	  infectivity	  of	  HCMV	  involved	  counting	  particles	  
by	  electron	  microscopy,	  and	  particle-­‐to-­‐PFU	  ratios	  ranging	  from	  approximately	  102	  
to	  108	  were	  reported	  (275–277).	  	  The	  wide	  ranges,	  and	  high	  values	  were	  likely	  due	  
in	  part	  to	  variable	  numbers	  of	  dense	  bodies	  (DB)	  and	  non-­‐infectious	  enveloped	  
particles	  (NIEPs),	  which	  lack	  genomes,	  and	  therefore	  cannot	  be	  PFUs	  (49,	  126,	  278).	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Our	  use	  of	  quantitative	  PCR	  avoided	  particles	  that	  lack	  genomes,	  and	  consequently,	  
values	  obtained	  were	  log-­‐orders	  lower,	  more	  consistent	  between	  independent	  
samples	  of	  the	  same	  virus,	  and	  consistent	  with	  previous	  uses	  of	  this	  approach	  (279).	  	  	  
	   While	  the	  specific	  infectivity	  measurements	  reported	  herein	  were	  highly	  
reproducible	  for	  any	  given	  strain	  of	  HCMV,	  there	  were	  large	  differences	  between	  
strains,	  and	  between	  cell	  types.	  Values	  on	  epithelial	  cells	  were	  considerably	  higher	  
than	  on	  fibroblasts	  for	  all	  strains	  analyzed.	  	  This	  indicates	  that	  the	  susceptibility	  and	  
permissiveness	  of	  different	  cell	  types	  to	  HCMV	  is	  not	  a	  simple	  “yes-­‐no”	  binary,	  but	  
rather	  a	  continuum	  that	  likely	  reflects	  complex	  differences	  including	  receptor	  
availabilities,	  and	  the	  mechanism	  of	  entry	  and	  spread	  on	  different	  cell	  types.	  	  
Indeed,	  entry	  of	  HCMV	  into	  fibroblasts	  likely	  occurs	  through	  fusion	  at	  the	  cell	  
surface,	  whereas	  entry	  into	  other	  cell	  types,	  such	  as	  epithelial	  cells,	  likely	  involves	  
internalization	  of	  the	  virus	  by	  endocytosis-­‐like	  processes,	  and	  subsequent	  fusion	  
from	  within	  endosomes	  (79,	  102,	  280).	  	  Additionally,	  the	  large	  differences	  between	  
strains	  of	  HCMV	  observed	  likely	  have	  multi-­‐locus	  genetic	  underpinnings,	  since	  
plaque	  formation	  is	  a	  function	  of	  every	  stage	  of	  the	  replication	  cycle.	  
	   Comparative	  western	  blot	  analyses	  indicated	  considerable	  variation	  in	  the	  
amounts	  of	  gH/gL	  complexes	  in	  the	  virion	  envelope	  between	  strains	  of	  HCMV.	  	  TB	  
and	  TR	  were	  found	  to	  contain	  gH/gL	  mostly	  in	  the	  form	  of	  gH/gL/gO,	  and	  
comparatively	  less	  gH/gL/UL128-­‐131,	  whereas	  ME	  virions	  contained	  much	  less	  
total	  gH/gL,	  and	  that	  was	  mostly	  in	  the	  form	  of	  gH/gL/UL128-­‐131.	  	  These	  results	  
were	  consistent	  with	  the	  previous	  data	  reported	  in	  Chapter	  2	  (232).	  Importantly,	  
despite	  the	  overall	  low	  amount	  of	  the	  amount	  of	  gH/gL	  in	  ME,	  the	  amount	  of	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gH/gL/UL128-­‐131	  was	  dramatically	  more	  than	  was	  detected	  in	  TB	  or	  TR	  virions.	  	  
While	  the	  HCMV	  virions	  analyzed	  here	  were	  produced	  in	  fibroblasts,	  Murrell	  et	  al.	  
produced	  virions	  in	  epithelial	  cells	  and	  found	  that	  TR	  contained	  amounts	  of	  
gH/gL/UL128-­‐131	  comparable	  to	  ME,	  and	  TB	  had	  noticeably	  less	  (281).	  	  These	  
discrepancies	  suggest	  that	  factors	  of	  the	  host	  cell	  type	  can	  influence	  the	  assembly	  of	  
HCMV	  gH/gL	  complexes.	  	  Furthermore,	  our	  analyses	  suggest	  that	  the	  gH/gL	  deficit	  
in	  ME	  represents	  a	  deficit	  of	  gH/gL/gO.	  This	  was	  reversed	  by	  Tet-­‐repression	  of	  
gH/gL/UL128-­‐131,	  resulting	  in	  ME	  virions	  contained	  similar	  amounts	  of	  total	  
gH/gL,	  but	  it	  was	  mostly	  in	  the	  form	  of	  gH/gL/gO	  ((232)	  and	  Figure.	  3-­‐3).	  	  This	  virus	  
was	  denoted	  ME-­‐trimer	  (ME-­‐T).	  	  These	  characterizations	  of	  gH/gL	  complexes	  
among	  HCMV	  strains	  allowed	  for	  studies	  into	  the	  mechanisms	  by	  which	  gH/gL/gO	  
and	  gH/gL/UL128-­‐131	  facilitate	  entry	  into	  different	  cell	  types.	  	  
	   Characterization	  of	  gH/gL/gO	  and	  gH/gL/UL128-­‐131	  mechanisms	  has	  relied	  
largely	  on	  the	  analysis	  of	  UL128-­‐131,	  and	  gO	  deletion	  mutants.	  (77–79,	  227)	  (42,	  
234,	  235,	  238).	  	  UL128-­‐131	  mutants	  replicate	  well	  on	  fibroblasts,	  allowing	  them	  to	  
be	  easily	  propagated,	  and	  clearly	  characterized	  for	  their	  defective(s)	  on	  select	  cells	  
such	  as	  epithelial,	  and	  endothelial	  cells.	  In	  contrast,	  gO	  mutants	  are	  severely	  
impaired	  on	  all	  cell	  types.	  	  This	  suggests	  a	  fundamental	  role	  for	  gH/gL/gO	  in	  entry,	  
but	  without	  a	  complementation	  system,	  further	  characterization	  of	  mechanism	  has	  
been	  difficult	  since	  the	  rare	  infection	  events	  observed	  likely	  represent	  non-­‐
physiologic	  mechanisms.	  Thus,	  there	  has	  been	  no	  clear	  data	  to	  distinguish	  two	  
mutually	  exclusive	  models	  for	  how	  HCMV	  gH/gL	  complexes	  facilitate	  entry	  into	  
different	  cell	  types.	  	  A	  commonly	  assumed	  model	  is	  one	  in	  which	  gH/gL/gO	  and	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gH/gL/UL128-­‐131	  each	  performs	  a	  mechanistically	  analogous	  function	  for	  entry	  
into	  different	  cell	  types.	  Under	  this	  model,	  that	  analogous	  function	  is	  likely	  the	  
“core”	  herpesvirus	  gH/gL	  function	  of	  promoting	  gB-­‐mediated	  membrane	  fusion	  
during	  entry,	  and	  the	  basis	  of	  cell	  type	  selectivity	  is	  alternate	  receptor	  binding.	  	  An	  
alternative	  model	  however,	  is	  that	  gH/gL/gO	  promotes	  gB-­‐mediated	  fusion	  for	  
entry	  into	  all	  cell	  types,	  where	  as	  gH/gL/UL128-­‐131	  facilitates	  infection	  of	  select	  
cell	  type,	  including	  epithelial	  cells,	  though	  a	  distinct	  mechanism	  that	  does	  not	  
functionally	  replace	  the	  need	  for	  gH/gL/gO.	  	  
	   Our	  use	  of	  ME	  virions	  enriched	  for	  either	  gH/gL/UL128-­‐131	  or	  gH/gL/gO	  
(ME	  and	  ME-­‐T,	  respectively)	  avoided	  many	  of	  the	  caveats	  associated	  with	  null	  
mutants.	  	  Since	  the	  viruses	  are	  not	  devoid	  of	  either	  gH/gL/gO,	  or	  gH/gL/UL128-­‐131,	  
they	  are	  theoretically	  capable	  of	  physiologically	  relevant	  viral	  entry	  mechanisms	  on	  
all	  cell	  types,	  albeit	  with	  different	  efficiencies.	  	  Furthermore,	  since	  they	  are	  
genetically	  identical	  viruses,	  after	  the	  initial	  entry	  event,	  replication	  and	  plaque	  
spread	  should	  be	  identical.	  	  Indeed,	  plaque	  size	  and	  morphologies	  were	  
indistinguishable	  on	  all	  cells	  lacking	  TetR	  expression	  (177).	  	  The	  higher	  particle-­‐to-­‐
PFU	  ratio	  of	  ME	  compared	  to	  ME-­‐T	  on	  both	  fibroblasts	  and	  epithelial	  cells	  indicated	  
that	  a	  greater	  fraction	  of	  virions	  in	  ME	  stocks	  failed	  to	  form	  plaques.	  	  Experiments	  
involving	  PEG-­‐induced	  fusion	  indicated	  that	  these	  ME	  virions	  failed	  largely	  because	  
they	  could	  not	  accomplish	  the	  fusion	  event	  of	  entry.	  The	  fate	  of	  non-­‐fusing	  virions	  is	  
unclear	  but	  may	  include	  endocytosis,	  and	  destruction	  within	  the	  lysosome.	  
Regardless,	  these	  results	  are	  inconsistent	  with	  the	  model	  that	  gH/gL/gO	  and	  
gH/gL/UL128-­‐131	  are	  each	  sufficient	  as	  a	  “herpesvirus	  core-­‐fusion	  gH/gL”	  for	  entry	  
	   109	  
into	  fibroblasts	  and	  epithelial	  cells,	  respectively.	  Rather,	  it	  is	  more	  likely	  that	  only	  
gH/gL/gO	  performs	  the	  conserved	  “herpesvirus	  gH/gL	  function”	  of	  promoting	  gB-­‐
mediated	  membrane	  fusion	  during	  entry	  into	  all	  cell	  types,	  and	  gH/gL/UL128-­‐131	  
provides	  a	  distinct,	  yet	  necessary	  function	  for	  entry	  into	  select	  cell	  types,	  such	  as	  
epithelial	  cells.	  	  	  
	   The	  exceedingly	  high	  particle-­‐to-­‐PFU	  ratio	  of	  TR	  on	  epithelial	  cells	  was	  
seemingly	  incongruent	  with	  the	  model	  of	  distinct	  functions	  for	  gH/gL	  complexes	  
since	  TR	  virions	  contained	  comparable	  amounts	  of	  gH/gL/gO	  and	  gH/gL/gUL128-­‐
131	  as	  TB,	  and	  contained	  more	  of	  both	  gH/gL	  complexes	  than	  ME-­‐T	  virions,	  yet	  both	  
TB	  and	  ME-­‐T	  were	  vastly	  more	  efficient	  at	  plaque	  formation	  than	  TR.	  However,	  as	  
noted	  above,	  plaque	  formation	  reflects	  the	  entire	  entry-­‐replication-­‐spread	  cycle.	  	  
Analysis	  of	  the	  efficiency	  of	  post-­‐entry	  replication	  and	  spread	  indicated	  that	  TR	  was	  
much	  less	  likely	  to	  progress	  from	  entry	  to	  form	  an	  observable	  plaque	  on	  epithelial	  
cells	  than	  were	  TB	  or	  ME	  (Figure.	  3-­‐5).	  	  Furthermore,	  plaques	  on	  epithelial	  cells	  that	  
were	  observed	  for	  TR	  were	  notably	  smaller	  than	  those	  for	  TB	  and	  ME.	  	  Thus,	  it	  
seems	  likely	  that	  the	  poor	  plaque	  formation	  of	  TR	  on	  epithelial	  cells	  reflects	  genetic	  
differences	  between	  strains	  loci	  other	  than	  gO	  and	  UL128-­‐131,	  and	  underscores	  
observations	  that	  HCMV	  tropism	  is	  not	  only	  determined	  by	  entry	  mechanisms	  (268,	  
269).	  
	   The	  model	  of	  distinct	  mechanisms	  for	  HCMV	  gH/gL	  complexes	  fits	  well	  with	  
other	  recent	  observations	  of	  CMV	  entry	  and	  spread.	  First,	  HCMV	  entry	  into	  epithelial	  
cells	  likely	  involves	  membrane	  fusion	  from	  within	  low-­‐pH	  endosomes	  (79,	  190,	  
280).	  	  Nogalski	  et	  al.	  characterized	  the	  interaction	  of	  HCMV	  with	  monocytes,	  a	  cell	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type	  for	  which	  infection	  is	  also	  gH/gL/UL128-­‐131	  dependent	  (230,	  266).	  	  They	  
found	  positive	  correlation	  between	  the	  level	  of	  gH/gL/UL128-­‐131	  in	  the	  virion	  
envelope,	  and	  the	  intensity	  of	  Src	  kinase	  activation	  following	  virion	  attachment	  
(230).	  	  Thus,	  one	  possibility	  is	  that	  signaling	  through	  gH/gL/UL128-­‐131	  receptors	  
might	  affect	  the	  nature	  of	  the	  endosome	  in	  a	  way	  that	  fosters	  subsequent	  membrane	  
fusion	  mediated	  by	  gB	  and	  gH/gL/gO.	  	  Second,	  while	  data	  presented	  here	  indicate	  
that	  gH/gL/gO	  is	  important	  for	  infection	  of	  all	  cell	  types	  by	  cell-­‐free	  HCMV,	  analyses	  
of	  gO	  mutants	  suggested	  that	  cell-­‐to-­‐cell	  spread	  on	  epithelial	  or	  endothelial	  cells	  and	  
monolayers	  does	  not	  require	  gH/gL/gO	  (235,	  238).	  	  Furthermore,	  a	  recent	  in	  vivo	  
study	  involving	  murine	  CMV	  suggesting	  that	  gH/gL/gO	  is	  important	  for	  initial	  
infection	  of	  mice,	  but	  less	  important	  for	  subsequence	  spread	  to	  distal	  organs	  and	  
tissues	  (282).	  
	   	  The	  proposed	  mechanistic	  distinction	  between	  gH/gL/gO	  and	  
gH/gL/UL128-­‐131	  may	  provide	  a	  unique	  opportunity	  to	  study	  the	  general	  
principles	  of	  how	  the	  herpesvirus	  gH/gL	  promotes	  fusion	  by	  gB	  (i.e.,	  the	  “core	  
fusion”	  function	  of	  gH/gL).	  Herpesvirus	  fusion	  has	  been	  most	  extensively	  studied	  for	  
HSV,	  which	  has	  only	  one	  form	  of	  gH/gL,	  and	  EBV,	  which	  has	  two,	  gH/gL,	  and	  
gH/gL/gp42	  (reviewed	  in	  (189)).	  	  In	  the	  case	  of	  EBV,	  both	  complexes	  appear	  to	  
perform	  the	  conserved	  function	  of	  promoting	  gB-­‐mediated	  membrane	  fusion	  for	  
entry	  into	  either	  epithelial,	  or	  B-­‐cells,	  indicating	  that	  gp42	  does	  not	  cover,	  or	  
otherwise	  alter	  the	  profusion	  surfaces	  of	  gH/gL.	  	  Fusion	  by	  HCMV	  also	  likely	  
involves	  interactions	  between	  gB	  and	  surfaces	  of	  gH/gL	  (122,	  216).	  	  However,	  data	  
presented	  here	  suggest	  that	  gH/gL	  cannot	  promote	  gB	  fusion	  when	  the	  UL128-­‐131	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proteins	  are	  bound.	  	  This	  could	  be	  due	  to	  differential	  allosteric	  effects	  on	  gH/gL	  
conformation	  as	  the	  result	  of	  gO	  versus	  UL128-­‐131	  binding.	  Alternatively,	  it	  could	  
be	  that	  gO	  and	  UL128-­‐131	  physically	  cover	  different	  surfaces	  of	  gH/gL.	  	  Recent	  
cryo-­‐EM	  analyses	  reported	  by	  Ciferri	  et	  al.	  indicated	  that	  gO	  and	  UL128-­‐131	  bind	  
the	  same	  face	  of	  gH/gL,	  but	  the	  data	  provided	  neither	  support	  nor	  contradiction	  to	  
either	  aforementioned	  possibility	  (215).	  It	  is	  also	  noteworthy	  that	  Ciferri	  et	  al.	  
suggested	  that	  gH/gL/UL128-­‐131	  was	  capable	  of	  facilitating	  gB-­‐mediated	  
membrane	  fusion	  in	  cell-­‐cell	  fusion	  experiments.	  However,	  these	  data	  were	  difficult	  
to	  interpret	  because	  in	  the	  same	  experiments,	  unbound	  gH/gL	  (lacking	  UL128-­‐131	  
or	  gO)	  failed	  to	  promote	  gB-­‐mediated	  fusion.	  This	  was	  an	  important	  discrepancy	  
with	  the	  results	  of	  Vanarsdall	  et	  al.	  showing	  that	  gH/gL	  alone	  was	  capable	  of	  
promoting	  gB	  fusion	  in	  the	  same	  type	  of	  cell-­‐cell	  fusion	  experiment,	  though	  Ciferri	  et	  
al.	  did	  not	  comment	  on	  this	  (215,	  216).	  	  
	   Several	  recent	  studies	  have	  characterized	  the	  antibody	  response	  to	  the	  
pentameric	  gH/gL/UL128-­‐131	  with	  an	  aim	  towards	  vaccine	  development	  (283–
285).	  Pentamer	  vaccines	  clearly	  elicit	  antibodies	  that	  are	  specific	  to	  epitopes	  that	  
are	  contained	  on	  the	  UL128-­‐131	  proteins	  surfaces	  themselves,	  or	  present	  on	  the	  
gH/gL	  surfaces	  that	  are	  allosterically	  dependent	  on	  UL128-­‐131	  (i.e.,	  pentamer-­‐
specific	  antibodies),	  as	  well	  as	  antibodies	  that	  react	  to	  surfaces	  of	  gH/gL	  that	  are	  
independent	  of	  the	  UL128-­‐131	  proteins	  (i.e.,	  gH/gL-­‐specific	  antibodies).	  Pentamer-­‐
specific	  antibodies	  powerfully	  neutralize	  HCMV	  infection	  of	  epithelial	  cells,	  but	  
show	  little	  to	  no	  neutralizing	  potency	  on	  fibroblasts.	  	  In	  contrast,	  the	  gH/gL-­‐specific	  
antibodies	  have	  significantly	  lower	  neutralizing	  potency,	  but	  block	  infection	  of	  both	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fibroblasts	  and	  epithelial	  cells	  with	  comparable	  potency.	  	  In	  the	  context	  of	  the	  model	  
of	  distinct	  mechanisms	  proposed	  here,	  it	  seems	  likely	  that	  the	  pentamer-­‐specific	  
antibodies	  interfere	  with	  the	  binding	  of	  the	  pentamer	  to	  cell-­‐type	  specific	  receptors,	  
and	  thus	  block	  the	  subsequent	  signaling	  cascades	  that	  enhance	  infection	  of	  select	  
cell	  types,	  whereas	  the	  gH/gL-­‐specific	  antibodies	  block	  the	  role	  of	  gH/gL/gO	  in	  
promoting	  gB	  fusion	  on	  all	  cell	  types.	  	  The	  disparity	  in	  potency	  between	  pentamer-­‐
specific	  and	  gH/gL-­‐specific	  antibodies	  may	  be	  due	  to	  any	  of	  several,	  non-­‐mutually	  
exclusive	  factors	  including;	  1)	  the	  differential	  abundance	  of	  gH/gL/gO	  and	  
gH/gL/UL128-­‐131	  in	  the	  virion	  envelope,	  2)	  the	  apparent	  fact	  that	  infection	  of	  
epithelial	  cells	  can	  likely	  be	  inhibited	  at	  either	  of	  two	  independent	  mechanisms,	  
internalization	  or	  fusion,	  compared	  to	  only	  fusion	  on	  fibroblasts,	  3)	  the	  relevant	  
gH/gL-­‐specific	  epitopes	  may	  be	  differentially	  displayed	  due	  to	  different	  allosteric	  
effects	  of	  UL128-­‐131	  binding	  compared	  to	  gO	  binding,	  or	  by	  the	  presence	  of	  the	  
extensive	  gO	  glycan	  network.	  The	  latter	  possibility	  seems	  especially	  plausible	  given	  
that	  gH/gL-­‐specific	  antibodies	  described	  have	  been	  raised	  either	  against	  gH/gL	  
alone,	  or	  gH/gL/UL128-­‐131	  (i.e.,	  in	  the	  absence	  of	  gO).	  	  	  
	   In	  summary,	  the	  observations	  reported	  here	  and	  elsewhere	  strongly	  argue	  
that	  the	  fusion	  event	  of	  entry	  of	  HCMV	  into	  all	  cell	  types	  is	  mediated	  by	  gB	  and	  
gH/gL/gO.	  	  On	  some	  cell	  types,	  such	  as	  epithelial	  cells,	  efficient	  fusion	  must	  be	  
preceded	  by	  a	  process	  mediated	  by	  the	  pentameric	  gH/gL/UL128-­‐131	  complex.	  	  
This	  model	  of	  entry	  and	  tropism	  may	  have	  important	  implications	  for	  the	  
development	  of	  HCMV	  vaccines	  as	  well	  as	  broader	  implications	  for	  understanding	  
the	  principles	  of	  that	  the	  herpesvirus	  gH/gL	  does	  to	  promote	  gB-­‐fusion.	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CHAPTER	  4. CHARACTERIZATION	  OF	  THE	  
VIRAL	  FACTORS	  THAT	  INFLUENCE	  HUMAN	  
CYTOMEGALOVIRUS	  gH/gL	  COMPLEXES	  
ASSEMBLY	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INTRODUCTION	  
Human	  cytomegalovirus	  (HCMV)	  is	  a	  member	  of	  beta-­‐herpesvirus	  family,	  which	  
is	  widespread	  and	  can	  infect	  up	  to	  95%	  of	  the	  population	  in	  the	  United	  States	  (9).	  
The	  primary	  infection	  of	  HCMV	  in	  healthy	  host	  is	  normally	  subclinical,	  followed	  by	  
life-­‐long	  persistent	  and	  latent	  infection.	  However,	  with	  immunocompromised	  (e.g.,	  
HIV/AIDS	  patients)	  or	  immunosuppressed	  (e.g.,	  transplant	  recipients)	  individuals,	  
HCMV	  primary	  infection,	  reinfection	  by	  another	  strain,	  or	  reactivation	  from	  latency	  
can	  cause	  life-­‐threatening	  diseases	  (reviewed	  in	  (240)).	  The	  virus	  is	  also	  a	  leading	  
cause	  for	  congenital	  birth	  defects.	  Each	  year	  about	  0.2%	  of	  all	  live	  births	  are	  infected	  
by	  HCMV,	  resulting	  in	  approximately	  1%	  death	  and	  20%	  with	  permanent	  
neurological	  impairments	  (18).	  HCMV	  can	  infect	  a	  wide	  spectrum	  of	  cell	  types	  in	  the	  
human	  body,	  including	  epithelial/endothelial	  cells,	  fibroblasts,	  monocytes,	  placental	  
trophoblasts,	  smooth	  muscle	  cells,	  hepatocyte	  and	  neuronal	  cells	  (147,	  149–157).	  
The	  broad	  cell	  tropism	  reflects	  that	  this	  virus	  is	  capable	  of	  entering	  numerous	  cell	  
types.	  No	  matter	  which	  cell	  type	  the	  virus	  encounters,	  as	  an	  enveloped	  virus,	  the	  key	  
event	  is	  to	  fuse	  viral	  envelope	  with	  cellular	  membranes,	  which	  is	  mediated	  by	  the	  
viral	  envelope	  glycoproteins.	  
All	  herpesviruses	  share	  conserved	  fusion	  machinery	  comprised	  of	  gB	  and	  
heterodimeric	  complex	  gH/gL.	  gB	  is	  the	  fusion	  protein,	  while	  gH/gL	  provides	  
essential	  regulatory	  role,	  probably	  involving	  in	  direct	  interaction	  with	  gB	  (67,	  189,	  
198,	  209,	  210,	  213,	  214,	  219,	  286).	  Besides	  gB	  and	  gH/gL,	  each	  herpesvirus	  also	  
encodes	  accessory	  proteins	  that	  can	  regulate	  the	  action	  of	  the	  core	  fusion	  
machinery,	  for	  instance,	  herpes	  simplex	  virus	  (HSV)	  gD,	  and	  Epstein-­‐Barr	  virus	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(EBV)	  gp42	  (214,	  218,	  221–223,	  247,	  262).	  The	  accessory	  proteins	  could	  either	  
transiently	  or	  stably	  interact	  with	  gH/gL,	  and	  are	  often	  involved	  in	  receptor	  binding	  
and	  can	  act	  as	  viral	  tropism	  determinants.	  For	  both	  HSV	  and	  EBV,	  their	  unbound	  
gH/gL	  or	  gH/gL	  complex	  could	  provide	  essential	  regulation	  for	  gB’s	  fusion	  activity,	  
which	  is	  referred	  to	  as	  the	  “core	  fusion	  function”.	  	  
HCMV	  gH/gL	  has	  two	  sets	  of	  binding	  partners,	  gO	  and	  UL128-­‐131,	  forming	  
gH/gL/gO	  and	  gH/gL/UL128-­‐131	  complexes	  on	  the	  virion	  envelope	  (73,	  74,	  77,	  80,	  
227).	  Both	  complexes	  could	  influence	  HCMV	  cell	  tropism,	  but	  the	  mechanisms	  are	  
poorly	  understood.	  In	  vitro	  cell-­‐cell	  fusion	  assay	  demonstrated	  that	  gB	  and	  gH/gL	  
formed	  the	  minimal	  set	  of	  HCMV	  glycoproteins	  that	  are	  required	  for	  membrane	  
fusion,	  while	  adding	  UL128-­‐131	  or	  gO	  didn’t	  inhibit	  or	  enhance	  cell-­‐cell	  fusion	  
efficiency	  (216,	  239).	  However,	  there	  is	  little,	  if	  any,	  unbound	  gH/gL	  dimer	  on	  the	  
virion	  envelope	  (data	  reported	  in	  Chapter	  2),	  thus	  it	  is	  possible	  that	  either	  one	  of	  
HCMV	  gH/gL	  complexes	  or	  both	  of	  them	  could	  provide	  the	  “core	  fusion	  function”.	  
Data	  reported	  in	  Chapter	  3	  supported	  a	  model	  where	  gH/gL/gO	  provides	  the	  
conserved	  herpesvirus	  “core	  fusion	  function”	  of	  promoting	  gB	  fusion	  for	  entry	  into	  
all	  cell	  types,	  whereas	  gH/gL/UL128-­‐131	  provides	  a	  non-­‐fusion,	  yet	  necessary	  
function	  on	  select	  cell	  types	  (i.e.	  epithelial/endothelial	  cells). This	  model	  is	  
consistent	  with	  the	  phenotype	  of	  UL128-­‐131,	  and	  gO	  deletion	  mutants:	  the	  UL128-­‐
131	  mutants	  fail	  to	  infect	  epithelial/endothelial	  cells	  but	  can	  still	  infect	  fibroblast	  
cells	  as	  efficiently	  as	  wild	  type	  viruses	  while	  the	  gO	  mutants	  fail	  to	  enter	  any	  cell	  
type	  (77–79,	  227,	  238). 	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The	  other	  important	  finding	  in	  both	  Chapter	  2	  and	  Chapter	  3	  was	  that	  strain	  
Merlin	  (ME)	  contained	  less	  total	  amount	  of	  gH/gL	  than	  strains	  TB40/e	  (TB)	  or	  TR,	  
and	  the	  majority	  of	  ME	  gH/gL	  was	  in	  the	  form	  of	  gH/gL/UL128-­‐131	  while	  TB	  and	  
TR	  contained	  mostly	  gH/gL/gO. The	  aim	  of	  the	  research	  in	  this	  chapter	  was	  to	  
characterize	  the	  mechanism(s)	  that	  regulates	  the	  differential	  assembly	  of	  gH/gL	  
complexes	  among	  strains	  of	  HCMV.	  Strain	  TR	  and	  ME	  were	  chosen	  to	  represent	  
gH/gL/gO-­‐rich	  and	  gH/gL/UL128-­‐131-­‐rich	  viruses	  respectively	  for	  studies	  carried	  
out	  in	  this	  Chapter.	  	  
Herpesvirus	  glycoproteins	  are	  synthesized	  in	  the	  endoplasmic	  reticulum	  (ER),	  
and	  have	  to	  be	  transported	  to	  trans-­‐Golgi-­‐derived	  viral	  assembly	  compartment	  in	  
order	  to	  be	  incorporated	  into	  the	  virion	  envelope.	  So	  either,	  or	  both	  of	  the	  
glycoprotein	  expression	  level	  and	  trafficking	  efficiency	  from	  ER	  to	  Golgi	  
compartment	  could	  affect	  the	  assembly	  of	  glycoprotein	  complexes.	  Moreover,	  
UL148,	  an	  ER-­‐chaperone	  protein,	  was	  recently	  reported	  to	  favor	  the	  formation	  of	  
gH/gL/gO	  (287).	  Comparison	  of	  the	  glycoprotein	  levels	  in	  the	  infected	  cells	  showed	  
that	  ME	  expressed	  much	  more	  of	  UL128-­‐131	  proteins,	  less	  of	  UL148,	  and	  
comparable	  amount	  of	  gH/gL	  as	  compared	  to	  TR.	  However	  while	  TR	  gH/gL	  were	  
efficiently	  transported	  to	  the	  trans-­‐Golgi	  derived	  virus	  assembly	  compartment,	  ME	  
gH/gL	  remained	  mostly	  in	  the	  ER.	  Moreover,	  the	  transport	  of	  ME	  gH/gL	  out	  of	  ER	  
was	  even	  worse	  in	  fibroblast	  cells	  where	  UL128-­‐131	  expression	  was	  repressed,	  
suggesting	  that	  ME	  gH/gL/gO	  assembly	  was	  inherently	  inefficient.	  It	  is	  likely	  that	  
both	  high	  expression	  of	  UL128-­‐131	  and	  low	  expression	  of	  UL148	  contributed	  to	  the	  
poor	  assembly	  of	  ME	  gH/gL/gO	  in	  ER,	  which	  dampened	  the	  transport	  of	  gH/gL	  to	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trans-­‐Golgi	  derived	  assembly	  compartment,	  and	  thus	  resulted	  in	  the	  less	  total	  
gH/gL,	  and	  dearth	  of	  gH/gL/gO	  in	  ME	  virion	  envelope.	  Further	  characterization	  
showed	  that	  neither	  gO	  sequence	  diversity	  nor	  gH	  N-­‐term	  polymorphisms	  had	  great	  
affect	  in	  regulating	  the	  gH/gL	  complexes	  assembly.	  Taken	  together,	  report	  here	  
demonstrated	  that	  multiple	  viral	  factors	  are	  involved	  in	  the	  regulation	  of	  gH/gL	  
complexes	  assembly,	  and	  helped	  us	  better	  understand	  how	  HCMV	  adjusts	  tropism	  
and	  navigates	  through	  the	  host.	  	  
MATERIALS	  AND	  METHODS	  
Cell	  lines.	  Primary	  human	  foreskin	  fibroblasts	  (HFF)	  (Life	  Technologies),	  HFF	  
tet	  cells	  (which	  express	  the	  tetracycline	  repressor	  protein	  (177)),	  and	  MRC-­‐5	  
fibroblasts	  (ATCC	  CCL-­‐171)	  were	  grown	  in	  Dulbecco’s	  modified	  Eagle’s	  medium	  
(DMEM)	  (Life	  Technologies)	  supplemented	  with	  6%	  heat-­‐inactivated	  fetal	  bovine	  
serum	  (FBS)	  and	  6%	  bovine	  growth	  serum	  (Rocky	  Mountain	  Biologicals,	  Inc.).	  The	  
retinal	  pigment	  epithelial	  cell	  line	  ARPE-­‐19	  (American	  Type	  Culture	  Collection,	  
Manassas,	  VA,	  USA)	  was	  grown	  in	  a	  1:1	  dilution	  mixture	  of	  DMEM	  and	  Ham’s	  F-­‐12	  
medium	  (DMEM:	  F12)	  (Life	  Technologies)	  supplemented	  with	  10%	  FBS.	  
HCMV.	  The	  HCMV	  strains	  were	  derived	  from	  bacterial	  artificial	  chromosome	  
(BAC)	  clones.	  BAC	  clone	  TR	  was	  provided	  by	  Jay	  Nelson	  (Oregon	  Health	  and	  Science	  
University,	  Portland,	  OR,	  USA)	  (41).	  BAC	  clone	  Merlin	  (ME)	  (pAL1393),	  which	  
contains	  tetracycline	  operator	  sequences	  inserted	  in	  front	  of	  the	  promoter	  of	  UL130	  
and	  UL131,	  was	  provided	  by	  Richard	  Stanton	  (Cardiff	  University,	  Cardiff,	  United	  
Kingdom)	  (177).	  Infectious	  HCMV	  was	  recovered	  by	  electroporation	  of	  BAC	  DNA	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into	  MRC-­‐5	  fibroblasts,	  as	  described	  by	  Wille	  et	  al.	  (238).	  Cell-­‐free	  TR	  and	  ME	  stocks	  
were	  produced	  by	  infecting	  HFF	  and	  HFFtet	  at	  0.1	  PFU	  per	  cell	  respectively.	  At	  8	  to	  
14	  days	  postinfection	  (when	  90%	  of	  the	  cells	  were	  still	  visually	  intact),	  culture	  
supernatants	  were	  harvested,	  and	  cellular	  contaminants	  were	  removed	  by	  
centrifugation	  at	  1,000X	  g	  for	  10	  min	  and	  again	  at	  6,000Xg	  for	  10	  min.	  Stocks	  were	  
judged	  cell	  free	  by	  the	  lack	  of	  calnexin	  in	  western	  blotting	  analyses,	  and	  were	  
aliquoted	  in	  adequate	  amounts	  and	  stored	  at	  -­‐80°C.	  The	  number	  of	  PFU	  was	  
determined	  by	  plaque	  assay	  on	  triplicate	  HFF.	  
Recombineering.	  The	  gO	  inter-­‐strain	  swap	  mutants	  were	  constructed	  by	  
Richard	  Stanton	  (Cardiff	  University,	  Cardiff,	  United	  Kingdom)	  using	  two-­‐step	  
galactokinase	  (GalK)	  selection	  as	  described	  previously	  (281).	  The	  gH	  N-­‐term	  inter-­‐
strain	  swap	  mutants	  were	  generated	  in	  our	  lab	  by	  en	  passant	  mutagenesis	  (288,	  
289).	  A	  selectable	  kanamycin	  (Kan)-­‐resistance	  cassette	  with	  endonuclease	  I-­‐SceI	  
restriction	  site,	  duplications	  of	  the	  target	  gene	  sequences	  and	  short	  homologous	  
sequences	  flanking	  at	  either	  end	  was	  PCR	  amplified.	  Insertion	  of	  the	  cassette	  into	  
the	  region	  to	  be	  modified	  on	  the	  BAC	  DNA	  that	  contained	  chloamphenicol	  (Cm)	  
resistance	  gene	  was	  allowed	  by	  recombination	  at	  the	  short	  homologous	  sequences,	  
followed	  by	  positive	  selection	  for	  Cm	  and	  Kan	  resistance.	  Next,	  expression	  of	  I-­‐SceI	  
was	  induced	  and	  the	  BAC	  DNA	  was	  cleaved	  into	  linear	  dsDNA.	  The	  resulting	  dsDNA	  
ends	  recombined	  at	  the	  duplicated	  sequences	  of	  target	  gene,	  resulting	  in	  the	  
completely	  removal	  of	  all	  foreign	  sequences	  including	  the	  selection	  marker.	  The	  
recombined	  BAC	  was	  selected	  by	  Cm	  resistance.	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Antibodies.	  Monoclonal	  antibodies	  (MAbs)	  specific	  for	  HCMV	  major	  capsid	  
protein	  (MCP)	  28-­‐4	  and	  gB	  27-­‐156	  were	  provided	  by	  Bill	  Britt	  (University	  of	  
Alabama,	  Birmingham,	  AL,	  USA)	  (45,	  267).	  Anti-­‐UL128	  MAb	  4B10	  was	  provided	  by	  
Tom	  Shenk	  (Princeton	  University,	  Princeton,	  NJ,	  USA)	  (77).	  Rabbit	  polyclonal	  
antipeptide	  antibodies	  directed	  against	  HCMV	  gH,	  gL,	  UL130,	  and	  Ul131	  were	  
provided	  by	  David	  Johnson	  (Oregon	  Health	  and	  Sciences	  University,	  Portland,	  OR,	  
USA)	  (80).	  Rabbit	  polyclonal	  antipeptide	  antibody	  directed	  against	  HCMV	  UL148	  
was	  provided	  by	  Jeremy	  Kamil	  (Louisiana	  State	  University,	  Health	  Sciences	  Center,	  
Shreveport,	  LA,	  USA)	  (287).	  Anti-­‐IE1/2	  MAb	  was	  commercially	  purchased	  from	  
abcam.	  
Western	  blotting	  analysis.	  Cell-­‐free	  virions	  from	  culture	  supernatants	  were	  
concentrated	  by	  centrifugation	  at	  50,000Xg	  for	  1	  h	  and	  resuspended	  in	  2%	  SDS,	  
20mM	  Tris-­‐buffered	  saline	  (TBS)	  (pH	  6.8),	  followed	  by	  heating	  at	  95°C	  for	  10	  min.	  
Insoluble	  material	  was	  removed	  by	  centrifugation	  at	  16,000Xg	  for	  30	  min,	  and	  the	  
cleared	  supernatants	  were	  saved	  as	  virion	  extract	  and	  stored	  at	  -­‐80°C.	  For	  cell	  
extract,	  HCMV	  infected	  cells	  were	  scraped	  into	  medium	  at	  either	  2	  dpi	  or	  5	  dpi,	  and	  
cell	  fractions	  were	  separated	  by	  centrifugation	  at	  1,000Xg	  for	  10	  min.	  Cell	  pellets	  
were	  resuspended	  in	  2%	  SDS,	  20	  mM	  TBS,	  followed	  by	  heating	  at	  95°C	  for	  10	  min.	  
Insoluble	  material	  was	  removed	  by	  centrifugation	  at	  16,000Xg	  for	  30	  min,	  and	  the	  
cleared	  supernatants	  were	  saved	  as	  cell	  extract	  and	  stored	  at	  -­‐80°C.	  For	  
endoglycosidase	  H	  (endo	  H)	  and	  peptide	  N-­‐glycosidase	  F	  (PNGase	  F)	  treatment,	  cell	  
extract	  were	  incubated	  with	  endo	  H	  or	  PNGase	  F	  for	  3~5	  h	  at	  37°C	  in	  the	  buffer	  
specified	  by	  the	  enzyme	  manufacturer	  (New	  England	  Biolabs).	  For	  reducing	  blots,	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extracts	  were	  then	  adjusted	  to	  25mM	  dithiothreitol	  (DTT),	  and	  proteins	  were	  
separated	  by	  SDS-­‐PAGE	  and	  transferred	  to	  polyvinylidene	  difluoride	  (PVDF)	  
membranes	  (Whatman)	  in	  a	  buffer	  containing	  10	  mM	  NaHCO3	  and	  3	  mM	  Na2CO3	  
(pH	  9.9)	  plus	  10%	  Methanol.	  The	  transferred	  proteins	  were	  probed	  with	  MAbs	  or	  
rabbit	  polyclonal	  antibodies	  specific	  for	  HCMV	  proteins,	  followed	  by	  horseradish	  
peroxidase-­‐conjugated	  secondary	  antibodies;	  chemiluminescence	  was	  detected	  
using	  a	  Bio-­‐Rad	  ChemiDoc	  MP	  imaging	  system.	  
qPCR.	  Cell-­‐free	  HCMV	  stock	  (20	  μl)	  was	  first	  treated	  with	  DNase	  I	  to	  remove	  
DNA	  not	  protected	  within	  viral	  capsids.	  Capsids	  were	  disrupted	  by	  using	  the	  viral	  
lysis	  buffer	  and	  proteinase	  K	  provided	  in	  the	  PureLink	  Viral	  RNA/DNA	  minikit	  (Life	  
Technologies).	  Viral	  DNA	  was	  eluted	  in	  50	  μl	  RNAase-­‐free	  water.	  A	  region	  within	  
UL83	  conserved	  among	  TR	  and	  ME	  was	  chosen	  as	  the	  amplicon	  (as	  described	  in	  
Chapter	  3),	  and	  genomes	  were	  quantified	  by	  real-­‐time	  quantitative	  PCR	  (qPCR)	  
using	  SYBR	  green	  dye	  (Bio-­‐Rad)	  and	  the	  forward	  primer	  
TGGTCACCTATCACCTGCAT	  and	  the	  reverse	  primer	  GAAAGAGCCCGACGTCTACT.	  
PCR	  samples	  were	  made	  to	  a	  total	  well	  volume	  of	  20	  μl	  with	  1X	  SYBR	  green	  master	  
mix	  (Bio-­‐Rad),	  a	  1:100	  dilution	  of	  viral	  DNA,	  and	  500	  nM	  forward	  and	  reverse	  
primers.	  PCR	  products	  were	  detected	  using	  MyiQ	  real-­‐time	  PCR	  detection	  system	  
(Bio-­‐Rad).	  The	  qPCR	  results	  were	  compared	  to	  a	  plasmid	  pTRUL83	  standard	  and	  
then	  calculated	  as	  genomes	  per	  ml.	  For	  each	  experiment,	  two	  independent	  viral	  DNA	  
extractions	  and	  three	  independent	  qPCRs	  were	  performed.	  
Plaque	  assay.	  Cell-­‐free	  HCMV	  were	  serially	  10	  fold	  diluted	  in	  DMEM	  medium	  
and	  subsequently	  used	  to	  infect	  monolayers	  of	  HFF	  or	  ARPE-­‐19	  cells.	  After	  2	  h	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incubation,	  cells	  were	  overlaid	  by	  1:1	  mixture	  of	  2X	  DMEM,	  and	  1.2%	  Sea-­‐Plaque	  
agarose	  to	  prevent	  the	  spread	  of	  progeny	  virus	  by	  diffusion.	  Plaques	  were	  counted	  
by	  light	  microscopy	  three	  weeks	  later	  and	  titer	  was	  calculated	  as	  plaque	  forming	  
unit	  (PFU)	  per	  ml.	  For	  each	  experiment,	  three	  independent	  plaque	  assays	  were	  
performed.	  
Multi-­‐step	  growth	  curve.	  HFF	  cells	  were	  infected	  by	  HCMV	  at	  0.1	  PFU	  per	  cell,	  
and	  cell-­‐free	  supernatant	  viruses	  were	  harvested	  at	  various	  time	  points	  (4,	  8,	  14,	  21	  
dpi)	  as	  described	  above.	  Quantitation	  of	  cell-­‐free	  virus	  infectivity	  was	  performed	  by	  
plaque	  assay	  on	  HFF	  cells.	  
RESULTS	  
Analysis	  of	  viral	  glycoprotein	  expression	  levels	  and	  trafficking	  efficiency	  
in	  fibroblast	  cells	  infected	  by	  different	  HCMV	  strains.	  To	  compare	  the	  
glycoprotein	  expression	  level,	  fibroblast	  HFF	  cells	  were	  infected	  with	  either	  TR	  or	  
ME	  at	  MOI=1.	  Cell	  lysate	  were	  prepared	  at	  different	  time	  points	  post	  infection	  and	  
analyzed	  by	  western	  blotting	  under	  reducing	  conditions.	  Gel	  loads	  were	  normalized	  
to	  viral	  immediate-­‐early	  (IE)	  gene	  products	  (IE1	  and	  IE2)	  at	  2	  days	  post	  infection	  (2	  
dpi)	  to	  normalize	  the	  input	  of	  viral	  gene	  expression	  (Figure.	  4-­‐1A).	  Note	  that	  only	  
IE1	  was	  detected	  at	  2	  dpi	  while	  all	  the	  other	  viral	  glycoproteins	  of	  interest	  were	  not	  
(data	  not	  shown),	  which	  was	  consistent	  with	  the	  kinetic	  profiles	  of	  those	  proteins.	  





































Figure	   4-­‐1	   Comparison	   of	   glycoproteins	   expression	   level	   in	   the	   fibroblasts	   cells	  
infected	  with	  strains	  of	  HCMV	  TR	  and	  ME.	  
Cell	  lysate	  harvested	  from	  2	  dpi	  (A)	  or	  5	  dpi	  (B)	  were	  separated	  by	  reducing	  SDS-­‐PAGE	  and	  analyzed	  
by	   western	   blotting	   with	   antibodies	   specific	   for	   IE1/2,	   MCP,	   the	   55-­‐kDa	   fragment	   of	   gB,	   gH,	   gL,	  
UL128-­‐131	   respectively,	   and	  UL148.	  The	   gel	   loads	  were	  normalized	   to	   equal	   amount	   IE1	   at	   2	  dpi.	  
Mass	  markers	  (kilodaltons)	  are	  shown	  on	  the	  left.	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The	  steady-­‐state	  levels	  of	  glycoproteins	  were	  then	  compared	  at	  5	  dpi.,	  by	  the	  time	  of	  
which	  virus	  assembly	  occurred.	  One	  interesting	  observation	  was	  that	  IE	  gene	  
products	  appeared	  to	  show	  different	  patterns	  between	  TR	  and	  ME,	  with	  IE1	  being	  
the	  predominant	  species	  in	  TR	  infected	  cells	  whereas	  IE2	  in	  ME	  infected	  cells	  
(Figure.	  4-­‐1B).	  The	  significance	  of	  this	  difference	  is	  beyond	  the	  scope	  of	  study	  in	  this	  
dissertation,	  but	  since	  IE1	  and	  IE2	  are	  known	  as	  crucial	  transcriptional	  activators	  of	  
multiple	  viral	  and	  cellular	  genes	  (reviewed	  in	  (290)),	  this	  data	  might	  have	  
implication	  in	  interpreting	  potential	  strain-­‐specific	  viral	  replication	  or	  virus-­‐host	  
interaction	  characteristics.	  Nevertheless,	  the	  combined	  amounts	  of	  IE	  were	  
comparable	  at	  5	  dpi.	  The	  blotting	  of	  major	  capsid	  protein	  (MCP),	  gB,	  gH	  and	  gL	  
showed	  comparable	  amount	  of	  those	  proteins	  as	  well	  (Figure.	  4-­‐1B).	  Conversely,	  ME	  
infected	  cells	  contained	  dramatically	  more	  UL128,	  UL130	  and	  UL131	  proteins	  than	  
TR	  infected	  cells	  (Figure.	  4-­‐1B).	  This	  result	  correlated	  well	  with	  the	  amount	  of	  
UL128-­‐131	  detected	  in	  ME,	  and	  TR	  virions	  respectively,	  which	  may	  help	  explain	  
why	  ME	  is	  a	  gH/gL/UL128-­‐131-­‐rich	  virus.	  Note	  that	  gO	  could	  not	  be	  compared	  here	  
because	  the	  anti-­‐gO	  antibodies	  lacked	  cross-­‐reactivity	  as	  shown	  in	  Figure.	  2-­‐4.	  
	  However,	  the	  comparable	  amount	  of	  gH	  and	  gL	  expressed	  in	  the	  infected	  cells	  
was	  not	  consistent	  with	  the	  amount	  of	  those	  proteins	  detected	  in	  the	  virus	  envelope,	  
where	  TR	  virions	  contained	  greatly	  more	  total	  amount	  of	  gH/gL	  than	  ME.	  This	  
discrepancy	  suggests	  that	  ME	  gH/gL	  might	  not	  be	  efficiently	  transported	  to	  trans-­‐
Golgi-­‐derived	  assembly	  compartment.	  To	  test	  this	  hypothesis,	  cell	  lysate	  were	  
treated	  with	  endoglycosidase	  H	  (endo	  H),	  which	  removes	  the	  high-­‐mannose	  N-­‐
linked	  glycans	  that	  are	  added	  to	  proteins	  in	  the	  ER,	  or	  peptide	  N-­‐glycosidase	  F	  	  








Figure	  4-­‐2	  Western	  blotting	  analysis	  of	  the	  maturation	  of	  HCMV	  gH/gL	  in	  the	  infected	  
fibroblast	  cells.	  
TR-­‐	   and	   ME-­‐infected	   HFF	   cell	   lysate	   (A),	   or	   ME-­‐infected	   HFFtet	   cell	   lysate	   (B)	   were	   either	   left	  
untreated	  (-­‐),	  or	  treated	  with	  endo	  H	  (H)	  or	  PNGase	  F	  (F),	  and	  then	  were	  separated	  by	  reducing	  SDS-­‐
PAGE	  and	  analyzed	  by	  western	  blotting	  with	  antibodies	  specific	  to	  gH	  or	  gL.	  Bands	  corresponding	  to	  
glycosylated	   form,	   or	   endo	   H	   resistant	   form	   of	   the	   protein	   were	   pointed	   by	   arrow;	   and	   the	  
deglycosylated	  forms	  of	  the	  protein	  either	  by	  endo	  H	  or	  PNGase	  F	  was	  pointed	  by	  arrowhead.	  Mass	  
markers	  (kilodaltons)	  are	  shown	  on	  the	  left.	  
	  
(PNGase	  F),	  which	  removes	  all	  types	  of	  N-­‐linked	  glycans,	  including	  those	  ones	  that	  
have	  been	  modified	  by	  enzymes	  in	  the	  Golgi	  compartments.	  Thus,	  glycoproteins	  
retained	  in	  the	  ER	  should	  stay	  endo	  H	  sensitive,	  resulting	  in	  a	  faster	  migrating	  band	  
on	  SDS-­‐PAGE	  gels,	  while	  the	  ones	  present	  in	  Golgi	  should	  be	  endo	  H	  resistant.	  And	  
glycoproteins	  in	  either	  ER	  or	  Golgi	  compartments	  should	  be	  sensitive	  to	  PNGase	  F.	  
The	  treated	  samples	  were	  analyzed	  by	  western	  blotting	  under	  reducing	  conditions	  
and	  assessed	  for	  protein	  mobility.	  As	  expected,	  gH	  and	  gL	  in	  both	  TR	  and	  ME	  
infected	  cells	  were	  fully	  sensitive	  to	  PNGase	  F.	  However,	  the	  majority	  of	  gH	  and	  gL	  
were	  in	  the	  faster-­‐migrating,	  endo	  H	  sensitive	  form	  for	  ME,	  while	  the	  reverse	  
pattern	  was	  true	  for	  TR,	  with	  larger	  proportion	  of	  gH	  and	  gL	  remaining	  endo	  H	  
resistant	  (Figure.	  4-­‐2A).	  This	  result	  confirmed	  the	  hypothesis	  that	  most	  of	  ME	  gH/gL	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are	  not	  efficiently	  transported	  out	  of	  ER,	  which	  correlated	  with	  the	  significant	  lower	  
amount	  of	  total	  gH/gL	  present	  in	  ME	  virion	  envelope.	  	  
ER	  to	  trans-­‐Golgi	  transport	  of	  gH/gL	  is	  largely	  dependent	  on	  binding	  of	  gO	  or	  
the	  UL128-­‐131	  proteins	  (80).	  Analysis	  of	  the	  cell	  lysate	  from	  ME	  infected	  fibroblasts	  
where	  the	  expression	  of	  UL128-­‐131was	  repressed	  (HFF-­‐tet)	  showed	  that	  there	  was	  
even	  a	  smaller	  proportion	  of	  endo	  H	  resistant	  gH	  and	  gL	  detected	  (Figure.	  4-­‐2B),	  as	  
compared	  to	  that	  in	  regular	  fibroblast	  cells	  as	  shown	  in	  Figure.	  4-­‐2A.	  When	  the	  
assembly	  of	  gH/gL/UL128-­‐131was	  suppressed,	  the	  transport	  of	  gH/gL	  should	  be	  
mainly	  dependent	  on	  the	  assembly	  of	  gH/gL/gO,	  thus	  this	  result	  indicated	  that	  ME	  
gH/gL/gO	  assembly	  was	  inherently	  not	  efficient	  even	  without	  the	  competitor	  
UL128-­‐131.	  This	  finding	  was	  also	  consistent	  with	  previous	  reports	  that	  ME	  virions	  
produced	  from	  HFF-­‐tet	  cells	  contained	  elevated	  level	  of	  gH/gL/gO,	  but	  that	  amount	  
of	  gH/gL/gO	  didn’t	  compensate	  the	  amount	  of	  gH/gL	  that	  was	  used	  to	  be	  in	  the	  form	  
of	  gH/gL/UL128-­‐131.	  In	  summary,	  these	  results	  suggested	  that	  for	  ME,	  the	  endo	  H	  
resistant	  gH/gL	  observed	  in	  Figure.	  4-­‐2A	  was	  largely	  due	  to	  the	  formation	  of	  
gH/gL/UL128-­‐131,	  and	  that	  the	  deficit	  of	  total	  gH/gL	  in	  the	  virion	  represents	  an	  
inefficient	  assembly	  of	  gH/gL/gO.	  
Recently,	  Li	  et	  al.	  reported	  that	  a	  viral	  protein,	  UL148,	  likely	  acted	  as	  an	  ER-­‐
chaperone	  that	  favors	  the	  formation	  of	  gH/gL/gO	  (287).	  Analysis	  of	  TR	  and	  ME	  
infected	  fibroblast	  cell	  lysate	  showed	  that	  ME	  expressed	  quite	  less	  of	  UL148	  protein	  
(Figure.	  4-­‐1B).	  This	  result	  was	  consistent	  with	  the	  model	  that	  UL148	  promotes	  the	  
assembly	  of	  gH/gL/gO,	  and	  suggested	  that	  the	  dearth	  of	  gH/gL/gO	  in	  ME	  virions	  
was	  likely	  due	  to	  both	  high	  expression	  of	  UL128-­‐131	  and	  low	  expression	  of	  UL148.	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Characterizations	  of	  HCMV	  gO	  inter-­‐strain	  swap	  mutants.	  Compared	  to	  the	  
more	  conserved	  gH,	  gL	  and	  Ul128-­‐131	  proteins,	  gO	  is	  one	  of	  the	  most	  diverse	  
proteins	  encoded	  by	  the	  virus,	  with	  10	  to	  30%	  diversity	  at	  amino	  acid	  sequence	  
level	  among	  the	  eight	  families	  that	  are	  categorized	  based	  on	  phylogenetic	  analysis	  of	  
more	  than	  40	  clinical	  isolates	  (reported	  in	  (89)	  and	  Chapter	  2).	  Because	  gH/gL/gO	  
and	  gH/gL/UL128-­‐131	  are	  formed	  through	  competitive	  interactions,	  one	  
compelling	  hypothesis	  was	  that	  gO	  sequence	  diversity	  might	  influence	  the	  assembly	  
of	  the	  two	  gH/gL	  complexes	  through	  differential	  binding	  affinity	  to	  gH/gL.	  To	  test	  
this	  hypothesis,	  gO	  inter-­‐strain	  mutants	  were	  constructed	  by	  swapping	  the	  UL74	  
ORFs	  between	  strain	  ME	  and	  TR.	  ME	  virus	  with	  TRgO	  was	  designated	  as	  
MEdeltaTRgO,	  and	  TR	  virus	  with	  MEgO	  was	  designated	  as	  TRdeltaMEgO.	  Both	  
mutant	  viruses	  were	  viable,	  and	  further	  characterizations	  were	  performed.	  HFF	  
cells	  were	  infected	  with	  MEdeltaTRgO,	  ME,	  TR	  and	  TRdeltaMEgO	  at	  MOI=1,	  and	  
extracellular	  virions	  were	  analyzed	  by	  western	  blotting	  under	  non-­‐reducing	  
conditions.	  Gel	  loads	  were	  normalized	  to	  total	  amount	  of	  gH/gL	  for	  better	  
comparison	  of	  the	  ratio.	  Probing	  with	  common	  antigen	  gL	  showed	  that	  
MEdeltaTRgO	  was	  a	  gH/gL/UL128-­‐131-­‐rich	  virus	  as	  wild	  type	  ME,	  and	  
TRdeltaMEgO	  was	  a	  gH/gL/gO-­‐rich	  virus	  as	  wild	  type	  TR.	  There	  might	  be	  slightly	  
more	  gH/gL/gO	  in	  MEdeltaTRgO	  virus	  than	  ME,	  but	  this	  clearly	  did	  not	  fully	  explain	  
why	  ME	  virion	  is	  deficient	  in	  gH/gL/gO	  (Figure.	  4-­‐3A).	  Therefore,	  swapping	  gO	  did	  
not	  drastically	  affect	  the	  assembly	  of	  gH/gL	  complexes,	  suggesting	  that	  the	  sequence	  
diversity	  of	  gO	  did	  not	  greatly	  influence	  the	  binding	  affinity	  of	  gO	  to	  gH/gL.	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Figure	  4-­‐3	  Characterizations	  of	  HCMV	  gO	  inter-­‐strain	  swap	  mutants.	  
(A)	  Cell-­‐free	  virions	  of	  MEdeltaTRgO,	  ME,	  TR	  and	  TRdeltaMEgO	  were	  analyzed	  by	  western	  blotting	  
under	  non-­‐reducing	  condition.	  Gel	   loads	  were	  normalized	  to	  equal	  amount	  of	  total	  gL	  and	  blot	  was	  
probed	  with	  antibody	  specific	  to	  gL.	  Mass	  markers	  (kilodaltons)	  are	  shown	  on	  the	  left.	  (B)	  HFF	  cells	  
were	   infected	   with	   the	   indicated	   viruses	   at	   MOI=0.1,	   and	   cell-­‐free	   supernatants	   were	   retained	   at	  
different	   time	  points	  after	   infection	  and	   then	   titrated	  on	  HFF	   to	  measure	   the	   infectivity	  of	  cell-­‐free	  
progeny	  viruses.	  (Note:	  titer	  of	  ME	  and	  TRdeltaMEgO	  were	  zero	  at	  4	  dpi,	  which	  cannot	  be	  plotted	  on	  
a	  log	  scale	  axis).	  
	  
To	  test	  whether	  the	  virus	  infectivity	  is	  altered	  in	  the	  presence	  of	  different	  gO	  
isoform,	  multi-­‐step	  growth	  curve	  analysis	  was	  performed.	  HFF	  cells	  were	  infected	  
by	  the	  indicated	  viruses	  at	  MOI=0.1.	  Extracellular	  viruses	  were	  harvested	  at	  various	  
time	  points	  post	  infection,	  and	  the	  infectivity	  was	  measured	  by	  plaque	  assay	  on	  HFF	  
cells.	  TR	  produced	  higher	  peak	  titers	  of	  cell-­‐free	  virus	  than	  those	  of	  ME	  by	  more	  
than	  40-­‐fold,	  which	  is	  consistent	  with	  previous	  report	  in	  Chapter	  3	  that	  TR	  had	  a	  
better	  specific	  infectivity	  on	  fibroblasts	  than	  ME	  (291).	  Mutant	  viruses	  exhibited	  
roughly	  similar	  pattern	  as	  their	  corresponding	  wild	  type	  viruses.	  However,	  in	  both	  
genetic	  backgrounds,	  TRgO	  seemed	  to	  correlate	  with	  a	  more	  robust	  replication	  of	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the	  virus	  (Figure.	  4-­‐3B).	  Since	  this	  experiment	  was	  only	  performed	  once,	  no	  
definitive	  conclusion	  can	  be	  drawn	  so	  far.	  	  
Characterizations	  of	  HCMV	  gH	  N-­‐term	  inter-­‐strain	  swap	  mutants.	  There	  are	  
small	  amino	  acids	  polymorphisms	  residing	  on	  the	  N-­‐term	  of	  gH.	  It	  seems	  possible	  
that	  these	  polymorphisms	  might	  influence	  the	  assembly	  of	  gH/gL	  complexes.	  To	  test	  
this	  hypothesis,	  gH	  N-­‐term	  inter-­‐strain	  mutants	  were	  constructed	  by	  swapping	  
between	  the	  N-­‐term	  of	  10~36	  amino	  acids	  sequence	  of	  ME	  gH	  and	  10~37	  amino	  
acid	  sequence	  of	  TR	  gH.	  Designations	  of	  the	  mutant	  viruses	  mimic	  gO	  swap	  mutants	  
for	  the	  purpose	  of	  consistency,	  with	  MEdeltaTRgH	  and	  TRdeltaMEgH	  respectively.	  	  
To	  characterize	  the	  level	  of	  gH/gL/gO	  and	  gH/gL/UL128-­‐131	  on	  virion	  
envelope,	  fibroblast	  HFF	  cells	  were	  infected	  by	  TR,	  TRdeltaMEgH,	  ME	  and	  
MEdeltaTRgH	  at	  MOI=1.	  Extracellular	  virions	  were	  harvested	  and	  analyzed	  by	  
western	  blotting	  under	  reducing	  conditions	  (Figure.	  4-­‐4A).	  When	  gel	  loads	  were	  
normalized	  to	  equal	  amount	  of	  MCP,	  all	  viruses	  contained	  comparable	  amount	  of	  gB,	  
while	  TR	  contained	  more	  total	  amount	  of	  gH/gL	  than	  ME	  (consistent	  with	  the	  report	  
in	  Chapter	  3).	  Swapping	  the	  N-­‐term	  of	  gH	  didn’t	  dramatically	  change	  this	  pattern.	  
Analysis	  of	  gH/gL	  complexes	  ratio	  by	  non-­‐reducing	  western	  blotting	  showed	  that	  
the	  vast	  majority	  of	  gH/gL	  was	  in	  the	  form	  of	  gH/gL/gO	  in	  TR	  while	  most	  of	  gH/gL	  
in	  ME	  was	  in	  the	  form	  of	  gH/gL/UL128-­‐131	  (consistent	  with	  report	  in	  Chapter	  3).	  
The	  corresponding	  mutant	  viruses	  didn’t	  change	  the	  ratio	  pattern	  either	  (Figure.	  4-­‐
4B).	  Thus,	  N-­‐term	  polymorphisms	  in	  gH	  didn’t	  dramatically	  influence	  the	  assembly	  
of	  gH/gL	  complexes.	  	  
	  















Figure	  4-­‐4	  Characterizations	  of	  HCMV	  gH	  N-­‐term	  inter-­‐strain	  swap	  mutants.	  
Cell-­‐free	   virions	   of	   HCMV	   TR,	   TRdeltaMEgH,	   ME,	   and	   MEdeltaTRgH	   were	   analyzed	   by	   western	  
blotting	   under	   reducing	   (A)	   and	   non-­‐reducing	   (B)	   conditions.	   Gel	   loads	  were	   normalized	   to	   equal	  
amount	  of	  MCP.	  Reducing	  blots	  were	  probed	  with	  antibodies	  specific	   for	   the	  55-­‐kDa	  portion	  of	  gB,	  
and	  gL.	  Non-­‐reducing	  blot	  was	  probed	  with	  antibody	  to	  gL.	  Mass	  markers	  (kilodaltons)	  are	  shown	  on	  
the	  left.	  Cell-­‐free	  stocks	  of	  indicated	  viruses	  were	  analyzed	  by	  qPCR	  to	  quantitate	  genome-­‐containing	  
virions,	  and	  PFU	  were	  determined	  on	  fibroblasts	  (C)	  or	  epithelial	  cells	  (D).	  The	  particle-­‐to-­‐PFU	  ratio	  
was	   calculated	   as	   the	   number	   of	   genomes	   per	   milliliter	   to	   the	   number	   of	   PFU	   per	   milliliter.	   The	  
averages	  and	  standard	  deviations	  of	  three	  experiments	  are	  plotted.	  	  
	  
To	  test	  whether	  gH	  N-­‐term	  sequence	  polymorphisms	  affect	  gH/gL	  complexes	  
functions,	  particle-­‐to-­‐PFU	  ratio	  on	  either	  fibroblasts	  or	  epithelial	  cells	  were	  
characterized.	  Cell-­‐free	  virions	  of	  indicated	  viruses	  were	  analyzed	  by	  qPCR	  to	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measure	  genome-­‐containing	  virions	  and	  plaque	  assay	  on	  both	  cells	  type	  to	  
determine	  titers,	  and	  particle-­‐to-­‐PFU	  ratio	  was	  calculated.	  Consistent	  with	  the	  
report	  in	  Chapter	  3,	  on	  fibroblasts	  TR	  was	  more	  infectious	  than	  ME.	  Interestingly,	  
TRdeltaMEgH	  was	  about	  5-­‐fold	  more	  infectious	  than	  TR	  while	  MEdeltaTRgH	  was	  
reciprocally	  less	  infectious	  than	  ME,	  although	  with	  less	  than	  2-­‐fold	  difference	  
(Figure.	  4-­‐4C).	  Since	  the	  amount	  of	  gH/gL/gO	  was	  not	  greatly	  changed,	  it	  is	  possible	  
that	  the	  gained	  replication	  efficiency	  of	  TRdeltaMEgH	  on	  fibroblast	  cells	  is	  due	  to	  the	  
qualitative	  differences	  in	  gH/gL/gO	  complex	  exerted	  by	  ME	  N-­‐term	  of	  gH.	  Particle-­‐
to-­‐PFU	  measurements	  were	  generally	  higher	  on	  epithelial	  cells.	  Extremes	  were	  TR	  
and	  TRdeltaMEgH,	  again	  with	  TRdeltaMEgH	  slightly	  more	  infectious	  than	  TR;	  
MEdeltaTRgH	  and	  ME	  were	  comparable	  to	  each	  other	  at	  intermediate	  values	  
(Figure.	  4-­‐4D).	  Therefore,	  the	  specific	  infectivity	  on	  epithelial	  cells	  was	  roughly	  
unaffected	  by	  swapping	  the	  N-­‐term	  of	  gH.	  	  
DISCUSSION	  
During	  initial	  infection,	  dissemination,	  establishment	  of	  latent/persistent	  
infection,	  and	  reactivation/shedding,	  HCMV	  requires	  a	  “entry	  machinery”	  that	  
enables	  itself	  to	  enter	  a	  wide	  array	  of	  distinct	  cell	  types	  in	  the	  host.	  HCMV	  employs	  
two	  gH/gL	  complexes	  that	  could	  influence	  cell	  tropism.	  Our	  current	  model	  suggests	  
that	  gH/gL/gO	  provides	  the	  “core-­‐fusion	  function”	  for	  entry	  into	  all	  cell	  types,	  
probably	  through	  interaction	  with	  the	  fusion	  protein	  gB.	  Meanwhile,	  gH/gL/UL128-­‐
131	  acts	  through	  a	  distinct	  function	  for	  virus	  entry	  into	  select	  cell	  types,	  like	  
epithelial/endothelial	  cells,	  which	  broadens	  viral	  tropism.	  The	  fact	  that	  different	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HCMV	  strains	  vary	  in	  the	  relative	  amount	  of	  gH/gL/gO	  and	  gH/gL/UL128-­‐131	  on	  
the	  virion	  envelope	  indicates	  that	  the	  amount	  of	  the	  two	  gH/gL	  complexes	  could	  be	  
adjusted	  by	  the	  virus	  differentially.	  However,	  the	  mechanisms	  that	  regulate	  the	  
assembly	  of	  the	  two	  gH/gL	  complexes	  have	  remained	  mostly	  elusive.	  	  
Comparison	  of	  glycoproteins	  steady-­‐state	  levels	  in	  the	  infected	  cells	  showed	  
that	  strain	  ME	  expressed	  considerably	  more	  UL128-­‐131	  proteins,	  which	  correlated	  
well	  with	  the	  high	  level	  of	  gH/gL/Ul128-­‐131	  in	  its	  virion.	  And	  this	  result	  is	  
consistent	  with	  the	  observation	  reported	  in	  Murrell	  et	  al.,	  where	  polymorphisms	  in	  
the	  UL128-­‐131	  locus	  of	  strains	  TB40/E	  and	  FIX,	  both	  of	  which	  contained	  little	  
gH/gL/UL128-­‐131	  in	  the	  virion,	  when	  introduced	  into	  ME,	  were	  found	  to	  reduce	  the	  
incorporation	  of	  gH/gL/UL128-­‐131	  (281).	  However,	  ME	  is	  not	  only	  gH/gL/UL128-­‐
131-­‐rich,	  but	  also	  contains	  less	  total	  amount	  of	  gH/gL,	  and	  apparently	  the	  UL128-­‐
131	  locus	  cannot	  be	  the	  sole	  reason	  to	  explain	  why	  ME	  behaves	  the	  way	  it	  does.	  
Intracellular	  trafficking	  studies	  showed	  that	  ME	  gH/gL	  was	  poorly	  transported	  from	  
ER	  to	  trans-­‐Golgi	  apparatus,	  albeit	  the	  similar	  expression	  levels	  of	  gH/gL	  compared	  
to	  strain	  TR,	  which	  contains	  a	  lot	  more	  total	  amount	  of	  gH/gL	  in	  the	  virion.	  The	  
finding	  that	  even	  less	  efficient	  transport	  of	  ME	  gH/gL	  from	  ER	  to	  trans-­‐Golgi	  
apparatus	  in	  fibroblast	  cells	  where	  the	  expression	  of	  UL128-­‐131	  were	  repressed	  
suggested	  that	  the	  inefficient	  transport	  of	  ME	  gH/gL	  was	  likely	  due	  to	  the	  poor	  
assembly	  of	  gH/gL/gO.	  	  	  
Recently,	  Li	  et	  al.	  reported	  that	  another	  viral	  glycoprotein	  UL148	  could	  increase	  
the	  virion	  incorporation	  of	  gH/gL/gO,	  and	  this	  effect	  may	  or	  may	  not	  comes	  at	  the	  
expense	  of	  gH/gL/UL128-­‐131	  (287).	  Given	  the	  positive	  role	  of	  UL148	  in	  favoring	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the	  formation	  of	  gH/gL/gO,	  it	  is	  possible	  that	  the	  expression	  level	  of	  UL148	  could	  
affect	  the	  assembly	  of	  the	  gH/gL	  complexes.	  Data	  here	  showed	  that	  ME	  expressed	  
considerably	  less	  UL148,	  which	  correlated	  with	  its	  poor	  assembly	  efficiency	  of	  
gH/gL/gO.	  In	  the	  future,	  it	  would	  be	  important	  to	  characterize	  whether	  boost	  of	  ME	  
UL148	  level	  by	  trans-­‐expression	  would	  influence	  the	  abundance	  of	  gH/gL/gO	  in	  ME	  
virion,	  and	  ask	  why	  different	  strains	  of	  HCMV	  differ	  in	  the	  expression	  level	  of	  UL148.	  
Disruption	  of	  UL148	  in	  TB	  decreased	  the	  level	  of	  gH/gL/gO	  in	  virion	  envelope	  
without	  largely	  increasing	  the	  amount	  of	  gH/gL/UL128-­‐131.	  The	  resulting	  UL148-­‐
null	  virus	  had	  similar	  infectivity	  on	  fibroblast	  cells,	  but	  improved	  replication	  
efficiency	  on	  epithelial	  cells	  as	  compared	  to	  wild	  type	  TB	  (287).	  On	  the	  other	  hand,	  
disruption	  of	  UL148	  in	  ME	  resulted	  in	  a	  decreased	  infectivity	  on	  epithelial	  cells	  
(Brent’s	  communication	  with	  Richard	  Stanton),	  although	  the	  influence	  on	  the	  level	  
of	  gH/gL	  complexes	  hasn’t	  been	  looked	  carefully	  to	  date.	  Thus,	  the	  effect	  of	  UL148	  
on	  HCMV	  infectivity	  seems	  to	  vary	  depending	  on	  the	  genetic	  background	  of	  the	  
virus.	  And	  this	  discrepancy	  draws	  attention	  to	  the	  unaddressed	  question,	  what	  is	  
the	  minimum	  amount	  of	  either	  gH/gL/gO	  or	  gH/gL/UL128-­‐131	  required	  for	  their	  
function	  respectively.	  It	  is	  likely	  that	  the	  amount	  of	  gH/gL/gO	  in	  TB	  virus	  is	  in	  large	  
excess	  above	  the	  “threshold”	  of	  gH/gL/gO	  required	  to	  promote	  gB-­‐fusion,	  such	  that	  
even	  though	  the	  amount	  of	  gH/gL/gO	  was	  reduced	  in	  UL148-­‐null	  virus,	  that	  amount	  
is	  still	  ample	  to	  keep	  gH/gL/gO	  at	  comparable	  efficiency.	  The	  little	  amount	  of	  
gH/gL/UL128-­‐131	  in	  TB	  is	  probably	  close	  to	  the	  “threshold”	  of	  gH/gL/UL128-­‐131	  
required	  for	  its	  function	  on	  select	  cell	  types,	  and	  the	  increased	  infectivity	  of	  TB	  
UL148-­‐null	  virus	  on	  epithelial	  cells	  could	  be	  due	  to	  the	  possibility	  of	  slightly	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increased	  gH/gL/UL128-­‐131,	  which	  was	  not	  detected	  in	  Li	  et	  al.	  (287).	  However,	  for	  
ME,	  a	  gH/gL/gO-­‐deficit	  virus,	  the	  amount	  of	  gH/gL/gO	  it	  contains	  might	  be	  closer	  to,	  
or	  even	  below	  the	  “threshold”,	  such	  that	  decreasing	  the	  amount	  of	  gH/gL/gO	  might	  
result	  in	  a	  “sharp”	  drop	  in	  infectivity.	  Disruption	  of	  UL148	  in	  ME	  might	  result	  in	  
reduced	  amount	  of	  gH/gL/gO,	  which	  decreases	  the	  virus	  infectivity,	  like	  on	  
epithelial	  cells,	  as	  mentioned	  above.	  Therefore,	  the	  different	  amount	  of	  gH/gL	  
complexes	  that	  strains	  of	  HCMV	  contain	  indicates	  where	  they	  are	  relative	  to	  the	  
minimum	  amount	  of	  either	  gH/gL/gO	  or	  gH/gL/UL128-­‐131	  required,	  and	  that	  
would	  be	  important	  reference	  to	  the	  interpretation	  of	  mutant	  phenotypes,	  when	  the	  
abundances	  of	  gH/gL	  complexes	  are	  changed.	  
The	  mechanisms	  by	  which	  UL148	  works	  remain	  largely	  uncharacterized	  at	  this	  
time.	  Interestingly,	  what	  Li	  et	  al.	  found	  is	  that	  UL148,	  an	  ER	  retained	  protein,	  
exclusively	  interacted	  with	  gH/gL	  complexes	  containing	  UL130	  and	  UL131,	  but	  not	  
with	  UL128	  or	  gO	  (287),	  suggesting	  that	  UL148	  might	  compete	  with	  either	  gO	  or	  
UL128	  for	  binding	  onto	  gH/gL,	  but	  the	  binding	  of	  UL148	  apparently	  doesn’t	  hurt	  the	  
loading	  of	  UL130/UL131.	  Therefore,	  UL148	  seems	  to	  temporally	  “reserve”	  a	  
reservoir	  of	  gH/gL	  in	  ER	  from	  forming	  either	  gH/gL/gO	  or	  gH/gL/UL128-­‐131	  
complexes.	  But	  how	  does	  UL148	  eventually	  favor	  the	  assembly	  of	  gH/gL/gO?	  One	  
possibility	  is	  that	  UL148	  passively	  promote	  gH/gL/gO	  formation	  by	  occluding	  
gH/gL/UL128-­‐131.	  Because	  gO	  and	  UL128	  each	  covalently	  binds	  to	  gH/gL	  through	  
the	  disulfide-­‐bond	  with	  the	  same	  cysteine	  residue	  on	  gL,	  whereas	  UL130	  and	  UL131	  
do	  not	  (76,	  77,	  80,	  215),	  binding	  of	  UL148	  with	  gH/gL	  may	  prevent	  UL128	  from	  
forming	  a	  disulfide-­‐bond	  with	  gL,	  which	  could	  be	  an	  irreversible	  process	  required	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for	  gH/gL/UL128-­‐131	  assembly.	  On	  the	  other	  hand,	  the	  resulting	  intermediate	  
complex	  “gH/gL/UL148/U130/UL131”	  might	  be	  less	  stable	  given	  the	  noncovalent	  
linkage	  between	  UL130/UL131	  and	  gH/gL.	  Thus,	  at	  some	  point	  this	  complex	  would	  
dissociate,	  providing	  the	  opportunity	  for	  gO	  to	  load	  to	  gH/gL,	  which	  then	  allows	  the	  
assembly	  of	  gH/gL/gO.	  Alternatively,	  another	  non-­‐mutually	  exclusive	  possibility	  is	  
that	  binding	  of	  UL148	  to	  gH/gL	  may	  actively	  help	  gH/gL	  fold	  into	  a	  favorable	  
conformation	  for	  gO	  to	  bind.	  Since	  whether	  UL148	  specifically	  binds	  to	  the	  
immature	  form	  of	  gH/gL/UL130/UL131	  or	  also	  binds	  to	  gH/gL	  dimer	  in	  the	  absence	  
of	  UL128-­‐131	  is	  currently	  not	  known,	  it	  is	  hard	  to	  distinguish	  the	  abovementioned	  
“passive”	  versus	  “active”	  mechanisms.	  But	  if	  UL148	  could	  bind	  to	  gH/gL	  dimer	  in	  the	  
absence	  of	  UL128-­‐131,	  and	  still	  promote	  the	  formation	  of	  gH/gL/gO,	  it	  would	  
suggest	  UL148	  could	  act	  actively	  for	  gH/gL/gO	  assembly.	  Nevertheless,	  in	  either	  
scenario,	  the	  loading	  of	  gO	  would	  likely	  displace	  UL148	  in	  some	  manner	  in	  order	  to	  
form	  gH/gL/gO.	  Characterization	  of	  the	  working	  mechanism	  of	  UL148	  would	  be	  an	  
interesting	  spot	  of	  research	  in	  the	  future.	  
Although	  neither	  gO	  or	  gH	  N-­‐term	  inter-­‐strain	  swap	  mutants	  showed	  obvious	  
changes	  on	  the	  viral	  composition	  of	  gH/gL	  complexes,	  there	  were	  slightly	  better	  
replication	  efficiency	  associated	  with	  TRgO,	  and	  the	  N-­‐term	  of	  MEgH	  on	  fibroblast	  
cells	  respectively.	  It	  is	  not	  clear	  yet	  if	  the	  increased	  infectivity	  is	  the	  result	  of	  slight	  
changes	  in	  the	  amount	  of	  gH/gL/gO,	  or	  is	  indicative	  of	  functional	  differences	  of	  
TRgO	  and	  N-­‐term	  of	  MEgH.	  Future	  work	  is	  needed	  to	  clarify	  those	  possibilities	  in	  
detail,	  and	  if	  the	  growth	  difference	  is	  not	  due	  to	  the	  alteration	  in	  the	  abundance	  of	  
gH/gL/gO,	  these	  results	  would	  be	  the	  first	  piece	  of	  evidence	  suggesting	  that	  the	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sequence	  diversity	  of	  gO	  or	  the	  polymorphisms	  of	  gH	  N-­‐term	  could	  influence	  the	  
function	  of	  gH/gL/gO.	  	  
In	  summary,	  studies	  in	  this	  chapter	  helped	  to	  sort	  out	  some	  viral	  factors	  that	  
underpin	  the	  differential	  regulation	  of	  the	  gH/gL	  complexes	  assembly,	  that	  was	  
expression	  levels	  of	  UL128-­‐131	  and	  UL148	  likely	  contribute	  to	  the	  regulation	  
through	  the	  influence	  on	  the	  competitive	  assembly	  between	  gH/gL/gO	  and	  
gH/gL/UL128-­‐131.	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CHAPTER	  5. GENERAL	  DISCUSSION	  AND	  
FUTURE	  DIRECTIONS	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HCMV	  is	  a	  significant	  public	  health	  concern	  due	  to	  the	  severe	  diseases	  that	  it	  
can	  cause	  in	  immunocompromised	  and/or	  immunoimmature	  individuals.	  The	  
toxicity	  and	  drug-­‐resistance	  associated	  with	  antiviral	  drugs	  and	  the	  lack	  of	  licensed	  
vaccine	  have	  highlighted	  the	  need	  for	  a	  better	  understanding	  of	  the	  molecular	  
biology	  of	  the	  virus,	  which	  will,	  in	  turn,	  aid	  the	  development	  of	  effective	  vaccines	  
against	  this	  virus,	  as	  well	  as	  the	  design	  of	  antiviral	  therapeutic	  treatment	  in	  the	  
future.	  	  
The	  overall	  focus	  of	  this	  dissertation	  is	  on	  the	  mechanisms	  by	  which	  HCMV	  
manages	  to	  enter	  different	  cell	  types.	  The	  current	  consensus	  is	  that	  the	  interaction	  
between	  gH/gL	  and	  the	  fusion	  protein	  gB	  serves	  as	  the	  conserved	  entry	  mechanism	  
among	  all	  herpesviruses	  (reviewed	  in	  (189)).	  Additionally,	  each	  herpesvirus	  
encodes	  accessory	  proteins	  that	  bind	  to	  gH/gL,	  and	  can	  regulate	  the	  action	  of	  the	  
core	  fusion	  machinery.	  HCMV	  gH/gL	  can	  be	  bound	  by	  gO,	  or	  by	  the	  set	  of	  proteins	  
UL128,	  UL130,	  and	  UL131,	  forming	  gH/gL/gO	  and	  gH/gL/UL128-­‐131	  complexes	  on	  
the	  virion	  envelope	  (73,	  74,	  76,	  77,	  80,	  227).	  There	  has	  been	  a	  lot	  of	  interest	  in	  these	  
complexes	  as	  targets	  for	  vaccine	  development.	  However,	  the	  mechanisms	  by	  which	  
these	  complexes	  facilitate	  virus	  entry	  are	  still	  poorly	  understood.	  Moreover,	  the	  
specific	  function	  of	  gO	  in	  gH/gL/gO	  complex	  has	  not	  been	  addressed	  in	  detail	  yet.	  
gO	  is	  among	  the	  most	  diverse	  proteins	  encoded	  by	  the	  virus.	  There	  are	  at	  least	  8	  
isoforms	  of	  gO	  in	  nature,	  varying	  by	  10~30%	  at	  amino	  acid	  sequence	  level	  (89).	  It	  is	  
reasonable	   to	   hypothesize	   that	   the	   amino	   acid	   differences	   of	   gO	  might	   affect	   the	  
properties	  of	  gO	  isoforms.	  Thus,	  the	  research	  work	  in	  this	  dissertation	  was	  started	  
by	   addressing	   the	   function	   of	   gO	   through	   comparative	   analysis	   of	   different	   gO	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isoforms.	  The	   results	   of	   these	   studies,	   as	  detailed	   in	  Chapter	   2,	   indicated	   that	   gO	  
and	   UL128-­‐131	   competed	   for	   binding	   to	   gH/gL,	   and	   that	   the	   ratio	   of	   the	   two	  
complexes	  on	  the	  virion	  envelope	  can	  vary	  dramatically	  among	  strains.	  The	  finding	  
that	   some	   strains	   contain	   mostly	   gH/gL/gO,	   whereas	   others	   contain	   mostly	  
gH/gL/UL128-­‐131	  was	  quite	   surprising.	  While	   these	   studies	  did	  not	   shed	   light	  on	  
the	  function	  of	  gO,	  they	  did	  provide	  an	  opportunity	  to	  address	  the	  important	  roles	  
that	  the	  two	  gH/gL	  complexes	  play	  in	  virus	  entry	  into	  different	  cell	  types.	  	  
gH/gL	  and	  gB	  comprised	  the	  minimum	  set	  of	  requirement	   for	  HCMV	  fusion	   in	  
cell-­‐cell	  fusion	  experiment,	  suggesting	  HCMV	  gH/gL	  is	  able	  to	  promote	  gB-­‐mediated	  
fusion	   (216).	   This	   function	   of	   gH/gL	   is	   referred	   to	   as	   the	   “core	   fusion	   function”.	  
However,	  in	  virus	  scenario,	  there	  is	  little,	  if	  any,	  unbound	  gH/gL.	  Most	  of	  the	  gH/gL	  
is	  in	  the	  form	  of	  gH/gL/gO	  or	  gH/gL/UL128-­‐131	  complexes,	  thus	  it	  is	  possible	  that	  
either	   one	   of	   those	   two	   complexes	   or	   both	   of	   them	   can	   perform	   the	   core	   fusion	  
function.	  
The	   functions	   of	   HCMV	   gH/gL	   complexes	   have	   been	   mostly	   studied	   with	  
deletion	  mutants.	  UL128-­‐131	  deletion	  mutants	  replicate	  well	  on	  fibroblasts	  but	  fail	  
to	  enter	  epithelial/endothelial	   cells,	   suggesting	   that	  gH/gL/UL128-­‐131	   is	   required	  
for	   entry	   into	   epithelial/endothelial	   cells	   but	   is	   dispensable	   on	   fibroblasts.	   This	  
phenotype	  is	  often	  interpreted	  to	  mean	  that	  entry	  into	  epithelial/endothelial	  cells	  is	  
facilitated	   by	   gH/gL/UL128-­‐131,	   whereas	   entry	   into	   fibroblasts	   is	   facilitated	   by	  
gH/gL/gO.	   The	   resulting	   model	   suggests	   that	   both	   gH/gL/UL128-­‐131,	   and	  
gH/gL/gO	  provide	  essentially	   the	  same	   function	   for	  entry	   into	  different	  cell	   types,	  
i.e.,	  promoting	  gB-­‐mediated	  membrane	  fusion.	  This	  was	  an	  attractive	  model	  due	  to	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the	   analogy	  with	   the	  well-­‐studied	   Epstein-­‐Barr	   virus	   (EBV)	   tropism	  model.	   EBV’s	  
gH/gL	  exists	  in	  two	  forms	  as	  well,	  naked	  gH/gL	  or	  gH/gL/gp42	  complex.	  Entry	  into	  
epithelial	  cells	  is	  facilitated	  by	  gH/gL,	  through	  interactions	  with	  specific	  integrin	  on	  
the	   cell	   surface.	   Binding	  with	   gp42	   blocks	   the	   interaction	   of	   gH/gL	  with	   integrin,	  
instead,	  gH/gL/gp42	  interacts	  with	  MHCII	  molecule	  on	  B	  cell	  surface,	  thus	  facilitates	  
virus	  entry	   into	  B	  cells.	  Therefore,	  EBV	  gH/gL	  and	  gH/gL/gp42	  can	  both	  promote	  
gB-­‐mediated	  fusion	  into	  different	  cell	  types,	  with	  gp42	  acting	  like	  a	  tropism	  switch	  
adapter.	   While	   UL128-­‐131	   deletion	   mutants	   replicate	   well	   on	   fibroblasts,	   gO	  
deletion	  mutants	  fail	  to	  enter	  any	  cell	  type,	  suggesting	  that	  gH/gL/UL128-­‐131	  is	  not	  
sufficient	  to	  promote	  gB-­‐mediated	  fusion	  into	  epithelial/endothelial	  cells,	  and	  entry	  
into	   that	   cell	   type	   requires	   both	   complexes.	   However,	   further	   analysis	   is	   largely	  
limited	   due	   to	   the	   severe	   growth	   defect	   of	   the	   gO	   mutants	   and	   the	   lack	   of	   a	  
complementation	  system.	  
The	  work	  in	  Chapter	  3	  avoided	  the	  caveats	  of	  gO-­‐null	  mutants	  by	  employing	  a	  
panel	   of	   HCMV	   strains	   that	   contained	   different	   amounts	   of	   gH/gL/gO	   and	  
gH/gL/UL128-­‐131	   complexes.	   Since	   none	   of	   the	   viruses	   were	   absolutely	   lacking	  
either	   complex,	   they	   did	   not	   exhibit	   severe	   growth	   defect	   as	   observed	   in	   gO-­‐null	  
mutants,	   thus	   the	   infectivity	   measured	   were	  more	   biologically	   relevant.	   Cell-­‐type	  
specific	  particle-­‐to-­‐PFU	  ratios	  were	  determined	  and	  showed	   that	   infection	  of	  both	  
fibroblasts	   and	   epithelial	   cells	   was	   positively	   correlated	   with	   the	   abundance	   of	  
gH/gL/gO,	  but	  not	  with	  gH/gL/UL128-­‐131.	  And	  the	  low	  infectivity	  of	  the	  gH/gL/gO-­‐
deficit	   virus	   on	   both	   cell	   types	   could	   be	   recovered	   by	   treatment	   with	   chemical	  
fusogen	   PEG,	   indicating	   that	   the	   deficiency	   of	   infection	   was	   due	   to	   less	   efficient	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fusion.	  These	  results	  confirmed	  that	  infection	  of	  fibroblasts	  requires	  gH/gL/gO,	  and	  
further	   showed	   that	   infection	   of	   epithelial	   cells	   requires	   both	   gH/gL/gO	   and	  
gH/gL/UL128-­‐131.	   The	   sufficient	   role	   of	   gH/gL/gO	   in	   promoting	   gB-­‐mediated	  
fusion	  on	  fibroblasts	  demonstrated	  that	  gH/gL/gO	  is	  clearly	  fusion	  competent.	  The	  
necessary	  role	  of	  gH/gL/gO	  on	  epithelial	  cells	  suggested	  that	  gH/gL/gO	   likely	  acts	  
as	  the	  fusion	  competent	  complex	  on	  that	  cell	  type	  as	  well.	  This	  speculation	  supports	  
the	   data	   described	   above	   better	   than	   either	   of	   the	   other	   two	   explanations:	   1)	  
gH/gL/gO	   is	   fusion	   competent	   on	   fibroblasts	   but	   not	   on	   epithelial	   cells,	   instead	   it	  
performs	  an	  alternate	  function.	  2)	  The	  two	  different	  gH/gL	  complexes	  perform	  the	  
same	  (redundant)	  core	  fusion	  function	  on	  epithelial	  cells.	  Therefore,	  we	  proposed	  a	  
new	  model	  where	  gH/gL/gO	  provides	  the	  conserved	  herpesvirus	  gH/gL	  “core	  fusion	  
function”	   of	   promoting	   gB-­‐mediated	   fusion	   for	   entry	   into	   all	   cell	   types,	   whereas	  
gH/gL/UL128-­‐131	   provides	   a	   non-­‐fusion,	   yet	   necessary	   mechanism	   to	   allow	  
infection	  of	  select	  cell	   types	  (i.e.	  epithelial/endothelial	  cells). This	   is	  a	   lot	  different	  
from	   the	   EBV	   tropism	  model,	   and	   to	   our	   knowledge,	   is	   also	   the	   first	   report	   of	   a	  
fusion-­‐incompetent	  gH/gL	  complexes	  in	  the	  herpesvirus	  field,	  which	  might	  provide	  
an	   important	   opportunity	   to	   study	   the	   fundamental	   mechanism	   by	   which	   gH/gL	  
regulates	  gB	  fusion.	  These	  results	  also	  help	  explained	  the	  cell	  type-­‐dependent	  virus	  
neutralization	  exhibited	  by	  anti-­‐gH/gL/UL128-­‐131	  antibodies,	  and	  underscore	   the	  
importance	  of	  gH/gL/gO	  as	  a	  potential	  HCMV	  vaccine	  or	  therapeutic	  target.	  	  
Several	   important	   questions	   regarding	   to	   the	  model	   are	   still	   remaining	   to	   be	  
addressed:	   1)	   what	   underpins	   the	   distinct	   functions	   exhibited	   in	   gH/gL/gO	   and	  
gH/gL/UL128-­‐131?	  ,	  2)	  what	  is	  the	  non-­‐fusion	  function	  of	  gH/gL/UL128-­‐131?	  ,	  	  and	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3)	  What	  is	  gO’s	  role	  in	  the	  fusion	  competent	  complex	  gH/gL/gO?	  Some	  speculations	  
regarding	  those	  questions	  will	  be	  discussed	  below.	  
What	  underpins	  the	  distinct	  functions	  exhibited	  in	  gH/gL/gO	  and	  gH/gL/UL128-­‐
131?	   Studies	   of	   HSV	   and	   EBV	   suggest	   that	   the	   surfaces	   of	   gH/gL	   could	   directly	  
contact	  with	  gB	  to	  promote	  membrane	  fusion	  (reviewed	  in	  (189)).	  For	  HCMV,	  cell-­‐
cell	   fusion	   assay	   demonstrated	   that	   gH/gL	   and	   gB	   comprised	   the	   minimum	  
requirement	   for	   membrane	   fusion,	   indicating	   that	   HCMV	   gH/gL	   is	   capable	   of	  
triggering	  gB-­‐fusion	  as	  well	  (216).	  The	  distinct	  function	  model	  raises	  the	  possibility	  
that	   the	   “profusion”	   surfaces	   of	   HCMV	   gH/gL	   may	   be	   differentially	   formed	   or	  
exposed	  on	  gH/gL/gO	  versus	  gH/gL/UL128-­‐UL131.	  This	  discrepancy	  might	  be	  due	  
to	  the	  direct	  binding	  with	  gO	  versus	  UL128-­‐131,	  or	  allosteric	  conformation	  changes	  
of	   gH/gL	  as	   a	   result	   of	   the	  binding	  with	  gO	  versus	  UL128-­‐131.	  Although	  Cryo	  EM	  
revealed	   overall	   similar	   architecture	   between	   the	   two	   complexes	   (215,	   215),	  
detailed	   structure	   differences	   were	   not	   resolved	   in	   those	   studies.	   Our	   lab	   have	  
created	  a	  library	  of	  gH	  and	  gL	  charge-­‐cluster-­‐to-­‐alanine	  mutants,	  which	  might	  allow	  
more	  detailed	  structure	  differences	  between	  gH/gL/gO	  and	  gH/gL/UL128-­‐131	  to	  be	  
elucidated	  in	  the	  future.	  	  
The	   other	   possibility	   is	   that	   gH/gL/gO	   and	   gH/gL/UL128-­‐131	   might	   not	   be	  
uniformly	  distributed	  on	  the	  virion	  envelope;	  in	  other	  words,	  they	  might	  cluster	  in	  
different	  “landscape”.	  One	  speculation	  could	  be	  that	  the	  fusion	  competent	  gH/gL/gO	  
complex	  might	  either	  be	  spatially	  closer	  to	  gB	  or	  be	  more	  flexible	  in	  mobility	  on	  the	  
viral	  membrane,	  such	  that	  upon	  triggering,	  it	  could	  interact	  with	  gB	  with	  proximity	  
or	  “swim”	  around	  and	  have	  higher	  probability	  to	  interact	  with	  gB.	  In	  contrast,	  fusion	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incompetent	   gH/gL/UL128-­‐131	   complex	   might	   be	   more	   spatially	   sequestered	   or	  
restricted	   in	   mobility.	   Precedents	   have	   been	   reported	   in	   herpesvirus	   that	  
glycoproteins	  could	  be	  associated	  with	  the	  less	  fluid	  lipid	  raft	  on	  membranes	  (292–
294).	   It	   could	  be	  possible	   that	   lipid	   raft	  might	  play	  a	   role	   in	   the	  distinct	   functions	  
model	  of	  gH/gL/gO	  and	  gH/gL/UL128-­‐131.	  
What	   is	   the	   non-­‐fusion	   function	   of	   gH/gL/UL128-­‐131?	   	   gH/gL/UL128-­‐131	   null	  
virus	   cannot	   replicate	   on	   epithelial/endothelial	   cells,	   but	  with	   the	   aid	   of	   chemical	  
fusogen	  PEG,	   the	  mutant	   virus	   could	   establish	   infection	  as	  well	   as	  wild	   type	  virus	  
(79),	   suggesting	   that	   the	   deficiency	   is	   at	   pre-­‐fusion	   but	   not	   post-­‐fusion	   steps.	  
Infection	   of	   HCMV	   on	   epithelial/endothelial	   cells	   has	   been	   showed	   to	   happen	  
through	   endocytosis	   in	   a	   pH-­‐dependent	   manner	   (79).	   Trans-­‐expressed	  
gH/gL/UL128-­‐131	  was	   showed	   to	   exert	   interference	  on	   epithelial	   cells,	   indicating	  
that	   the	  complex	   is	   involved	   in	  receptor	   interaction	  (229).	  Moreover,	   recent	  study	  
showed	   that	   gH/gL/UL128-­‐131	   triggered	   specific	   signaling	   transduction	   pathway	  
for	   virus	   internalization	   into	   monocytes,	   the	   cell	   type	   where	   entry	   requires	  
gH/gL/UL128-­‐131	   as	   epithelial/endothelial	   cells	   does	   (230).	   Taken	   the	   above	  
evidences	   together,	   one	   compelling	   model	   would	   be	   that	   gH/gL/UL128-­‐131	  
interacts	   with	   its	   receptors	   on	   epithelial/endothelial	   cell	   surface	   and	   triggers	  
specific	   signaling/endocytosis	   pathway,	   the	   process	   of	   which	   is	   required	   for	  
subsequent	  gH/gL/gO-­‐promoted	  core	  fusion	  event	  to	  occur.	  	  
However,	   it	   is	   worth	   to	   note	   that	   gH/gL/UL128-­‐131-­‐null	   viruses	   are	   still	  
efficiently	   internalized	   into	   epithelial/endothelial	   cells	   (79,	   231,	   258,	   295),	  
suggesting	   gH/gL/UL128-­‐131	   is	   dispensable	   for	   the	   internalization	   of	   the	   virus.	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Perhaps,	   it	   is	  not	   surprising	   that	  non-­‐specific	   endocytosis	   could	  be	   triggered	  even	  
without	   gH/gL/UL128-­‐131	   given	   that	   the	   virus	   contains	   numerous	   different	  
glycoproteins	  on	   the	  virion	  envelop.	  However,	   the	  non-­‐specific	   endocytosis	  would	  
not	   lead	   to	   productive	   infection,	   indicating	   that	   efficient	   fusion	   can	   only	   occur	   in	  
specific	   endosome	   compartments	   triggered	   by	   gH/gL/UL128-­‐131-­‐dependent	  
endocytosis.	  	  
What	   is	   gO’s	   role	   in	   the	   fusion-­‐competent	   complex	   gH/gL/gO?	   	   It	   seems	   quite	  
clear	  now	  that	  at	  least	  one	  conserved	  function	  of	  gO	  is	  to	  facilitate	  the	  incorporation	  
of	   the	   fusion-­‐competent	   gH/gL/gO	   into	   the	   virion	   envelope.	   But	   does	   gO	   perform	  
more	  function	  other	  than	  that?	  	  
gH/gL/gO	  expressed	  in	  trans	  system	  exerted	  interference	  on	  fibroblasts	  but	  not	  
on	   epithelial	   cells	   (239),	   suggesting	   that	   the	   complex	   engages	   some	   currently	  
uncharacterized	   receptor	   on	   the	   surface	   of	   fibroblasts.	   This	   receptor-­‐gH/gL/gO	  
interaction	   likely	   triggers	   gB-­‐mediated	   fusion,	   resulting	   in	   virus	   entry	   into	  
fibroblasts	   through	   either	   direct	   fusion	   with	   plasma	   membrane	   or	   from	   within	  
endosomes	   followed	   by	  macropinocytosis	   at	   neutral	   pH	   (185,	   186).	   The	   negative	  
data	  of	   interference	  on	  epithelial	  cells	  could	  be	  explained	  at	   least	  by	   the	   following	  
two	   possibilities:	   1)	   in	   a	   trans-­‐expressed	   system,	   gH/gL/gO	   cannot	   reach	   to	   a	  
compartment	   where	   its	   receptor	   resides.	   In	   fact,	   trans-­‐expressed	   gH/gL/gO	   was	  
showed	  to	  be	  mostly	  retained	   in	  Golgi-­‐like	  compartments	  (239).	   It	   is	  possible	   that	  
receptor	  of	   gH/gL/gO	   in	   epithelial	   cells	   is	   sequestered	   in	  different	   compartments,	  
such	  as	  early	  endosomes	  or	  multivesicular	  bodies,	  thus	  making	  gH/gL/gO-­‐receptor	  
interaction	   spatially	   impossible.	   2)	   Or	   simply	   the	   receptor	   for	   gH/gL/gO	   is	   not	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available	   on	   epithelial	   cells,	   suggesting	   that	   the	   conformational	   change	   of	   the	  
complex	  on	  epithelial	  cells	  does	  not	  require	  a	  receptor;	  instead,	  the	  ligand	  could	  be	  a	  
proton,	  which	  is	  acquired	  in	  low-­‐pH	  endosomes	  after	  endocytosis.	  Recently,	  there	  is	  
evidence	   suggesting	   that	   gH/gL/gO	   can	   bind	   to	   PDGFRα,	   which	   is	   selectively	  
expressed	  on	  fibroblasts	  but	  not	  on	  epithelial	  cells	  (Manuscript	  reviewed	  by	  Brent).	  
This	   seems	   to	   favor	   the	   latter	   possibility,	   and	   also	   help	   to	   explain	   that	   the	  
requirement	   for	  gH/gL/UL128-­‐131	  on	  epithelial	   cells	   is	  probably	   to	  overcome	  the	  
lack	   of	   gH/gL/gO	   receptor,	   and	   that	   gH/gL/UL128-­‐131-­‐dependent	   endocytosis	  
somehow	  provides	  an	  alternative	  way	  for	  gH/gL/gO-­‐mediated	  gB	  fusion	  to	  occur.	  	  
gO	  might	  directly	  involve	  in	  gH/gL/gO’s	  function	  (i.e.	  receptor	  interaction),	  and	  
it	  is	  conceivable	  that	  gO	  sequence	  diversity	  might	  affect	  the	  “efficiency”	  of	  gH/gL/gO	  
in	   performing	   its	   job.	   In	   line	   with	   this	   hypothesis,	   ME-­‐TR	   inter-­‐strain	   gO	   swap	  
mutants	  displayed	  slight	  growth	  difference	  as	  compared	  to	  wild	  type	  virus	  (data	  in	  
Chapter	   4).	  However,	  more	  detailed	   studies	   in	   the	   future	  are	  warranted	   to	  verify	  
whether	   the	   growth	  difference	   is	   due	   to	   entry,	   and	   also	  whether	   this	   observation	  
applies	   to	   other	   gO	   isoforms.	   Moreover,	   since	   gO	   is	   heavily	   glycosylated,	   it	   is	  
possible	   that	   it	   could	   also	   act	   like	   a	   glycan	   shield,	   protecting	   gH/gL	   from	  
neutralizing	  antibodies.	  No	  research	  has	  been	  carried	  out	  in	  testing	  this	  hypothesis	  
in	  the	  context	  of	  gO	  sequence	  diversity.	  Our	  lab	  has	  created	  a	  library	  of	  anti-­‐peptide	  
antibodies	  raised	  against	  gH	  and	  gL	  and	  there	  are	  also	  anti-­‐gH	  mAbs	  library	  created	  
by	  Brent’s	  colleague	  Bill	  Britt.	  So	  future	  research	  could	  include	  the	  screening	  of	  the	  
strain-­‐specific	   neutralizing	   antibodies	   from	   the	   above	   antibody	   resources	   and	  
testing	  the	  correlation	  of	  neutralization	  specificity	  with	  gO	  isoforms.	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In	  summary,	  the	  work	  in	  Chapter	  2	  and	  Chapter	  3	  showed	  that	  different	  strains	  
of	  HCMV	  varied	  dramatically	  in	  the	  relative	  amount	  of	  gH/gL/gO	  and	  gH/gL/UL128-­‐
131,	  and	  this	  could	  influence	  virus	  infectivity	  on	  different	  cell	  types	  due	  to	  the	  
distinct	  functions	  of	  the	  two	  gH/gL	  complexes	  during	  entry	  and	  tropism.	  The	  next	  
question	  was	  that	  why	  strains	  differ	  in	  the	  abundance	  of	  the	  gH/gL	  /gO	  and	  
gH/gL/UL128-­‐131.	  Recently,	  Li	  et	  al.	  reported	  a	  viral	  protein,	  UL148,	  which	  might	  
act	  as	  an	  ER-­‐chaperone	  to	  promote	  the	  formation	  of	  gH/gL/gO	  over	  gH/gL/UL128-­‐
131	  (287).	  The	  research	  work	  in	  Chapter	  4	  found	  that	  strains	  of	  HCMV	  varied	  in	  the	  
protein	  expression	  level	  in	  the	  infected	  cells.	  ME	  expressed	  much	  more	  of	  UL128-­‐
131	  proteins,	  but	  less	  of	  UL148	  protein	  as	  compared	  to	  TR.	  gH/gL	  levels	  were	  more	  
comparable,	  however	  while	  TR	  gH/gL	  were	  efficiently	  transported	  to	  the	  trans-­‐
Golgi	  derived	  virus	  assembly	  compartment,	  ME	  gH/gL	  remained	  mostly	  in	  the	  ER.	  	  
These	  results	  suggested	  that	  both	  high	  expression	  of	  UL128-­‐131	  and	  the	  low	  
expression	  of	  UL148	  probably	  contributed	  to	  the	  poor	  assembly	  of	  ME	  gH/gL/gO	  in	  
ER,	  which	  likely	  dampened	  the	  transport	  of	  gH/gL	  to	  trans-­‐Golgi	  derived	  assembly	  
compartment,	  and	  thus	  resulted	  in	  the	  less	  total	  gH/gL,	  and	  dearth	  of	  gH/gL/gO	  in	  
ME	  virion	  envelope.	  Therefore,	  the	  assembly	  of	  gH/gL/gO	  and	  gH/gL/UL128-­‐131	  is	  
probably	  regulated	  through	  interstrain	  variability	  at	  multiple	  loci.	  In	  the	  future,	  a	  
further	  characterization	  of	  how	  the	  virus	  adjusts	  the	  level	  of	  those	  viral	  factors	  (i.e.,	  
Ul128-­‐131	  and	  UL148)	  would	  help	  us	  better	  understand	  how	  HCMV	  determines	  
tropism	  and	  navigates	  through	  the	  host.	  	  
The	  abovementioned	  distinct	   function	  model	   is	   focused	  on	   the	  contribution	  of	  
gH/gL	  complexes	   to	   cell-­‐free	  entry	  of	  HCMV.	  Another	  way	  of	  virus	   infection	   is	  via	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cell-­‐to-­‐cell	   spread.	   While	   cell-­‐free	   entry	   is	   apparently	   important	   for	   HCMV	   to	  
establish	   infection	   in	  a	  new	  host,	   cell-­‐to-­‐cell	   spread	   is	  probably	  essential	   for	  virus	  
dissemination	  within	  a	  host	  and	  can	  be	  one	  of	  the	  strategies	  that	  the	  virus	  utilize	  to	  
evade	   immune	   surveillance.	   Cell-­‐free	   infection	   and	   cell-­‐to-­‐cell	   spread	   could	   be	  
mechanistically	   distinguished	   by	   using	   neutralizing	   antibodies:	   cell-­‐free	   entry	   is	  
sensitive	   to	  neutralizing	  antibodies	  whereas	  cell-­‐to-­‐cell	   spread	   is	   largely	   resistant.	  
How	  HCMV	  spreads	  cell-­‐to-­‐cell	  is	  currently	  unknown.	  The	  fact	  that	  double	  deletions	  
of	   gO	   and	   UL128-­‐131	   proteins	   are	   lethal	   to	   the	   virus	   indicates	   that	   viral	   spread	  
absolutely	   depends	   on	   either	   of,	   or	   both	   of	   gH/gL/gO	   and	   gH/gL/UL128-­‐131,	   but	  
not	   on	   gH/gL	   dimer	   (180).	   Single	   deletion	   of	   either	   gO	   or	   UL128-­‐131	   proteins	  
results	   in	   a	   phenotype	   with	   similar	   spreading	   efficiency	   on	   fibroblast	   cells,	  
suggesting	   that	   gH/gL/gO	   and	   gH/gL/UL128-­‐131	   probably	   provide	   redundant	  
function	   for	   viral	   spread	   on	   fibroblast	   cells	   (79,	   180).	   On	   epithelial	   cells,	   single	  
deletion	   mutants	   of	   UL128-­‐131	   proteins	   cannot	   spread,	   while	   single	   deletion	  
mutants	  of	  gO	  spread	  slightly	  better,	  suggesting	  that	  gH/gL/UL128-­‐131	  is	  necessary	  
and	  sufficient	  for	  cell-­‐to-­‐cell	  spread	  on	  epithelial	  cells,	  but	  gH/gL/gO	  is	  dispensable	  
(79,	  238).	  Note	  how	  gH/gL/gO	  and	  gH/gL/UL128-­‐131	  are	  differentially	  required	  in	  
cell-­‐free	   entry	   versus	   cell-­‐to-­‐cell	   spread,	   and	   this	   discrepancy	   can	   be	   important	  
consideration	   to	   take	  when	   it	   comes	   to	   studies	  on	   the	  molecular	  biology	  of	  HCMV	  
transmission	  and	  dissemination.	  An	  intriguing	  difference	  between	  virus	  cell-­‐to-­‐cell	  
spread	  and	  transiently	  cell-­‐cell	  fusion	  is	  that	  gH/gL	  dimer	  is	  sufficient	  to	  trigger	  gB-­‐
mediated	  cell-­‐cell	  fusion	  but	  it	  cannot	  do	  it	  in	  the	  context	  of	  virus	  cell-­‐to-­‐cell	  spread.	  
This	  fits	  so	  well	  with	  the	  observation	  that	  HCMV	  infection	  usually	  would	  not	  result	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in	  the	  formation	  syncytium	  (massive	  cell-­‐cell	  fusion),	  while	  gH/gL	  and	  gB	  expressed	  
in	   trans	   exclusively	   generates	   syncytium,	   indicating	   that	   the	   cell-­‐to-­‐cell	   spread	  
during	   virus	   infection	   is	   somehow	   less	   “disruptive”	   and	   mechanistically	   different	  
from	  gH/gL	  and	  gB	  promoted	  cell-­‐cell	  fusion	  in	  trans.	  One	  speculation	  could	  be	  that	  
during	  HCMV	  infection,	  gH/gL	  dimer	  is	  prevented	  to	  reach	  to	  the	  cell	  surface	  or	  cell-­‐
cell	   junction	  where	   it	   can	   interact	  with	   gB	   to	   trigger	   cell-­‐cell	   fusion.	   If	   so,	   UL148	  
might	  be	  a	  potential	   candidate	  since	   it	   is	  an	  ER-­‐chaperone	   that	  can	  bind	   to	  gH/gL	  
(Kamil’s	   new	   abstract),	   and	   probably	   holds	   off	   the	   immature	   gH/gL	   in	   ER,	   thus	  
negatively	  controls	  the	  extent	  of	  cell-­‐cell	  fusion	  during	  virus	  infection.	  	  
HCMV	  is	  a	  virus	  that	  has	  been	  successfully	  adapted	  to	  the	  human	  host,	  which	  
exhibits	  significant	  levels	  of	  genetic	  diversity	  between	  individuals	  (interhost	  
diversity)	  and	  also	  within	  a	  single	  individual	  (intrahost	  diversity)	  (reviewed	  in	  
(142)).	  The	  intrahost	  diversity	  of	  HCMV	  has	  been	  largely	  underappreciated	  
previously	  in	  the	  field,	  and	  it	  might	  have	  important	  influence	  on	  virus	  pathogenesis.	  
This	  diversity	  may	  provide	  a	  mechanism	  by	  which	  the	  virus	  could	  rapidly	  adapt	  to	  
the	  changing	  host	  environments	  through	  influences	  on	  virus	  ability	  of	  dissemination.	  
The	  possible	  role	  in	  dissemination	  is	  likely	  based	  on	  viral	  glycoproteins,	  which	  are	  
involved	  in	  virus	  entry	  and	  tropism.	  Even	  with	  the	  glycoproteins	  that	  this	  
dissertation	  studies,	  there	  was	  a	  dramatic	  variation	  that	  different	  HCMV	  strains	  
exhibit	  in	  the	  relative	  amount	  of	  gH/gL/gO	  and	  gH/gL/UL128-­‐131	  complexes	  on	  the	  
virion	  envelope	  and	  this	  variation	  significantly	  influenced	  virus	  infectivity	  on	  
different	  cell	  types.	  It	  is	  conceivable	  that	  there	  are	  genetic	  bases	  that	  attribute	  to	  
this	  trait.	  One	  possibility	  is	  that	  during	  infection	  in	  human	  host,	  HCMV	  exists	  as	  a	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diverse	  population	  that	  may	  harbor	  different	  genetic	  variations	  affecting	  the	  relative	  
abundance	  of	  gH/gL/gO	  and	  gH/gL/UL128-­‐131,	  such	  that	  upon	  encountering	  
distinct	  host	  tissue/cell,	  subset	  of	  the	  population	  could	  replicate	  better	  than	  the	  
others,	  resulting	  in	  overall	  efficient	  dissemination.	  Although	  no	  clear	  conclusion	  can	  
be	  drawn	  to	  date	  on	  the	  correlation	  between	  the	  variation	  of	  HCMV	  genotypes	  and	  
the	  risk	  of	  virus	  transmission,	  or	  the	  outcome	  and	  severity	  of	  diseases,	  HCMV	  
intrahost	  diversity	  is	  an	  important	  aspect	  that	  needs	  more	  appreciation	  and	  might	  
help	  with	  future	  vaccine	  or	  antiviral	  drug	  design.	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